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Abstract 
 
Cystic fibrosis (CF) and Primary Ciliary Dyskinesia (PCD) are chronic suppurative lung diseases 
(CSLD). CF is characterised by inherited mutations affecting the cystic fibrosis transmembrane 
regulator (CFTR) protein, which is thought to be normal in PCD, however the role of CFTR in 
disease is incompletely understood. This thesis investigates the relationship between CFTR, 
inflammation and airway health, firstly in the context of the CF gene therapy Multidose trial followed 
by contrasting CF, PCD and control patients. 
The first study explored the relationship between lower airway potential difference (LAPD) 
measurements performed in the Multidose trial as a measure of CFTR function, and physiological, 
radiographic and inflammatory markers of disease severity. At baseline, FEV1 correlated with basal 
LAPD measurements, however not between restored chloride secretion and change in airway 
disease following treatment; implicating the role of sodium transport, not chloride in disease 
pathogenesis. As no direct correlation was seen, I went on to explore an alternative theory that a 
bi-directional relationship exists between CFTR and inflammation; CFTR dysfunction triggers a 
hyper-inflammatory state and inflammation causes secondary CFTR dysfunction. 
Cell cultures were cultivated from the nasal epithelium of patients with CF, PCD and controls. Both 
at baseline and following stimulation with common respiratory pathogens, the levels of 
inflammatory mediators in the supernatant from each group of cells were comparable. The 
numbers involved with this study were small, however did not indicate that CF cells cultured in 
these conditions (in vitro) were hyper-inflammatory.  
The final study explored in vivo whether inflammation causes secondary CFTR dysfunction. Nasal 
potential difference (NPD) measurements were compared with localised levels of inflammation in 
subjects with CF, PCD and controls. PCD traces showed reduced chloride secretion, however it 
was not possible to differentiate secondary CFTR dysfunction from damage to epithelial cell 
integrity. Elevated levels of inflammatory mediators were detected in PCD nasal fluid, however the 
results were variable and these levels did not correlate with NPD measurements of ion channel 
function. 
These studies did not support the hypothesis that there is a direct relationship between CFTR 
function and airway disease, that in vitro CF cells are hyperinflammatory, or in vivo that 
inflammation leads to secondary CFTR dysfunction. The experiments performed in this thesis 
provide a basis for future work exploring this relationship, and may help guide future trials for novel 
therapies in CF.  
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1 Chapter 1 - Introduction 
 
 
The cystic fibrosis transmembrane regulator (CFTR) protein is a cAMP-regulated ion channel 
expressed on the apical surface of epithelial cells. It is clear that within the respiratory tract CFTR 
plays a crucial role in maintaining airway health. Patients with cystic fibrosis (CF), a disease in 
which mutations in the CFTR gene results in reduced or absent CFTR function suffer recurrent 
respiratory tract infections leading to chronic airway inflammation and usually terminal lung 
disease. The mechanisms by which impaired CFTR function leaves the CF airway vulnerable to 
infection, and the progression to the subsequent infective and inflammatory lung disease are 
currently incompletely understood. It has recently been proposed that a complex relationship exists 
between CFTR and inflammation, with studies indicating that the relationship is circular: CFTR 
dysfunction results in inflammation and inflammatory mediators lead to impaired CFTR function. A 
better understanding of the link between CFTR dysfunction, inflammation and the progression of 
lung disease could significantly influence the development of novel therapeutic targets for CF. In 
addition there could be consequences for patients with other chronic suppurative lung diseases 
(CSLD), in which CFTR dysfunction secondary to inflammation may contribute to disease 
progression.  
This thesis has explored the complex, possible bi-directional relationship between CFTR protein 
function and markers of disease severity in CSLD in order to better understand how close the 
relationship is between the loss of CFTR function and the pathogenesis of inflammatory airway 
diseases. The introduction will explore what is currently known about why CFTR function is 
important in airway health and introduce the themes that are developed in subsequent chapters.  
 
1.1 Host defence of the lung: an overview 
 
In order to explore the effect of impaired CFTR protein function on the airway, it is necessary to 
understand how the airway protects itself from recurrent exposures to infections, allergens and 
pollutants in the inspired air.  
1.1.1 Innate immune response: 
The lung possesses an array of innate defence mechanisms designed to detect foreign particles 
and remove them from the epithelial surface. First line barriers consist of physical and anatomical 
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mechanisms designed to remove pathogens followed by a vast array of antimicrobial compounds, 
and pathogen receptors to facilitate elimination from the airway.  
1.1.1.1 Mucociliary clearance 
 
The respiratory tract is protected by local mucociliary clearance (MCC), a process considered to be 
fundamental to the airway’s innate defence [1] [2]. The mechanism involves the integration of 
ciliated epithelium, periciliary fluid and mucus, the latter two components constituting the airway 
surface liquid (ASL). The mucus acts as a physical and chemical barrier onto which particles and 
organisms adhere. Once attached, immune cells can act upon the pathogen, assisted by 
antimicrobial peptides, immunoglobulins and proteins. The collection of cells, bacteria and mucus 
is then removed from the airway by ciliary beating and either expectorated by coughing, or 
swallowed [3, 4]. This process is illustrated in Figure 1.1-1.  
 
 
Figure 1.1-1: Diagram of mucus ciliary clearance aiding the elimination of anti-microbial factors in the airway. 
Reproduced from Brodie et al  
 
Ciliated epithelium 
 
Ciliated cells line parts of the nasal cavity, and from the trachea to the termination of the respiratory 
bronchioles, interspersed with mucus secreting goblet cells, serous and club cells. Approximately 
200 motile cilia project from the cell surface; the ciliary beat is regulated by local signaling resulting 
in a rapid and coordinated wavelike movement across the epithelial cells. A description of the 
structure of each individual cilium is covered later in 1.2.1.1.  
 
Epithelial cells first act as a barrier, but are also critically involved in the regulation of both the 
innate and adaptive immune responses. They play a vital role in the recognition of pathogens, and 
antimicrobial responses, partly due to secretion of numerous cytokines, discussed below [5]. 
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Airway surface liquid 
 
The ciliated epithelium is lined with periciliary fluid and mucus [6]. The periciliary liquid layer is 5-10 
microns deep and the volume is tightly regulated by the epithelial cells as it is critical for effective 
ciliary beating [3]. Respiratory mucus consists of ions (1%), protein and glycoproteins (mucins) (2-
3%), and water (95%), and acts as a visco-elastic gel within which enzymes and immunoglobulins 
are found. Mucin is produced from goblet cells and submucosal glands. There are a large number 
of mucin genes, of which at least 12 are expressed in the airway [7]. Once released by the cell, a 
conformational change occurs and the mucin rapidly expands by hydration. Inhaled particles are 
entrapped in the mucus layer by the glycoprotein structure. The consistency of the mucus is tightly 
controlled so as to provide an adhesive but easily transported barrier for pathogens, and is 
dependent on airway salt concentration, osmolality, water content and ASL pH [8] [9].  
 
1.1.1.2 Soluble factors 
 
Epithelial cells and submucosal glands secrete antimicrobial peptides and proteins into the ASL, which 
provide an additional layer of protection against invading microorganisms.  
Table 1.1-1 lists some of the most abundant factors. 
 
Small antimicrobial peptides 
Defensins 
Cathelicidins 
Large antimicrobial peptides 
Lysozyme 
Lactoferrin 
Palate-lung-nasal-clone (PLUNC) 
proteins 
Proteins 
Secretory IgA 
 
Table 1.1-1:  List of some of the most abundant soluble factors [10-12].  
 
The composition of the ASL is critical to the function of these antimicrobials, with studies 
demonstrating that variations in the osmotic and electrolyte balance and ASL pH result in impaired 
antimicrobial activity and ineffective bacterial killing [13-15]. This is covered in detail in 1.2.3.3.  
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1.1.1.3 Pattern recognition receptors  
 
Pathogens are detected in the airway epithelium via pattern-recognition molecules (PRMs); 
epithelial trans-membrane molecules, that bind to pathogen-associated molecular patterns 
(PAMPs) present on the microorganism. Toll-like receptors (TLRs) are a group of proteins that are 
PRMs. They are present on airway epithelial cells and play a critical role in the recognition of 
microorganisms. [16]. TLRs increase transcription factors such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and regulate the expression of a number of genes, including 
those encoding adhesion molecules, antimicrobial peptides, and pro-inflammatory cytokines [17].  
 
1.1.2 Inflammatory response 
 
The inflammatory response is the body’s response to insults including infection and trauma that are 
not eliminated by the primary defence barriers. A complex, finely orchestrated interaction occurs 
between soluble mediators (cytokines) and immune cells to destroy the invading organisms and 
repair the tissue, consisting of 4 stages: initiation, amplification, phagocytosis and resolution. Acute 
inflammation in the airway is essential to protect the organ; however excessive inflammation can 
be harmful and a delicate balance is required.  
 
1.1.2.1 Soluble mediators 
 
Cytokines are secreted polypeptides that are important in cell signaling, and modulating immunity 
and inflammation. Many cell types release cytokines, including epithelial cells and immune cells 
and they function via complex interactions. Table 1.1-2 lists the most important cytokines involved 
in neutrophilic inflammation in the airway. Anti-inflammatory cytokines are crucial to down-regulate 
the response and include interleukins 6 and 10 (IL-6, IL-10), interleukin-1 receptor antagonist 
protein (IRAP), transforming growth factor- β (TGF- β) [18]. 
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Table 1.1-2: Action of the main pro-inflammatory and anti-inflammatory cytokines in the airway [19-21] 
 
1.1.2.2 Immune cells  
 
There are a large number of diverse cells of the immune system, all of which have vital roles in the 
inflammatory response. Amongst these include: 
o Dendritic cells are antigen-presenting cells (APCs), which identify pathogens via PRMs, 
which are ingested and processed. These molecules are subsequently presented to 
resident T cells which induce the immune effector response [18]. 
 
o Macrophages, abundant in the lower airways, phagocytose bacteria and release 
cytokines to recruit neutrophils and other mononuclear cells to the site. They bridge the 
innate and adaptive immune system, acting as APCs. They phagocytose dead cells and 
cellular debris; contributing to resolution of inflammation [22]. 
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o Neutrophils are the first cells to be recruited to a site of injury/ infection when stimulated 
by cytokines, including IL-8 and TNFα, and eliminate microorganisms by both 
phagocytosis and extracellular microbe elimination. When activated neutrophils release 
products (DNA, chromatin and granule proteins) which form a neutrophil extracellular 
traps (NETS) [23] Neutrophils die during the formation of NETS, with the whole process 
known as NETosis [24]. They also release cytokines, which further amplify the 
inflammatory reaction by other cell types. 
The subsequent adaptive immune response includes antigen-specific defence mechanisms and 
takes days to develop. [25].  
 
1.1.2.3 Resolution of inflammation 
 
Resolution is an active process and describes the suppression of inflammatory mediator 
production and removal of acute inflammatory cells, and is an integral part of the physiological 
response to infection and tissue injury [26] [27]. The most important mediators involved in this 
process are listed in Table 1.1-3 
Mediators involved in resolution of inflammation 
T regulatory cells (CD4+CD25+FoxP3+ and CD4+IL-10+ cells) 
Cytokines (IL-10, TGFβ and IL-35) 
Arachidonic acid derived lipid mediators (lipoxins, resolvins, protectins and 
maresins) and other lipids such as ceramide 
Chemerin (a chemottractant protein) and its receptor Chem R23 
Transcription factors (e.g. lung krüppel-like factor) 
Proteins (e.g. annexin A1) 
Cell surface markers (e.g. CD200 / CD200R  - required for macrophage 
immune homeostasis) 
 
Table 1.1-3: List of mediators involved in resolution of inflammation [27, 29-31] 
The innate host defence and the inflammatory response pathways are necessarily complex and 
finely integrated systems designed to protect the airway from invading pathogens, eliminate them 
and restore the lung homeostasis.  
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1.2 Genetic diseases leading to defects in MCC 
 
Genetic diseases affecting either the cilium itself or the ciliary environment, can compromise MCC 
giving rise to recurrent infections, chronic inflammation and subsequent respiratory disease [3]. 
This section describes the inherited condition primary ciliary dyskinesia (PCD) and how defects in 
the ciliary structure lead to the clinical features of the disease. This is followed by an overview of 
CF, and our current understanding of how defective CFTR impairs MCC in addition to other 
proposed mechanisms of how loss of CFTR function contributes to airway disease in CF.  
 
1.2.1 Primary ciliary dyskinesia 
 
PCD is an autosomal recessive disorder of motile cilia, affects up to 1 per 10,000-20,000 births 
(higher in certain ethnic groups) [32, 33]. Mutations in genes encoding proteins involved in the 
biogenesis, structure, and/or function of motile cilia can result in PCD. Motile cilia are present in the 
respiratory tract and elsewhere, therefore PCD manifests as a multi-organ disease.   
 
1.2.1.1 Cilia 
 
Cilia are microscopic hair like structures that protrude from the cell body that are constructed from 
a microtubule cytoskeleton, the axoneme, which is surrounded by a ciliary membrane. There are 3 
main groups: non-motile (primary) cilia which function as sensory organelles and coordinate 
signaling pathways during development and in tissue homeostasis, nodal cilia, which are a unique 
type of motile cilia expressed on the embryonic node and help determine left-right asymmetry of 
the body and motile cilia, discussed below [34] [35] [36].  
 
Motile cilia:  
 
Motile cilia line the surface of the respiratory tract, the female reproductive tract and the cerebral 
ventricles. Figure 1.2-1 illustrates a transverse section of a motile cilium demonstrating the 
longitudinal microtubules arranged as 9 doublets forming an outer circle around a central pair 
(called a 9+2 axoneme). The main structural protein of these doublets is tubulin. The structure is 
maintained by nexin and radial spokes which connect the outer microtubular doublets with a central 
sheath of protein around the central tubules. Inner dynein arms (IDA) and outer dynein arms (ODA) 
are attached to the microtubules and it is the dynein that generates the force for the ciliary beating. 
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The cilium is composed of over 600 proteins in molecular complexes, which combine functions to 
produce the ciliary beat.  
 
The most commonly identified abnormalities in PCD are defects in the cilia ultrastructure; dynein 
arm deficiency (ODA/IDA or both), the central tubules and radial spokes Figure 1.2-1. 
 
 
 
 
Figure 1.2-1: Common ultrastructural defects found in PCD. (A) Normal ciliary ultrastructural cross section 
and Transmission electron micrograph of (B) normal ciliary cross-section (C absent inner dynein arms. (D) 
radial spoke defect. (E) absent central pair found in ciliary transposition defect and central pair agenesis. (F) 
absent inner and outer dynein arms [37]  
 
The genetics of PCD is complex; with over 30 genes now identified. Most of the genes encode for 
proteins in the ciliary axoneme however rarer causes of PCD, where no axoneme ultrastructure 
defect has been identified are also now being classified genetically. Frequently the genetic cause 
of the disorder is unknown [38] [39] [40].  
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1.2.1.2 Clinical features of PCD  
 
Symptoms and diagnosis 
 
PCD manifests in organs in which ciliary motility is a critical component of normal function. It is 
characterised by chronic lung disease, rhinosinusitis, hearing impairment, sub-fertility and organ 
laterality defects; usually situs inversus (around 50% of cases). Kartagener’s syndrome describes 
the combination of dextrocardia, bronchiectasis and sinusitis, with dextrocardia reflecting abnormal 
function of the nodal cilia. Additional features are listed Table 1.2-1[41]. 
 
 
Table 1.2-1: Clinical features of PCD 
 
Patients usually present in the neonatal period with continuous rhinorrhoea, respiratory distress or 
radiographic evidence of dextrocardia; or in childhood with a chronic productive cough, daily 
rhinosinusitis or/and otitis media with effusion [42]. Infrequently a diagnosis is made in adulthood 
following either similar symptoms, investigations for infertility, or following the diagnosis of a family 
member.  
 
Combinations of tests are used to diagnose PCD. Nasal NO (nNO) is usually low in patients with 
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PCD (although the cause is unknown) and is used as sensitive screening tool; although 
occasionally nNO values are low in other conditions therefore it is not used as an isolated 
diagnostic test [43]. Most frequently the ciliary ultrastructure is examined by transmission electron 
microscopy (TEM) on strips of nasal epithelium obtained by brush biopsy, allowing defects to be 
identified. If secondary cilia damage is suspected, ciliated cells can be cultured and re-examined, 
as secondary damage is absent following ciliogenesis in culture [44]. TEM however does not 
provide a definitive diagnosis, as cases of PCD with normal TEM are well described and there is 
currently no ‘gold standard’ [45]. There is ongoing research on new diagnostic techniques including 
immunofluorescence labeling and electron microscopy tomography, in addition to genetic mutation 
analysis [46]. 
 
Inflammation in PCD 
 
Sputum from subjects with PCD is predominantly neutrophilic (median neutrophil differential of 
70%) [47]. Studies have demonstrated comparatively elevated numbers of inflammatory mediators 
(neutrophils, IL-8 and protease concentrations) in PCD sputum and BAL compared with subjects 
with CF of comparable disease severity, both at baseline and during pulmonary exacerbations, in 
addition to comparatively increased IL-8 in the upper airway [48, 49]. Further research is required 
to explore the inflammatory profile of the airways in subjects with PCD both at health and during 
infective exacerbations to better understand how it correlates with disease severity.  
 
Management options in PCD 
 
There are no therapies available that correct ciliary dysfunction, although these are being explored. 
Currently treatment focuses on managing the downstream effects of the disease (Table 1.2-2). 
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Table 1.2-2: List of management options available in PCD [50-53]. 
 
The outcome for patients with PCD is diverse. Most patients live an active life with a normal life 
span, however a minority of patients suffer severe disease, requiring lung transplant, or die 
prematurely due to respiratory failure or cardiac abnormalities [54, 55].  
 
1.2.1.3 Acquired ciliary defects 
 
Ciliary defects may also be acquired secondary to infection, inflammation and pollutants, which are 
localised to the area of insult and are reversible following removal from exposure to the toxin [56]. It 
is essential that these acquired defects are distinguished from PCD. 
 
1.2.2 Comparison of PCD and CF 
 
PCD and CF have many similar characteristics: defective MCC, airway neutrophilic inflammation, 
chronic respiratory infections and deteriorating lung function. They are often clinically managed in 
similar ways, with many of the PCD guidelines being extrapolated from evidence from CF, the 
more prevalent and better-studied disease. There is growing evidence that they should be treated 
as separate entities due to differences in their clinical expression; different radiological distribution 
of disease, inflammatory profile and disease progression [47, 57-59]. It is likely that many factors 
contribute to these differences in disease expression, including the different origin for impaired 
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MCC; a primary defect in PCD, but normal in CF until it is impaired by secondary processes 
(discussed below) [60]. Whilst MCC contributes to lung disease in CF, the role of CFTR in immune 
function is increasingly thought to play a pivotal role in the pathogenesis and account for the faster 
progressing lung disease seen in CF. Comparison of patients with PCD and CF provides a useful 
model to further our understanding of the role of CFTR in disease pathogenesis in CSLD.  
 
1.2.3 Cystic Fibrosis 
CF is the most common lethal autosomal recessive genetic disease in Caucasians, with an 
incidence of 1 in 2000-2500 live births [61].The genetic mutation results in a defect in the CFTR 
protein, which predominantly functions as a cyclic adenosine monophosphate (cAMP) regulated 
chloride ion channel. CFTR is expressed in the apical surface of epithelia and CF is characterised 
by the accumulation of viscous mucus within the exocrine organs, which results in obstruction, 
infection, inflammation and leads to organ failure. Although CF is a multi-organ disease, it is the 
pulmonary manifestations that are the principal cause of morbidity, and responsible for 90% of the 
mortality [62] 
 
1.2.3.1 CFTR  
 
The gene encoding CFTR was discovered in 1989 on chromosome 7q31 [63] [64]. Over 2000 
mutations in the CFTR gene have been described, however to date less than 150 have been 
shown to cause CF [65]. Most mutations are rare, with the exception of the loss of the 
phenylalanine residue at position 508 of the CFTR protein sequence (F508del). Over 70% of 
patients are F508del homozygous and 90% are heterozygous, although the frequency varies 
geographically [66]. CFTR mutations are divided into groups according to the stage of the 
processing of the CFTR protein that the defect arises as illustrated in Figure 1.2-2. Many mutations 
are as yet unclassified as they are extremely rare; a matter that is being address in the CFTR2 
project. 
 
 31 
 
 
Figure 1.2-2: Summary diagram showing classes of CFTR mutations with examples of disease-causing 
mutations, Reproduced from Boyle and De Boeck, 2013 [67] 
 
1.2.3.2 Structure and function of CFTR 
 
The CFTR gene is translated into an amino acid chain in the endoplasmic reticulum, where it is 
processed and folded. Quality control is tightly regulated and misfolded CFTR is degraded. A small 
percentage of normal CFTR moves to the Golgi apparatus for further maturation before trafficking 
to the cell membrane where the final stage of CFTR processing occurs [68, 69]. It is a glycoprotein 
comprised of 1480 amino acids that is bound to the cell membrane and is constructed of 2 
membrane-spanning domains, which form an ion channel, 2 nucleotide binding domains (NBD 1 
and 2) which bind to ATP, and a regulatory domain (R) which regulates CFTR channel opening 
(Figure 1.2-3). 
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Figure 1.2-3: Proposed structure of the CFTR protein demonstrating its function as a chloride ion channel. 
MSD- membrane spanning domain; NBD- nucleotide-binding domain; R (regulatory) domain; Cl- represents a 
chloride ion. Reproduced from Rogan et al [70] 
 
CFTR is part of a multi-protein assembly in the apical plasma membrane and lies close to a 
number of other membrane receptors and ion channels. In addition to facilitating chloride ion 
transport, it is proposed to have multiple other functions listed in Table 1.2-3 [71-73]. Importantly 
CFTR has an inhibitory effect on the neighbouring amiloride-sensitive epithelial Na+ channel 
(ENaC), which results in enhanced absorption of sodium ions by airway epithelium. The exact 
method of the interaction is currently unknown, and is thought to be either a direct interaction via 
the transmembrane domains, or indirectly via loss of CFTR transport regulatory substances, loss of 
chloride transport and/or altered genomic expression.  
 
 
Functions of CFTR protein 
Chloride ion channel 
Pathway for bicarbonate (HCO3), glutathione and thiocyanate 
Inhibits the epithelial sodium channel (ENaC) 
Activates an associated ATP channel 
Sensitises potassium channels to sulfonylurea compounds 
Inhibits volume-regulated anion channels 
Inhibits endogenous calcium-activated chloride currents 
Alters the ion composition of intracelleular compartments 
Regulates intracellular vesicle transport 
 
Table 1.2-3: Some important postulated functions of the CFTR protein 
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1.2.3.3 The role of defective CFTR in the disease pathogenesis  
 
The CF phenotype is complex, even within the same genotype there is a wide variability of disease 
severity, and a broad clinical spectrum over the different organs and tissues involved. The 
mechanism by which impaired CFTR function leads to the subsequent clinical picture is currently 
unknown. Possible theories are discussed below, and are not mutually exclusive.  
 
Impaired CFTR function leads to airway surface dehydration - 'Low volume hypothesis'  
 
The ‘low volume hypothesis’ attributes the initiation of CF airway disease to airway surface 
dehydration. Studies under standard (static) conditions demonstrated that, in CF, excess sodium 
and water is absorbed, and decreased chloride secreted in to the airway. This results in 
dehydration of the airway surface with subsequent collapse of the PCL, and increased 
concentration of mucins within the mucus layer, which adhere to the airway surface [74]. Mucus 
stasis leads to impaired MCC, airflow obstruction and infection. Studies designed to mimic the 
phasic change in calibre of the airway during normal breathing in vivo demonstrated that under 
these conditions CF ion transport was rebalanced and the PCL volume was restored to adequate 
levels for MCC, however following infection, the PCL height again depleted, suggesting that airway 
dehydration in CF appears to occur after an insult to the vulnerable airway [75]. CFTR also 
contributes to mucus hydration, with absent CFTR function, resulting in a reduction in the water 
content of mucus, making it more viscous and difficult to clear. This hypothesis is illustrated in 
Figure 1.2-4 [76, 77].  
 
 
 
Figure 1.2-4: Illustration of the role of the ‘low volume hypothesis’ in disease pathogenesis in CF 1) normal 
ASL hydration in health and 2) the pathological changes occurring in the ASL in the CF airway. Reproduced 
from Althaus, 2013 [78] 
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This model has been supported by in vitro cell culture systems and animal models demonstrating 
that decreased ASL precedes impaired MCC, however human clinical studies are difficult to 
perform, as the volume of ASL is so small, leading to high variability in results due to sampling 
techniques. [79-82]. 
 
Impaired CFTR function leads to alterations in the microenvironment  
 
CFTR in airway epithelia also conducts bicarbonate (HCO3), which regulates the pH of the ASL [4]. 
Loss of CFTR impairs HCO3 secretion and leads to a decrease in ASL pH in preclinical and animal 
models [83]. CF ASL has been shown to have a lower pH than non-CF tracheal ASL from newborn 
pigs [84]. In one small clinical study, this difference appeared to diminish with age, with pH in older 
children and adults with CF comparable to non-CF values. The relevance of this finding to clinical 
CF disease therefore remains to be determined [85]. 
 
Altered ASL pH affects MCC 
 
The composition of ASL in newborn CF pigs has been shown to have an increased viscosity 
compared to non-CF pigs, thought to be due to the altered pH of its environment, as increasing the 
pH of the ASL reduced the overall viscosity [86]. These results were consistent with previous 
groups who had reported that mucins become more viscous at acidic pH [87, 88]. Previous studies 
had demonstrated that CF mucus in newborn pigs was altered compared to healthy controls, and 
remained anchored to the epithelial surface compromising MCC [89]. This was shown to persist 
even when the PCL was adequately hydrated suggesting the mucus abnormality was as a result of 
a reduced pH in the submucosal glands. The combination of more viscous mucins and adherent 
mucus are thought to contribute to airway obstruction and impairment of MCC. 
 
Altered ASL pH affects antimicrobial activity 
 
The antimicrobial products in the ASL have individual and synergistic effects designed to rapidly kill 
bacteria. Studies demonstrated that the reduced pH of ASL in piglets with CF inhibited the 
antimicrobial activity of these factors. Increasing the pH of ASL with the addition of sodium 
bicarbonate onto the airways corrected the bacterial-killing defect. This finding directly links the 
loss of CFTR function to a host-defence defect, which may be a critical step in initiating infection in 
the newborn lung [14].  
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Altered ASL pH affects other aspects of the host defence 
 
Some of the other proposed effects of reduced ASL pH on other components of airway defences are listed in  
Table 1.2-4 [90-94]. It is yet to be established whether normalizing ASL pH e.g. via aerosolised bicarbonate 
has a therapeutic role in CF lung disease [95] 
 
Proposed effects of reduced ASL pH on the airway defence 
Reduced ciliary beat frequency 
Regulation of ASL volume 
Macrophage phagocyte function 
Activation of harmful proteases which are released from over-abundant neutrophils 
 
Table 1.2-4: Proposed effects of reduced ASL pH on the airway defence 
 
Impaired CFTR function in inflammatory cells 
Recent evidence suggests that CFTR is expressed in non-epithelial tissues, including immune 
cells, which may contribute to disease pathogenesis [96]. CF macrophages may have defective 
ability to destroy pathogens, thought to be due to a pathogen–killing defect. The mechanism by 
which defective CFTR compromises pathogen-killing is incompletely understood, and it is likely that 
it may affect a broad range of cellular processes, including inhibiting macrophage activation, and 
altering pathogen recognition and gene expression leading to altered inflammatory signalling [97]. 
It was recently shown that both adhesion and chemotaxis were defective in mononuclear cells 
isolated from patients with CF, although these mechanisms appeared normal in 
polymorphonuclear (PMN) cells in this study. Another study showed significantly higher levels of 
cell surface proteins associated with inflammation on PMN cells of subjects with a single 
Gly551Asp mutation than healthy controls, which normalised following in vivo exposure to ivacaftor 
(discussed below) [98]. 
It has been proposed that CFTR mutation disrupts phagolysosomal function in neutrophils, plays a 
role in early neutrophil development, and alters the distribution of surface TLRs thus compromising 
the innate immune response and dysregulating inflammatory pathways [99-101]. Cells of the 
adaptive immune response, such as T lymphocytes, may also be affected by intrinsic CFTR 
dysfunction, which may lead to impaired ability to efficiently clear pathogens [102]. 
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1.2.3.4 CFTR dysfunction and inflammation in CF 
 
The inflammatory response in the lungs of patients with CF has been shown to be self-
perpetuating. The neutrophils that are recruited in response to infection synthesise an array of 
mediators, oxidants and proteases, which are critical for bacterial killing, and are involved in further 
recruitment of inflammatory cells [103]. Major neutrophil proteases include matrix metalloprotease-
8 and -9, neutrophil elastase (NE), and calprotectin, which have all been found in elevated 
concentrations in the sputum of subjects with CF [104]. This results in a vicious cycle, which 
eventually overwhelms the host defences Illustrated in Figure 1.2-5. When present in excess, 
these mediators and enzymes do not enhance bacterial eradication and clearance, but instead, 
digest structural proteins, weakening the airway structure causing bronchiectasis and contributing 
to the decline in lung function [105, 106].  
 
 
 
 
Figure 1.2-5: Vicious cycle of inflammation. Reproduced from Cole et al,1987 
There is accumulating evidence that the high levels of inflammatory cytokines and neutrophils in 
the CF lung may not be a direct response to the accumulation of CF pathogens and bacterial load, 
but that CF airway epithelia cells have an inherent defect, caused by CFTR dysfunction modifying 
the airway inflammatory response [105, 107-109]. The evidence supporting the presence of 
disproportionately high levels inflammation in the CF airway and the proposed mechanisms are 
covered in Chapter 5.  
 
This section has covered many proposed mechanisms by which defective CFTR is thought to 
affect the immune system, however this list is not all-inclusive and this is a rapidly expanding field 
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of research. A better understanding of these processes is required to move forward with our 
understanding of how CFTR dysfunction results in the clinical features of CF, described below. 
 
 
1.2.3.5 Clinical features of CF 
 
Diagnosis  
 
The diagnosis of CF requires detection of 2 disease causing genetic mutations, and/or evidence of 
CFTR dysfunction. Patients are identified either through the newborn screening (NBS) programme 
or following presentation with characteristic symptoms of the disease. Diagnostic algorithms for 
different presentations of CF have been developed by the European Diagnostic Working Group 
[110]. Sweat test is the most clinically utilised method, and measures the concentration of chloride 
in the sweat, with elevated levels consistent with a diagnosis of CF (>60mmol/L). Following this, 
CFTR mutation screens are performed to detect disease-causing mutations using the standard, or 
extended panel if required. If results are inconclusive, CFTR bioassays, which evaluate the ion 
channel activity are used to look for evidence of CFTR dysfunction, described in 1.3.1.2.  
 
Clinical features  
 
The main clinical features are summarised in Figure 1.2-6 
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Figure 1.2-6: Summary of the manifestations of cystic fibrosis [111] 
 
Pulmonary 
 
Chronic airway infection leads to inflammation, bronchiectasis and eventually respiratory failure. 
The lungs of infants with CF are thought to be normal at birth, but become damaged in early 
childhood [112-114]. Patients characteristically suffer from repeat bacterial infections with common 
organisms such as Haemophilus influenza (HI), Staphylococcus aureus (SA) and Pseudomonas 
aeruginosa (PA). PA is the most predominant airway infection in CF, with studies showing that over 
80% of patients are chronically infected with PA by the age of 18 [115]. Recent studies exploring 
the changes in the airway microbiome in patients with CF changes over time using molecular 
rather than culture based detection methods, reveal it to be more complex than previously thought 
[116] and groups of emerging CF organisms have been identified [117], in particular anaerobes 
[118, 119]. The contribution of the extended CF microbiome to airway disease is currently being 
explored [120]. 
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Pulmonary exacerbations  
 
There is no consensus definition of a pulmonary exacerbation however it is clinically defined by an 
episode combining some or all of cough, increased sputum production, wheeze, breathlessness, a 
fall from baseline lung function and elevated markers of inflammation in the blood [121]. The 
frequency of exacerbations correlates with the severity of lung disease, as patients do not fully 
regain baseline lung function resulting in progressive decline [122, 123]. 
Severity of disease  
 
The severity of CF lung disease clinically is measured most commonly using spirometry, and 
computerized tomography (CT) imaging (described in 1.3.2.1). Spirometry is used longitudinally to 
monitor disease as it has been shown to correlate with disease severity, morbidity and mortality, 
and acutely to guide management [124]. 
Extra pulmonary  
 
15% of infants with CF are born with meconium ileus, caused by inspissated material in the small 
and large bowels. 85-95% of patients develop pancreatic exocrine insufficiency (PI) and require life 
long enzyme and vitamin replacements [125]. Other common complications are as illustrated in 
Figure 1.2-6 
Disease progression  
 
When CF was first described (1938) the life expectancy was short. Following the introduction of 
NBS, the delivering care at specialist centres (MW 103) where patients are treated by a multi-
disciplinary team, and developments in treatments, the prognosis has significantly improved [126]. 
However, patients born today with a diagnosis of CF are only expected to live until an average age 
of mid 40s if female and mid 50s if male without lung transplantation [127].  
 
1.2.3.6 CF Therapies  
 
Current respiratory treatment options:  
 
Treatment strategies in CF currently manage the downstream effects of the disease to preserve 
lung function. Antibiotics, delivered either via nebulizer or dry powder inhaler (directly onto the 
airway) or administered orally or intravenously, form the mainstay of respiratory treatment. In 
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addition, antibiotics are used long-term to suppress bacterial load and as prophylaxis [128, 129]. 
Airway mucus clearance therapies (mucolyics such as Dornase alpha, hypertonic saline and 
mannitol), used in conjunction with physiotherapy, generally result in a modest 3-5% improvement 
in lung function upon initiation, and a reduction in the frequency of pulmonary exacerbations [130]. 
 
Anti-inflammatory therapies have been studied in CF, because the exaggerated inflammatory 
response is tissue-damaging. Oral corticosteroids and non-steroidal anti-inflammatory drugs 
(NSAIDs) had beneficial effects on lung function however the adverse effects are unacceptably 
high [131]. Azithromycin is the only therapy currently used routinely, which is thought in part to act 
as an anti-inflammatory agent however the mechanism of action is unknown [132]. Many of the 
components of the immune response are beneficial and there is a need to preserve these 
protective aspects. A trial in CF of a leukotriene B4 (LTB4) receptor antagonist led to increased 
pulmonary exacerbations in the treatment group, highlighting the balance of pro and anti-
inflammatory mediators in maintaining tissue homeostasis [133].  
 
Nutrition:  
 
Maintaining adequate nutrition with pancreatic enzymes, fat-soluble vitamins and a good calorie 
intake is essential, as optimal BMI has been associated with less severe disease. Impaired 
glycaemic control accelerates deterioration in lung function, and improved glycaemic control has 
been shown to increase long-term survival and lung health [134-136].  
 
Other disease manifestations are managed symptomatically as required. Genetic counseling and 
psychological support is essential, as is appropriate preparation for lung transplant or palliative 
management of end stage CF lung disease when required. 
 
1.2.3.7 Novel therapies 
 
Developments in the understanding of the genetics and molecular mechanisms of CF have led to 
new therapeutic targets, which aim to correct the basic defect itself by either modulating CFTR with 
small molecules, or by introducing a functional copy of the CFTR gene into the epithelial cells using 
gene therapy. This is a rapidly evolving area of research, which has progressed since this thesis 
was commenced in 2012. This section describes CFTR modulators whilst gene therapy, a major 
focus of this thesis is discussed in Chapter 3.  
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CFTR modulators 
 
These drugs are broadly divided into 3 types; read through drugs, correctors and potentiators.  
 
Read through drugs 
These target Class I mutations, which contain a premature termination codon (PTC), aiming to 
allow the ribosome to ‘skip’ the premature stop codon (but not the physiological stop signals) 
leading to a full-length stable and functional protein. Initial trials of ‘read through’ drugs focused on 
the therapeutic effects of aminoglycosides however results were mixed, and due to the potential 
side effects alternative agents were sought [137, 138]. Ataluren (PTC124) is the most promising 
agent to date, however, despite promising phase II results, the first phase III trial did not 
demonstrate any clinical efficacy and trials are on-going (ClinicalTrials.gov ID NCT02107859) 
[139].  
 
Correctors  
 
Correctors aim to address the mis-folding steps that occur in the production of CFTR in class II 
mutations, to produce a structurally normal protein that can traffic to the apical cell surface. The 
most studied corrector, lumacaftor (VX-809), improved chloride function in F508del cells in vitro, 
however in vivo resulted in only a small difference in sweat chloride with no clinical improvement 
identified [140]. The combination of lumacaftor with ivacaftor has been assessed in 2 large phase 
III trials, [141, 142] demonstrating a small but significant improvement in FEV1 (2.8-3.3% predicted 
compared to placebo) and a reduction in pulmonary exacerbations, leading to both FDA and EMA 
approval of a single-pill combination of lumacaftor/ivacaftor (Orkambi) for patients who are F508del 
homozygous, aged >12 years in July 2015, although NICE have currently not given approval. It 
does not benefit patients with a single F508del mutation. Alternative correctors are being 
developed such as VX-661, which are thought to be more effective and following successful phase 
II trials, and patients are being recruited into phase III trials [143].  
 
Potentiators 
 
Potentiators target CFTR present on the cell surface, increasing the channel open probability. The 
initial target was ‘gating’ mutations (class III) in which correctly-localised CFTR protein 
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demonstrates significantly reduced time open in response to intracellular signals, reducing trans-
epithelial ion transport. The most successful potentiator to date is VX-770, (ivacaftor), which was 
the first therapeutic registered as a CFTR modulator. Ivacaftor increases the probability of opening 
the CFTR protein via a non-PKA-dependent pathway, both in WT and many CFTR mutations. 
Trials focused initially on subjects with at least one Gly551Asp mutation as it is the most common 
class III mutation (approximately 4% of the CF population in Europe) [144]. The exact mechanism 
by which ivacaftor improves channel opening is unclear, but is thought to be secondary to ivacaftor 
stabilising the post hydrolytic open state of CFTR [145]. 
 
The first clinical trial in 2010, which was a phase II randomised control trial (RCT), established the 
safety of orally administered ivacaftor BD [146]. Secondary outcome measures demonstrated 
restoration of CFTR chloride transport with sweat chloride decreasing (towards normal) by 
(median) -59.5 mmol (range -66 to -19), and a modest increase in chloride transport measured by 
NPD of (median) -3.5mV (range -8.3 to 0.5). In the phase III RCT, subjects with CF, carrying at 
least one copy of the mutation Gly551Asp, aged >12, and FEV1 between 40% and 90% were 
randomised to receive 150mg BD of Ivacaftor (n=84) or placebo (n=84) [147]. Active patients had 
improvements in absolute FEV1 of 10.4% compared to a decline of 0.2% in the placebo group 
(p<0.001) (Figure 1.2-7 a), which were sustained through the 48 weeks of the trial. Secondary 
outcomes were also overwhelmingly positive: demonstrating decreased pulmonary exacerbations 
(p=0.001), improved quality of life (p<0.001) and improved weight (p<0.001) in active patients 
compared to placebo. Sweat chloride measurements decreased, with an average reduction in 
sweat chloride level to below the threshold for the diagnosis of CF into the equivocal range (Figure 
1.2-7 b). 
 
Figure 1.2-7: Changes in outcome measures following treatment with ivacaftor a) the absolute mean change 
from baseline in percent of predicted FEV1, through to week 48 b) the mean change from baseline in the 
concentration of sweat chloride. The values and 95% confidence intervals (indicated by I bars) in both panels 
are unadjusted. The first data points in both panels are baseline data. Reproduced from Ramsey et al 2011 
[147] 
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These results were replicated in the 6-11 years age group and further trials (PERSIST) 
demonstrated that safety and efficacy were sustained longer-term, over 144 weeks [148]. In 
January 2012 the US FDA approved the registration of ivacaftor for patients with CF, aged > 6 
years carrying at least one copy of the Gly551Asp gene mutation and the European Commission 
approved the drug in 2012. Regulatory approval has since been extended to children aged 2-5 
years of age after trials demonstrated its’ safety in this age group, although reimbursement has not 
yet been approved in the UK [149].  
The use of ivacaftor beyond patients with Gly551Asp has been evaluated with the KONNECTION 
trial leading to FDA approval for patients with a wider range of mutations, including class IV [150, 
151]. Other agents are under development by different companies including Galapagos, who have 
performed a phase I trial with a CFTR potentiator (GLPG1837) and Concert Pharmaceuticals who 
have commenced a phase I trial of deuterated ivacaftor [152] [153] 
 
Relationship between restoration of CFTR function and outcome measures of airway disease 
 
Attempts have been made to correlate the restoration of CFTR function with ivacaftor with markers 
of airway disease to help guide the development of therapies aiming to improve airway disease by 
specifically targeting the relevant CFTR function. Although ivacaftor led to a dose dependent 
change in sweat chloride concentration, the decrease was shown not to correlate with 
improvement in FEV1 or with improvement in LCI, although the latter has only been explored in 
patients with mild lung disease [154-156].  
 
The impact of ivacaftor on clinically relevant markers in CF subjects, including respiratory 
pathogens and airway inflammation, has been assessed in the GOAL study, a longitudinal cohort 
study of 151 patients eligible to commence ivacaftor [157].  Sputum samples were analysed for NE 
activity, α1-antitrypsin, secretory leukoprotease inhibitor, IL-1β, IL-6, and IL-8, revealing no 
significant change over 6 months. There was a significant reduction in sputum culture positivity for 
PA, but not other common CF pathogens, which was replicated when subjects were followed up at 
2 years. This may be due to direct interaction between CFTR and PA or due to downstream effects 
of improved MCC. The reduction in PA was not associated with change in FEV1, BMI or 
hospitalisations, however long-term follow up is being performed [158]. Muciliary and cough 
clearance were assessed using γ scintigraphy in a subset of patients, which demonstrated 
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substantially improved MCC. In a small study, ivacaftor was shown to result in a reduction in CRP, 
however other serum markers of systemic inflammation were not assessed [159]. 
 
Studies observing the effect of ivacaftor on innate immunity demonstrated that Gly551Asp mutation 
had a significantly higher expression of pro-inflammatory surface proteins on neutrophils and 
monocytes, which was normalized both by in vivo ivacaftor treatment and ex vivo exposure of 
blood cells to ivacaftor [98]. In addition, treatment of Gly551Asp patients with ivacaftor has been 
shown to normalise neutrophil cytosolic sodium, chloride and magnesium ion levels, thus improving 
degranulation and bacterial killing [160]. These findings suggest CFTR modulators modify host 
defence cells, which may contribute to the change in clinical picture demonstrated in patients on 
treatment.  
 
These results are interesting as they enhance our understanding of the relationship between CFTR 
function, and restoration of ion channel function and elements of airway disease, although longer-
term follow-up is required. The lack of a direct correlation between CFTR markers and disease 
outcome measures suggest either that the outcome measures used are too insensitive, or that the 
relationship between chloride ion transport and disease status is complex.  
 
 
1.2.4 Acquired CFTR dysfunction   
 
There has been emerging evidence that external mediators may have an affect on trans-epithelial 
ion transport, causing ‘acquired’ CFTR dysfunction. This is a relatively unexplored field, with only a 
few studies to date exploring this theory, which are reviewed below.   
 
1.2.4.1 Inflammatory mediators 
 
The first of these studies looked at the effect of IFN-γ and TNF-α on sodium and chloride ion 
channel function in CF and non-CF human bronchial epithelial cells (HBECs) using an Ussing 
Chamber [161]. The results demonstrated that in both cell types IFN-γ decreased CFTR-related ion 
transport, and surprisingly down regulated ENaC and up regulated Ca2+ dependent Cl-, thought to 
suggest that it has a specific modulatory effect rather than causing generalised ion transport 
defects. This indicates that the up regulation of ENaC in CF may be influenced by factors other 
than its interaction with CFTR. The effect of ion channel dysfunction following IFN-γ in vivo on ASL 
volume and subsequently the effects on MCC are currently unknown. Similar results were not 
demonstrated following the application of TNF-α, which the authors hypothesised may be due to 
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the different signaling pathways involved. 
 
Neutrophil elastase (NE) is a serine proteinase, released by neutrophils, which can contribute to 
proteolytic lung damage when present in excess, and has been shown to degrade cell-surface 
molecules including ENaC [162]. In vivo studies, measuring CFTR function using nasal potential 
difference measurements (NPD) in murine epithelium following 7 days of exposure to NE 
compared to controls revealed reduced chloride secretion, reflecting CFTR inhibition in those 
treated with NE. These results were repeatable in the presence of PA, and were dependent on NE, 
as CFTR degradation was spared in mice that were unable to produce NE [162]. A possible 
mechanism for the role of NE in affecting ion-transport is via its interaction with the SPLUNC1 
pathway [163]. SPLUNC1 is an extracellular protein that is present in the ASL and is thought to 
modulate ENaC activity by protecting it from proteolytic cleavage, in order to regulate airway 
hydration and mucus clearance. Studies have indicated that in health inflammatory mediators, in 
particular IL-8, upregulate SPLUNC1 secretion, subsequently decreasing ENaC activity and 
enhancing mucus clearance [164]. Studies indicate that NE can cleave the inhibitory domain of 
SPLUNC1 from the parent molecule, thus increasing its activity during inflammation [165]. 
 
1.2.4.2 Infective microbes 
 
Other studies have explored the interaction between CFTR and the infective microbes themselves, 
focusing on PA as it is the most abundant pathogen in patients with CF. In vitro studies 
demonstrated that non-CF and CF cells exposed to PA had reduced chloride secretion, thought to 
be due to inhibition of endocytic recycling of CFTR due to a factor secreted by PA, termed CFTR 
inhibitory factor (cif) that is capable of reducing apical membrane expression. Cif has been shown 
to be an epoxide hydrolase enzyme, which is released by PA in the airways into outer membrane 
vesicles and directly secreted into the ASL. When it enters the host epithelial cell, it is thought to 
diffuse to the cytoplasm and interact with the proteins involved in the final stages of the CFTR 
recycling process and instead of the recycled CFTR protein reaching the apical cell membrane it is 
instead degraded by the lysosome, thus decreasing cell surface expression. The resultant loss of 
chloride secretion and increased sodium absorption result in a reduction in ASL height and 
ciliostasis (1.2.3.3), and establish an environment in which PA infection becomes chronic [166].   
  
1.2.4.3 Other Respiratory diseases 
 
Currently, most work exploring acquired CFTR dysfunction in other respiratory diseases has 
focused on chronic obstructive pulmonary disease (COPD) due to its high prevalence, and its 
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many shared characteristic features with CF, including: reduced MCC, chronic neutrophilic airway 
inflammation and chronic bacterial infections. The epithelial effects of cigarette smoke (CS) 
contribute to the lung pathology in COPD, although other pollutants and infective agents are known 
to both initiate and contribute to disease progression; the full mechanisms of pathogenesis remain 
incompletely understood [167]. Studies have been designed to evaluate the effect of CS on CFTR 
function in patients with bronchitis and COPD.  
  
In vitro studies have consistently shown an effect of CS on CFTR. The results from a range of 
studies have demonstrated decreased levels of CFTR protein and reduced protein function thought 
to be caused by CS inducing rapid internalisation of the CFTR protein, resulting in decreased ASL 
height, which affects MCC and mucus secretion [168] [169]. The reduction in ASL height was 
reversed on addition of hypertonic saline. 
 
Experiments performed in vivo using NPD evaluated the level of CFTR function in smokers, 
patients with COPD and healthy controls demonstrating reduced chloride secretion in the nasal 
epithelium of non-CF subjects who smoked, when compared to healthy non-smokers [168]. Further 
studies have shown a large, acute, CS induced inhibition of chloride secretion following exposure 
of CS to the nasal epithelium of healthy ex-smokers who exhibited previously normal CFTR 
function [169]. A larger study showed that smokers either with, or without clinical symptoms of 
COPD had reduced CFTR activity measured by NPD compared to age-matched non-smokers, and 
the reduction in CFTR activity was associated with symptoms of chronic bronchitis [170]. A single 
study determined CFTR function in the lower airways, using lower airway potential difference 
(LAPD) measurements in healthy non-smokers, current smokers and former smokers with COPD. 
The results suggested reduced lower airway CFTR activity in smokers with and without COPD 
compared to healthy non-smokers [171]. Furthermore, recent data have demonstrated that CS 
reduces CFTR function at extra-pulmonary sites; with smokers and subjects with COPD having 
elevated sweat chloride values compared to controls, and decreased CFTR function in intestinal 
current measurements. This suggests that CS may cause systemic CFTR dysfunction. It is thought 
that acrolein, a bioactive component of cigarette smoke, may be a causative agent, as in vitro 
studies performed by the same group showed it to be a potent CFTR inhibitor; however it is 
possible that other agents present in CS may contribute [172]. A better understanding of acrolein 
and the mechanism of CS mediated CFTR dysfunction may reveal new therapeutic targets for 
subjects with COPD to alleviate both respiratory and systemic symptoms. 
1.2.4.4 Summary 
 
Collectively, these results suggest that external factors may cause an acquired dysfunction in 
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CFTR. If shown to be the case, this would have important implications. In the subset of CF patients 
who demonstrate residual chloride secreting capacity, the inflammatory markers may inhibit the 
residual CFTR function, thus eliminating any protective mechanisms that this may provide [173]. 
Novel treatments in CF aiming to restore CFTR function may have reduced success in the 
presence of chronic inflammation and/ or PA infection. Beyond CF, in other respiratory conditions 
in which there is a similar inflammatory profile, such as other CSLD, including PCD the presence of 
abnormal ion transport may contribute to the burden of disease. Therapies designed to restore 
CFTR function in CF may also be utilized in a wider population of patients. This has been explored 
in vitro but has not yet been studied in vivo to determine the potential benefit in patients with other 
respiratory diseases [170]. 
 
1.3 Outcome measures  
 
Outcome measures are required to assess the effects of defective CFTR on airway health. These 
must differentiate patients from healthy controls, be easy and safe to make over a range of disease 
severity, correlate with existing outcome measures and change with the clinical status of the 
patient. The following sections provide an overview of methods to measure CFTR and disease 
severity, and their uses and limitations. Finally there will be a review of previous attempts to 
correlate the measures of CFTR function with disease severity. 
 
1.3.1 Measurement of CFTR 
 
CFTR biomarkers either detect and quantify the amount of protein in the epithelial tissue, or 
measure its function as a trans-epithelial ion channel. Measurements of CFTR are used to help 
establish a diagnosis of CF, as an outcome measure in clinical trials for therapies aiming to restore 
CFTR function as evidence of efficacy, and as research tools.  
 
1.3.1.1 Quantitative assays of CFTR 
 
These assays are exclusively used as a research tool, and are relevant for interventions that aim to 
increase the quantity of CFTR protein in the cell membrane. Technologies, including TaqMan® 
Assays, detect both plasmid vector-derived and endogenous CFTR-DNA and mRNA. Vector-DNA 
in the target area demonstrates successful delivery of the product, whereas mRNA indicates 
successful transfection. The TaqMan probe is a hydrolysis probe designed to increase the 
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specificity of quantitative polymerase chain reaction (PCR). The probe attaches to a DNA region 
amplified by a specific primer, and extends to synthesise a nascent strand. When the probe 
releases flurophore, it is detected by a quantitative thermal cycler and the fluorescence is directly 
proportional to the amount of DNA template present in the PCR.  
 
Other possible methods to quantify CFTR expression include immunohistochemical techniques, 
however their use have been limited due to the low abundance of CFTR protein and the low 
sensitivity of anti-CFTR antibodies [174]. The presence of mRNA may not correspond with the level 
of function of the protein, and quantitative assays should be used in conjunction with functional 
assays in the assessment of CFTR correction in the airways [175].  
 
1.3.1.2 Functional assays of CFTR 
 
CFTR function can be measured from the epithelial tissue in any organ in which it is expressed, 
either in vitro or in vivo. In vitro methods listed in Table 1.3-1, and in vivo methods described in the 
upcoming section. Extra detail is provided for airway potential difference measurements in the 
nasal and lower airway epithelium as this is of particular relevance to the thesis.  
 
Tissue  CFTR measurement 
Single ion channel or cell Patch clamp - measures voltage across the cell membrane. Predominantly a research tool 
Monolayer/ tissue biopsies 
Ussing Chamber - measures net ion transport by measurement 
of the voltage across the epithelial surface. Used clinically to 
measure ICM on rectal biopsies 
Organoids  
 
 
Measurement of the change in organoid size following exposure 
to forskolin (a CFTR stimulator).  
 
These are a developing research tool 
 
Table 1.3-1: In vitro measurements of CFTR function [176-179] 
 
In vivo measurements of CFTR function: 
 
Sweat test 
 
Sweat tests were developed in 1959 after the observation that patients with CF had salty sweat 
and suffered from episodes of hyponatraemic dehydration [180]. In health, as sweat is conducted 
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towards the epithelial surface, sodium and chloride are reabsorbed. In CF, with impaired CFTR 
function, there is a failure of ion reabsorption in the water impermeable duct, resulting in a higher 
concentration of both sodium and chloride ions in the sweat [181, 182]. To perform a sweat test, 
sweat production is stimulated by pilocarpine iontophoresis, collected, and the concentration of 
chloride in the sample is measured. The chloride level is therefore utilised as a surrogate marker 
for CFTR dysfunction in the sweat ducts.  
 
Sweat testing is the main diagnostic test for CF, with studies clearly demonstrating the validity of 
measurements in discriminating between patients with CF and non-CF subjects [183]. A recent 
study looking at the variability of sweat chloride in CF subjects with Gly551Asp showed the 
between-subject standard deviation (SD) for sweat chloride was 8.9mmol/L (95% CI 7.4-10.6) and 
within-subject SD was 8.1mmol/L (95% CI 7.5-8.7) [184]. When standardised procedures are 
implemented, sweat chloride is a useful biomarker in multicenter trials evaluating CFTR 
potentiators, and it has been used as a major outcome measure in several large phase III clinical 
trials [154, 185]. Currently, the quantity of change in sweat chloride required to produce a clinical 
difference is unknown, and its use as an ongoing surrogate measure of clinical response to CFTR 
modulators is being explored [186]. 
 
Measurement of transepithelial potential difference 
 
CFTR regulates ion movement across the cell wall, promoting chloride secretion, and inhibiting 
sodium influx via ENaC. This trans-epithelial ion movement creates a potential difference (PD) 
across the cell wall, which is altered in the presence of CFTR dysfunction. PD measurements are 
electrophysiological tests designed to measure the PD in vivo between airway epithelium and a 
subcutaneous electrode. Measurements assess both chloride channel function and ENaC function 
independently, allowing real-time evaluation of CFTR and ENaC activity. Measurements can be 
taken from the nasal epithelium (nasal potential difference (NPD)), and the lower airway mucosa 
(LAPD). 
 
Nasal potential difference  
 
A catheter is placed against the nasal epithelium and measures the change in PD in response to 
the infusion of 4 solutions onto the mucosa:  
 
1. The basal PD following the perfusion of a physiological solution (typically Ringers solution),  
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2. The change in PD following the perfusion of a solution containing Ringers and amiloride (RA) 
(which blocks sodium channels in vivo). In the subsequent solutions, amiloride is present to 
maintain ENaC blockade throughout 
 
3. Passive chloride conductance (ie, through open channels; not specific to CFTR) generated 
by exposing the cell surface to a chloride free solution (zero chloride (ZCl)) in the presence 
of amiloride (ZClA) thus creating an electrochemical gradient  
 
4. Active chloride conductance in response to chloride free solution with the addition of 
isoprenaline (ZClA), a potent cAMP agonist; this opens CFTR and is therefore considered a 
more specific test of CFTR function. In practice, steps 3 and 4 are usually summed (total 
chloride secretion).  
 
Patients with altered/dysfunctional CFTR function (CF) have a characteristic response to these 
solutions. The increased sodium absorption is reflected by a hyperpolarized (more negative) basal 
PD measurement. Following perfusion with amiloride there is a larger change in voltage towards 
zero, demonstrating the inhibition of ENaC. There is reduced or absent re-polarisation in response 
to both solutions promoting chloride efflux. Figure 1.3-1 shows a PD trace obtained from a healthy 
control and a typical patient with CF respectively. Abnormal chloride transport is generally 
accepted as an NPD total response of less than -5mV to both ZCl solutions [187]. 
 
 
 
Figure 1.3-1: Examples of nasal potential difference traces from a) a healthy control and b) a CF patient. 
Phases of the NPD perfusion are labelled; Ringers, Ringers Amiloride (RA), Zero chloride/amiloride (ZClA) 
and zero chloride amiloride + isoprenaline (ZClA) 
 
Nasal epithelium is commonly used as a surrogate for the lower airway as it is more accessible. 
NPD has been shown to have strong discrimination validity between CF subjects and controls and 
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is used to aid the diagnosis of CF in borderline cases [110] [188]. In addition, NPD has been used 
as a research tool to detect restoration of CFTR function including trials assessing efficacy of 
CFTR modulators and in gene therapy however currently the minimal change NPD associated with 
clinical improvement still needs to be determined [137, 146, 189].   
 
 
Limitations of nasal PD 
 
An experienced operator and specialist equipment are required, the procedure can be time 
consuming and is technically challenging. There is often significant within subject variability of 
values, with the coefficient of variation (CV) of basal PD measurements recorded as 13 and 14%, 
the amiloride phase CV 33%, and even greater in the chloride response [190, 191]. There is 
inherent physiological variation, with CFTR expression not a static process however PD 
measurements are also affected by non-specific tissue damage e.g. nasal inflammation (secondary 
to rhinosinusitis), polyps and scarring. The epithelial damage results in a ‘blunted’ trace with a 
lower (less negative) basal value and reduced amiloride and chloride response [192].To minimise 
operator and inter-centre variability (important for multi-centre trials) standard operating procedures 
(SOPs) have been developed by the European Cystic Fibrosis Society (ECFS) Diagnostic Network 
Working Group to help standardise the procedure [193].  
 
 
Lower airway potential difference 
 
The lower airway manifests the majority of disease, and CFTR function in the bronchial epithelium 
may be more relevant clinically. LAPD measurements use a modified method to that used in the 
upper airway [194]. The technique is performed by inserting a single lumen catheter down the 
channel of a bronchoscope, which is used to both perfuse solutions and record measurements and 
can be used to  
 
The amiloride phase is omitted as the solution would pool in the lower airways and affect 
subsequent measurements. Basal measurements are taken in the proximal lower airway (level of 
the carina) and the basal PD, and the response to perfusion of ZCl/Iso, is measured typically in 3 
different areas in the distal airway (approximately 5th generation). Figure 1.3-2 demonstrates a 
LAPD trace obtained from a control and a patient with CF respectively, with reduced chloride 
secretion demonstrated in the CF patients. 
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Figure 1.3-2: LAPD measurements in a 3rd generation airway demonstrating chloride secretion in response to 
a zero chloride (ZCl) solution in CF children and non-CF children during 3 minutes (p<0.001). Reproduced 
from Davies et al 2005 [195] 
 
LAPD has been shown to successfully discriminate between subjects with and without CF including 
children [195]. As LAPD is more invasive than NPD, it is performed much less frequently and is 
used entirely in a research setting. It has been developed as an outcome measure for gene 
therapy trials described in Chapter 3 and 4, and was used in a study to explore CFTR function in 
COPD (Section 1.2.4.3). 
 
 
Limitations to Lower airway PD 
 
Measurements require anaesthesia and bronchoscopy and are therefore associated with increased 
risk and complications. The technical difficulties associated with the procedure set up will be 
discussed in Section 2.2.8.2. The procedure takes longer to perform than NPD, and the 
environment (in operating theatres) results in more electrical interference. In addition, lower airway 
mucus and secretions obstruct the contact between the catheter and the cell surface, interfering 
with the measurements. There are limited data on the variability of LAPD measurements and how 
they change in the presence of disease. A major limitation of this technique is the lack of amiloride 
perfusion stage in this procedure, which decreases the ability to monitor ENaC function, although 
the baseline PD provides some information.  
 
Currently there is little evidence comparing NPD results with those obtained using LAPD 
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techniques in the same subjects. This is currently being addressed by Dr Michael Waller in his PhD 
thesis [196]. 
 
1.3.2 Measurements of airway disease and inflammation 
 
There has always been a clinical need to detect both acute and chronic changes in CF lung 
disease; to allow for appropriate and timely medical interventions, to provide a means to evaluate 
therapeutic success, including medications acting directly on the CFTR protein, and to monitor 
disease progression longitudinally. CF outcomes have improved over recent years and as a result, 
more sensitive biomarkers are required, particularly in the children and for those with mild lung 
disease.  
 
The downstream effects of CFTR dysfunction include infection, inflammation and subsequent lung 
damage and methods to quantify these effects have been developed. The most obvious limitation 
of these downstream measures is that they are not specific to CFTR dysfunction. The following 
section provides an overview of the most important outcome measures currently used divided into; 
physiological, structural (radiographic) and measures of inflammation.  
 
1.3.2.1 Physiological outcome measures 
 
Measures derived from spirometry 
 
Forced expiratory volume in the 1st second (FEV1) is the most commonly used measure derived 
from spirometry and is currently the ‘gold standard’ measurement of lung damage in CF and other 
respiratory diseases; used in both clinical practice and research trials. Spirometry is quick, easy to 
perform, non-invasive and does not require specialist equipment or operators. Large cross 
sectional and longitudinal studies have generated ‘normal’ values allowing function to be 
evaluated. FEV1 is thought to mainly reflect pathology in the upper, larger airways, and is 
insensitive to distal airway disease.  
Other measures derived from spirometry are also commonly used to assess lung disease in 
patients with CF. Forced expiratory flow at low lung volumes, most usually 25-75% of FVC (FEF25-75) 
are thought be a more sensitive than FEV1 in the detection of obstructive small airway disease 
[197]. Spirometry is difficult to perform in young children, as it requires co-operation and the 
success of the procedure can be variable, particularly in the pre-school age group. [198].  
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FEV1 is currently the only primary pulmonary endpoint recommended by the European Medicines 
Agency for CF clinical trials [199]. However, although it is useful in advanced disease states, it has 
long been recognised as insensitive to detect early and mild disease with the mean rate of decline 
measured to be about 2% predicted per year [200]. New outcome measures are required for 
clinical monitoring and trial outcomes for patients with mild pathology, especially children.  
 
 
Multiple breath washout tests and derived measures  
 
Multiple breath washout (MBW) has been performed for over 50 years and involves monitoring a 
tracer gas as it is washed out of the lungs during tidal breathing [201]. The gas can be exogenous 
and inhaled into the lungs to equilibrium prior to washout commencing, or may be endogenous 
nitrogen that is normally resident in the lungs, which is washed out following the inhalation of 100% 
oxygen. With each successive breath of the washout there is a fall in the peak concentration of the 
tracer gas, Figure 1.3-3. 
 
 
 
 
Figure 1.3-3: Typical washout tracing in a healthy subject. Flow is shown in the upper trace with the scale on 
the y axis. Tracer gas (0.2% SF6) concentration is shown in the lower trace. Reproduced from Horsley et al 
2009.  
 
Lung clearance index 
 
Lung clearance index (LCI) is the most commonly used parameter derived from MBW tests. It is 
used to detect gas mixing efficiency and is defined as: the number of resting functional residual 
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capacity (FRC) turnovers (TO) required to wash out the tracer gas, with tidal breathing from 
equilibrium to a pre-defined end point. LCI is therefore calculated from the total volume of air 
breathed out known as the cumulative expired volume (CEV) during the washout divided by the 
FRC. 
 
Lung clearance index (LCI)    =    Cumulative Expired Volume (CEV) 
                                                     Functional Residual Capacity (FRC) 
 
Conventionally, the end point is where the end-tidal concentration reaches 1/40th of the initial 
concentration as this represented the limits of the original N2 analysers. When there is airway 
disease resulting from mucus retention, inflammation and patchy obstruction, a greater number of 
breaths are required to eliminate the gas, resulting in a higher LCI. LCI measures overall ventilation 
heterogeneity and is thus thought better to reflect airway disease in the small airways better than 
FEV1. 
 
MBW requires only passive cooperation and can therefore be achieved in young and unwell 
subjects. It is a safe and non-invasive outcome measure and is a repeatable and reliable marker of 
airway damage [202]. The intra-visit repeatability CV is between 3 and 8% [203] [204], with mean 
inter-visit reproducibility of 0.6u (measurements approximately 10 days apart) in healthy adults 
[203], and a CV of up to 9% in subjects with CF. LCI is increased in CF patients compared to 
healthy controls [205] from as early as 10 weeks of age up to adulthood [206], and correlates both 
with structural lung changes [207] and other markers of inflammation [208]. Most significantly, LCI 
has been shown to be more sensitive to CF lung disease than standard spirometry (FEV1), with 
abnormal results in patients with normal spirometry and lung volumes, providing an opportunity to 
detect early airway dysfunction in what was previously considered the ‘silent years’ in pre-school 
children and in subjects with mild disease [209-212].  
 
Use of LCI in clinical care and research   
 
Recent studies have shown that LCI is dependent on both age and height, principally in the first 5 
years of life [205]. It is important that dead space is minimised. A correction factor has been 
suggested to adjust for dead space although more studies are required to assess whether this is 
useful [213]. From aged 6 and above LCI is a useful tool for tracking disease progression and is 
being increasingly used in specialist respiratory centres. No trial of LCI-guided decision-making 
has yet been conducted however.  
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Studies exploring the role of LCI in evaluating the effectiveness of short-term interventions have 
produced inconsistent and variable results, including with chest physiotherapy and iv antibiotics 
[214] [215-217]. A possible explanation is that interventions that cause movement of mucus may 
either result in recruitment of additional lung units not previously contributing to the MBW, or 
blockage of other lung units, leading to variable changes in LCI. LCI should be viewed in 
combination with standard lung function and interpreted within the clinical setting [218]. 
 
LCI has been used as an outcome measure in a small number of clinical trials for mucus clearance 
agents, demonstrating a significant treatment effect and supporting its use as an outcome measure 
[219, 220]. More recently, LCI has been used to explore the effect of novel therapies in CF on 
airway dysfunction [156]. To date, the minimal change in LCI considered to be clinically significant 
is unknown, but if the measurement is to be useful, it must be larger than the difference seen 
between repeat measurements without intervention and no change in clinical status.  
 
Limitations of MBW techniques 
 
MBW requires expensive equipment and an experienced operator to perform and analyse the 
measurements. It is necessary for centres to align methods according to published consensus 
guidelines as different machines and analysis packages are not interchangeable [221] [222]. 
Measurements can be time consuming, particularly if performed on patients with severe lung 
disease. To date, much of the research surrounding LCI has focused on subjects with mild lung 
disease and relatively preserved lung function and its use in detecting and monitoring disease 
changes in subjects with a wider range of disease severity is yet to be established.  
 
 
1.3.2.2 Radiographic outcome measures 
 
Plain x-ray 
 
Plain x-ray is of limited value in the diagnosis of bronchiectasis and has been shown to have a 
sensitivity of only 37% [223].It is not a viable option for monitoring subtle changes in disease 
activity, although it can be useful in the event of acute deterioration.  
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High Resolution Computed Tomography (HRCT) Scans  
 
HRCT imaging of the chest provides structural information and has a sensitivity of 97% for the 
diagnosis of bronchiectasis [224]. Early manifestation of CF lung disease includes the presence of 
regional air trapping and increased bronchial wall thickness progressing to bronchiectasis, mucus 
plugging and progressive lung pathology. Scoring systems have been developed to standardise 
the interpretation of the images thus increasing their utility as an outcome measurement [225]. 
HRCT scans are more sensitive than other measures in monitoring disease progression, although 
this is limited in patients <1 year old, as CT changes during this period may be minimal [226, 227]. 
 
The major limitation of HRCT in routine monitoring of patients is the radiation exposure, which may 
be associated with a radiation-induced risk of cancer [228]. Recent developments have led to 
protocols in which the dose is reduced by 40-50%, however these are not always available, and 
significant doses of radiation are still involved [229]. To date no study has demonstrated that 
regular HRCT improves clinical outcomes in CF. 
 
MRI, which is a radiation-free imaging technique, has been shown to sensitively detect CF lung 
disease (structure and function), even in pre-school children, and detect changes associated with 
pulmonary exacerbations. Following recent technical advances it is emerging as a tool for non-
invasive monitoring of disease [230]. 
 
 
1.3.2.3 Markers of inflammation 
 
Inflammatory markers are measured both systemically in the blood and more locally in the sputum, 
obtained via induced or spontaneous expectoration of sputum or in bronchoalveolar lavage (BAL) 
samples. Novel methods are being are also being developed to analyse the level of inflammatory 
markers in nasal secretions, exhaled breath condensate (EBC) and urine, which are currently 
being evaluated as surrogate markers for the airway [231, 232]. 
 
Blood 
 
Systemic markers of inflammation include total white cell count (WCC), peripheral blood 
neutrophils, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). These are used 
commonly in adult clinical practice, and are elevated during infection and fall with antibiotic 
treatment in patients with CF [215].  
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Other markers utilised in research include calprotectin, a marker of neutrophilic inflammation, and 
the level of pro-inflammatory cytokines [233]. Our multi-centre observational study of adult and 
paediatric patients with CF (>10 years), the ‘tracking study’, evaluated the change in conventional 
and novel biomarkers of CF lung disease at the beginning of a CF pulmonary exacerbation and 
following a course of iv antibiotic therapy. A significant reduction was seen in serum CRP, IL-6 and 
calprotectin following treatment, no changes were observed in levels of IL-8 or TNF-α and IL-10 
levels were undetectable [215]. There were no changes in levels of sputum markers. 
Sputum 
 
Sputum analysis may be a useful tool in the assessment of disease. Clinically, the most commonly 
assessed markers are purulence, and presence of microbial growth on culture [234, 235]. In 
research, additional factors include: volume collected over 24 hours, proportion of solids (percent 
dry weight), DNA content, viscosity, total and differential cell count and the level of pro-
inflammatory markers.  
 
Studies correlating sputum biomarkers with disease severity have shown that levels of NE, matrix 
metalloproteinase (MMP-2 and MMP-9) anti proteases (NE a1 anti protease complexes [NEAPCs], 
secretory leukoprotease inhibitor [SLPI] and tissue inhibitor of metalloproteinase 1 [TIMP-1]) have 
the best predictive values for subsequent lung function decline [236], and elevated NE, neutrophil 
counts and IL-8 had a significant longitudinal association with  decreased FEV1. However others 
have found no correlation, and there is ongoing controversy regarding the role of these markers in 
monitoring airway inflammation and disease. Children are often unable to expectorate when 
required, although sputum production can be induced by using nebulised normal or hypertonic 
saline [237]. BAL collects fluid which is often of variable quantity and dilution; results may therefore 
be poorly reproducible. It is an invasive procedure and therefore only performed when clinically 
necessary.  
 
Bronchial biopsy 
 
Endobronchial biopsies have been shown to detect early pathological changes in the CF lung, 
demonstrating amongst other changes; increased basement membrane thickness, loss of ciliated 
epithelial cells and ultra structure abnormalities, goblet cell hyperplasia, increase in airway smooth 
muscle, and bronchial mucosal inflammation. These are associated with infection and 
inflammation, and provide insight into the mechanisms of airway remodeling in CF [238]. 
Limitations include that they only detect changes in the very small of proportion of the airway that 
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was sampled, and only in the proximal regions. Biopsies are invasive and this procedure cannot be 
recommended as a routine method of monitoring airway inflammation.  
 
Nasosorption  
 
Novel methods have been developed to collect nasal mucosal lining fluid which utilising a synthetic 
absorptive matrix (SAM). Strips of the material are passed into the nostril to collect nasal 
secretions which are then analysed to assess the levels of inflammatory markers. This method, 
known as nasosorption, has been shown to be superior to previous methods in recovery of 
cytokines however its use in monitoring disease status in CF has yet to be determined [239, 240]  
 
1.3.3 Relationship between quantity of CFTR and disease  
 
Since the discovery that a defect in CFTR protein leads to CF, studies have been performed to try 
and correlate the level of CFTR dysfunction with the severity of lung disease measured 
physiologically, structurally and by levels of infection and inflammation (above), and to try and 
quantify how much correction may be required to produce a clinical benefit. Better understanding of 
these issues will guide the development of novel therapies which aim to restore CFTR function; to 
help determine if a therapy will be effective, to measure its efficacy and to help establish dosing 
regimens. We know that carriers are to all intents and purposes normal, so 50% of CFTR function 
is sufficient. 
 
1.3.3.1 CFTR and disease phenotype 
 
Attempts to correlate sweat chloride concentration and clinical phenotypes have shown 
inconsistent results to date. Initial studies observed lower sweat chloride concentrations among 
patients with class IV mutations (associated with a milder disease) however within other class 
mutations, sweat chloride concentration does not correlate with pulmonary status, even in the 
subgroup of patients who are pancreatic sufficient and thought to have residual CFTR function 
[173, 241, 242]. As discussed, whilst the values of sweat chloride concentration, and FEV1 and LCI 
showed a significant improvement in patients with the Gly551Asp-CFTR mutation following 
treatment with ivacaftor, the changes were not found to correlate.  
 
The relationship between NPD measurements and disease severity CF is also undetermined. 
Some studies have shown no relationship with respiratory function, whilst others have shown a 
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correlation with a higher (more negative) baseline PD and a more exaggerated amiloride response 
(both indices of sodium hyperabsorption) with worse respiratory function and long-term survival 
and a normal basal PD with milder respiratory disease [243, 244] [173, 187, 245, 246]. A study of 
adult CF patients (n=79) demonstrated a relationship between increased chloride secretion and 
pancreatic status but not pulmonary phenotype, and a study of older CF patients failed to show a 
correlation between survival and residual CFTR chloride function in patients with severe CF 
mutations [247-250]. In contrast other studies have reported that residual chloride secretion was 
associated with higher FEV1 regardless of the genotype, and a statistical correlation has been 
reported between stimulated chloride transport in male patients with CF and FEV1, however this 
was not replicated in a comparable female cohort [249] 
 
A study exploring CFTR dysfunction in bronchiectasis patients with only one mutation in CFTR 
indicated that there is a continuum in airway ion transport which is strongly associated with CFTR 
genotype and clinical phenotype [251]. 
 
1.3.3.2 Level of CFTR required to achieve a clinical benefit 
 
In vivo studies suggested that low-levels of correction of CFTR expression in the airway epithelium 
can restore chloride transport levels to normal, however later studies indicate that nearer 25% may 
be required to allow efficient mucus transport. Recent animal studies demonstrated that low levels 
(7%) of adenovirus-mediated CFTR-gene expression into the sinus epithelial cells of CF-pigs can 
produce detectable levels of chloride correction, and that transfer into 20-30% of cells corrected 
chloride transport to 50% of non-CF levels. However, it is unknown what levels of chloride 
correction are required to produce a clinical benefit. Different organs require different levels of 
CFTR function to maintain function. The vas deferens is extremely sensitive to CFTR. Congenital 
bilateral absence of the vas deferens (CBAVD), which is present in most male CF patients, can 
also be a single-organ condition leading to male infertility. These men often have mutations in 
CFTR leading to partial function [252]. It appears that CFTR function of approximately 10% of 
normal causes disease in the genital tract but is sufficient to prevent lung disease. As discussed, it 
is unclear which features related to CF pathophysiology are the most important, and the amount of 
CFTR expression required to correct bicarbonate transport, mucus unfolding and ASL pH are 
currently unexplored.  
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1.4 Rationale for studies in this thesis 
 
It is clear that CFTR is vital to maintain airway health; however it is incompletely understood how 
impaired CFTR function results in the chronic inflammatory lung condition characteristic of CF. A 
better understanding of this process may help guide the development of novel therapies in CF that 
aim to restore CFTR function and to identify potential future therapeutic targets. In addition, if 
secondary CFTR dysfunction exists in other chronic suppurative lung diseases, it may contribute to 
the disease progression, and treatments that are useful in CF may be beneficial in a wider patient 
group. This thesis explores the relationship between CFTR ion transport function and markers of 
disease severity in order to better understand the complex relationship between CFTR, 
inflammation and disease progression. The start of a Multidose Trial of CFTR-gene therapy 
provided the unique opportunity to explore the effect of the restoration of CFTR by these novel 
therapies on markers of airway health. 
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1.5 Hypotheses, aims and objectives: 
 
1.5.1 Hypothesis 
 
1. There is a direct relationship between CFTR function as manifest by sodium and chloride 
transport and airway health 
 
2. There is a bidirectional relationship between CFTR function as manifest by sodium and 
chloride transport and airway inflammation, namely dysregulated chloride and sodium 
transport leads to inflammation and inflammation which in turn further impairs ion transport 
 
1.5.2 Aims  
 
1. To demonstrate the relationship between CFTR functional deficiency as manifest by 
dysregulated chloride and sodium transport and clinical markers of airway disease 
 
2. To define the relationship between CFTR function as manifest by dysregulated chloride and 
sodium transport and airway and systemic inflammation 
 
1.5.3 Objectives 
 
1. To measure lower airway potential difference and relating it to functional and structural 
markers of airway health in patients with CF 
 
2. To establish the relationship between changes in airway PD and those in clinically relevant 
markers after restoring CFTR function by repeated dosing with CFTR gene therapy  
 
3. To compare the inflammatory response to bacterial challenge of CF nasal epithelial cells to 
those of wild-type and non-CF CSLD, both of which have presumed normal CFTR function 
 
4. To assess CFTR function as manifest by dysregulated chloride and sodium transport using 
nasal PD in patients with secondary CFTR dysfunction in the CSLD, PCD, and relating it to 
the severity of inflammation 
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The next chapters detail the methods I have used to address these research questions. 
Techniques common to several studies are described in Chapter 2; techniques specific to 
particular studies are described with the relevant results in subsequent chapters.  
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2  General methodology 
 
 
The overarching theme of this thesis; exploring the relationship between loss of CFTR protein ion 
function and markers of disease severity in chronic suppurative lung disease, was explored in four 
studies. This chapter describes those parts of the methodology which were common throughout 
the work of thesis, whilst the methodology specific to a single study are described in the relevant 
Chapters (3-6). First, there is a definition of the diagnostic criteria used to confirm the subjects’ 
eligibility to participate, which was common throughout, followed by details of the methodology of 
the outcome measures.  
 
2.1 Disease group definitions (subjects) 
 
Between March 2012 and September 2014 patients were recruited to take part in either one or 
more of the studies outlined in Chapters 4-6. Subjects were defined as below: 
 
Cystic fibrosis:  
 
CF patients were required to have had the diagnosis confirmed by sweat test (sweat chloride levels 
> 60 mmol/ml) or by genetic analysis demonstrating 2 mutations recognised to be CF disease 
causing, in addition to clinical features as in the European Diagnostic Guideline [110]. 
 
Primary ciliary dyskinesia:  
 
PCD patients were required to have had the diagnosis confirmed by high-speed video-microscopy, 
or assessment of ciliary ultrastructure by transmission electron microscopy (TEM) revealing a 
ciliary defect known to cause PCD, or by genetic analysis demonstrating a mutation known to 
cause PCD and the presence of sinopulmonary disease. 
 
Healthy controls:  
 
Healthy controls were recruited from hospital staff with no history of respiratory disease, congenital 
cardiac disease, neuromuscular disease or history of premature delivery. All controls were required 
to be non-smokers and to be free from bacterial or viral infections of the upper respiratory tract 
symptoms for the preceding 4 weeks. The demographics of the control group was controlled so as 
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to not differ significantly from that of the patient population. CFTR mutation analysis was carried 
out on healthy controls to ensure that they were not carriers of a mutation (2.2.7). 
 
2.2 Outcome measures: methods 
 
2.2.1 Baseline measurements (Chapters 3,4,6) 
 
Height was recorded for both adults and children using a Leicester height measure and measured 
to the nearest centimetre. Weight was measured with shoes and outdoor clothing removed, and 
documented in kilograms, corrected to the nearest 100g. 
 
2.2.2 Spirometry (Chapters 3,4,6) 
 
Spirometry was performed using an EasyOne Spirometer attached to a disposable, single use 
EasyOne spirette. Calibration was performed daily using a 3 litre syringe, and was considered 
successful if the results were +/- 3%.  
Subjects attached a nose clip sealing both nostrils prior to starting the procedure. They were asked 
to breathe in until their lungs were full, take the EasyOne in both hands and seal their lips around 
the spirette to ensure no leak. They were then instructed to breathe out as hard and fast, with as 
minimal delay as possible from the inspiration and the breath was continued for as long as possible 
to ensure complete emptying of the lungs. If successful, the EasyOne instructs the patient to repeat 
the manoeuvre a minimum of 3 times with at least 30 seconds recovery time in between tests to 
ensure that the data was good quality. The EasyOne screen displayed a ‘Session Complete! Good 
Job!’ message if the within-manoeuvre and between-manoeuvre quality fulfilled the European 
Respiratory Society (ERS)/ American Thoracic Society (ATS) acceptability criteria, and the 
spirometry results were displayed on the screen [253]. Reasons for classifying a single manoeuvre 
as unacceptable include beginning too early or too late, if disturbed flow was detected e.g. by a 
cough or if the manoeuvre was too short. The difference between the FEV1 and/ or the FVC of the 
last and previous manoeuvre(s) was required to be <150ml (or 100mls if the FVC was less than 
1L). If the session did not fulfil the criteria, the subject was allowed a 10-minute break, and the 
procedure was repeated a maximum of 3 times to ensure that the subject did not tire. It was very 
rare that repeats were required.  
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To enable a single set of reference equations to be used in all ages for spirometry, the data were 
converted to percent predicted using the reference ranges produced by Stanojevic et al [254]. Data 
were converted using a plugin available from www.growinglungs.org. 
 
2.2.3 Multiple breath washout tests (Chapters 3,4,5) 
 
MBW was conducted either using the Innocor gas analyser coupled with 0.2% SF6 tracer gas. 
 
2.2.3.1 Innocor  
 
MBW tests were performed as according to the UKCFGTC ‘multiple breath washout using modified 
innocor device’ SOP which was developed using published guidelines [212]. The Innocor 
(Innovision, Odense, Denmark) is a photoacoustic gas analyser that has been validated to 
measure LCI in CF [203]. The Inncocor device uses 0.2% SF6 as the tracer gas as there is a high 
signal to noise ratio with this analyser throughout the washout.  
 
2.2.3.2 Equipment 
 
• Innocor device 
• Supply of 0.2% SF6 in air (BOC Ltd. Size L tank 2000ppm SF6 air/200)  
• Single use sterile filters: 
• Adult – Air Safety Ltd. Bacterial/viral filter 4000/01 
• Paediatric – Air Safety Ltd. Bacterial/viral filter 9070/01 
• Clean mouthpiece and noseclips 
• Mouthpiece (Ferraris) 
• 3L calibration syringe 
• Electric fan(s) 
• Innocor log to record settings 
 
2.2.3.3 Preparing the equipment 
 
Figure 2.2-1 illustrates the set up equipment for the MBW test using the Innocor. 
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Figure 2.2-1: LCI set up using the InnocorTM with SF6 as a tracer gas. The photograph shows the patient 
mouthpiece and filter with the flow pass of SF6 (left to right). The fan is to free the room of exhaled SF6 to 
prevent re-inspiration during the washout 
 
Calibration 
 
Flow-gas delay calibration was performed daily on the Inncocor. The operator breathed out slowly 
into the mouthpiece to establish a flat plateau of expired CO2 concentration. A sharp breath was 
then taken, with inspiration continued for at least 2-3 seconds, to ensure a sudden transition of flow 
from expired to inspired, leading to the CO2 concentration falling to ambient levels very quickly and 
staying there. The mean CO2 delay value was recorded. Calibration was acceptable if the 
individual gas delay did not vary by more than 20 ms, and did not vary compared to the previous 
days value by more than 20-40 ms.  
 
Flowmeter calibration was performed daily on the Innocor using a 3 litre calibration syringe. The 
syringe was filled and emptied by hand 5 times in total: 2 slow (1/2 - 3/4 L/s); 2 medium (1 1/2 L/s); 
and 1 fast (2 1/2 L/s). Speed was approximated. The volume measured at all rates was required to 
differ by less than +/- 2% (between 2.94 and 3.06L) to be acceptable. This was repeated if the 
initial calibration had been unsuccessful.  
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2.2.3.4 Performing MBW measurements  
 
The Innocor was turned on for at least 20 minutes before testing to allow the photo-acoustic gas 
analyser to warm up. Ambient temperature and humidity, flow meter calibration, and flow gas delay 
were recorded in the Innocor Log. 
 
Patients were asked to sit upright with legs uncrossed as this can affect functional residual 
capacity (FRC). A nose clip was attached to ensure no air leakage and the patient engaged with 
the mouthpiece, achieving a good seal. The patient was instructed to breathe ‘normal/ relaxed’ 
breaths.  
 
Wash-in Phase 
 
The tracer gas (0.2% SF6) was switched on at 10-15L/minute. After 1-2 minutes the patient’s 
breathing was generally at a comfortable, steady tidal volume and the Inncocor test screen tidal 
volume graph could be used to determine the patient’s breathing pattern. The Innocor machine 
reported the maximum, minimum, and the difference between these 2 SF6 concentrations. When 
this was 0.003% or less for three successive breaths the 'wash-in' phase was complete. 
 
Disconnection of flow-past 
 
The fan was then turned on and the patient asked to continue breathing normally as the gas was 
going to be disconnected. The subject’s chest movements were observed, and early in the 
expiration, the T-piece was rapidly and smoothly disconnected and covered with the operator’s 
hand. The tubing was quickly removed so that the SF6 was not blown close to the subject, and as 
soon as possible, the wash-in gas was turned off.  
 
Wash-out Phase 
 
The patient was then left, breathing room air, until the maximum concentration of SF6 displayed on 
the screen was 0.003% for 3 successive breaths. The mouthpiece was then removed, and the 
patient offered a glass of water and a short break. 
 
The test was repeated three times, or more if any of the tests were thought likely to be technically 
inadequate, e.g. due to coughing, unsteady breathing or inappropriate disconnection at any point. 
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Problems encountered 
 
Very few technical problems were encountered when performing MBW tests. The most common 
problems included: failure of the Innocor gas analyser, disruption to the breath trace caused by the 
subject coughing/ moving and imprecise disconnection of the tracer gas (Figure 2.2-2).  
 
 
 
Figure 2.2-2: Illustration of problems encountered when performing MBW traces using SF6 and the Innocor 
device with SF6 on y axis and time on x axis a) trace disrupted by a coughs (indicated by the 3 red arrows) b) 
imprecise disconnection of the tracer gas (indicated at the horizontal red arrow) 
Data export 
 
Raw data from the Innocor was exported to a .ino file on a USB memory stick before switching off 
the Innocor to ensure no data was lost. The file could then be uploaded for analysis.  
 
2.2.3.5 Calculation of LCI  
 
To obtain the final values for LCI, the SimpleWashout software (NB, University of Edinburgh) was 
used. This programme was written using the IGOR Pro (WaveMetrics Inc) data analysis platform. 
Data files were imported into the SimpleWashout software by converting the .ino file to .txt file 
containing flow, SF6 and CO2 data. The following data inputs were required: 
 
• Setting the disconnection point and grading the quality of the disconnection (ensuring it had not 
taken place during and the inspiratory phase) 
• The cursors for Cmax (concentration of SF6 at the end of the last inspiration before disconnection), 
and Cinit (average concentration of SF6 at the end of the last expiration before disconnection) 
were automatically placed on the trace by the software. If the concentration of SF6 varied even 
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slightly just before the disconnection these may be placed in the wrong part of the trace and 
require manual correction by eye. 
• Verifying that the first breath and subsequent breaths had been correctly identified 
• Checking the washout termination status 
• Checking the SF6 offsets 
 
The SimpleWashout software allowed an offset correction for any SF6 gas present in the room at 
the beginning of subsequent tests. The results from ‘Offset corrected’ LCI measurements were 
used to represent the final value for LCI. 
 
2.2.4 Nasal brush biopsies (Chapters 3,6) 
 
The nasal brushings obtained were performed as according to the Royal Brompton Hospital NHS 
Trust Electron Microscopy Unit - Primary Ciliary Dyskinesia diagnostic service SOP. The subject 
cleared their nose of mucus by gentle blowing, and sat down on a chair positioned against the wall, 
with their head reclined. A disposable cytology brush (Olympus) was inserted into the nose, 
beneath the inferior turbinate, using an otoscope for guidance. The ciliated epithelium in a single 
nostril was brushed against the inferior surface in an anterior-posterior motion with a degree of 
rotation for 5 seconds to collect strips of ciliated epithelium. Cells obtained were suspended in 
bronchial epithelium growth medium (BEGM) containing the antibiotics penicillin (100IU/ml) and 
streptomycin (100μg/ml) (PS) and stored immediately at 4oC. 
 
2.2.5 Assessment of inflammatory cytokine concentrations (Chapters 5,6) 
 
Samples of cell suspension, sputum, supernatant from cell culture and nasal epithelial lining fluid 
(NLF) were collected for analysis of the cytokine profile. Details on sample collection are described 
in the relevant chapters. 2 different platforms were used in this thesis to measure inflammatory 
cytokine concentrations. The IL-8 ELISA (ThermoFisher SCIENTIFIC (KHC0081)), and the Human 
ProInflammatory 9-plate Tissue Culture Kit (Meso Scale Discovery (MSD) platform) (K15007B-1), 
designed to quantify the presence of GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, and 
TNF-α in tissue culture supernatant. This plate was chosen as these cytokines play a role in pivotal 
role in the inflammatory response and have been shown to be elevated in the airway during 
infection (1.3.2.3). Both methods are described here.  
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2.2.5.1 IL-8 ELISA 
Each analysis was performed as per manufacturers guidelines [255]. 50µL samples of the sample 
and the control substance were added to microtitre wells prepared as per the SOP. 50 µL of the 
anti-IL-8 solution was added and the wells gently mixed and incubated. The solutions were then 
aspirated and the wells washed. 100µL of Streptavidin-HRP working solution was then added, and 
the wells incubated again. Finally, the wells were washed again, and 100µL of Stabilized 
Chromogen was added. The solution was incubated for a pre-determined time and then 100 
microlitres of Stop Solution was added. The optical density of the wells were then read at 450nm 
using a plate reader that had been blanked against a well containing only Stabilized Chromogen.  
 
2.2.5.2 MSD platform  
 
The MSD plates contain 96 wells, on the bottom of which is a multi-array plate. The plate is pre-
coated with the selected specific cytokine capture antibodies of interest. The sample is added to 
the well in addition to a solution containing detection antibodies conjugated with 
electrochemiluminescent labels (MSD SULFO-TAGTM ) and incubated for a defined period. 
Analytes in the sample bind to the capture antibody, which is immobilized on the electrode surface, 
and to the detection antibodies (Figure 2.2-3). MSD read buffer is added to the wells, which 
provides the appropriate chemical environment for electrochemiluminescence. When the plate is 
loaded into the MSD imager, a voltage is applied to the plate electrodes causing the MSD SULFO-
TAGTM  to emit light. The imager measures the intensity of the light emitted to provide a quantitative 
measure of analytes in the sample.  
 
 
Figure 2.2-3: Immunoassay format using capture antibodies on the MSD multi-array plate, illustrated on a 4 
spot MSD MULTI-SPOT plate. Reproduced from website [256] 
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Method 
Preparation 
 
o A calibration curve was created by diluting the stock calibration solution sequentially in 
a diluent containing a standard tissue culture growth medium with 10% serum. The 
calibration samples placed into the first 2 columns of the MSD plate (step 1). This 
created a standard curve ranging from 2.4ρg/ml to 10000ρg/ml.  
o The Detection Antibody Solution was prepared by diluting 60uL of the Detection 
Antibody Mix into 2.94ml of the provided diluting agent. This was kept in the dark, as 
some antibodies are light sensitive.  
o 10 ml of the Read Buffer were diluted in 10ml de-ionized water.  
Steps 
 
1. 25µL of each test sample or the calibration sample was dispensed into a separate well 
of the plate. The plate was sealed with an adhesive plate seal for 1-2 hours, shaking at 
300-1000rpm) at room temperature.  
2. 25µL of Detection Antibody Solution was dispensed into each well of the MSD plate and 
again sealed an incubated for 1-2 hours at room temperature, shaking 300-1000rpm) 
3. The plates were washed 3 times with PBS +0.05% Tween-20 followed by the addition of 
150µL of the Read Buffer solution to each well of the plate.  
4. Plates were read immediately using a a Bio-Rad Bio Plex 200 plate, after the addition of 
Read Buffer 
 
The results were generated on the plate reader and transferred to excel files for further analysis. 
The calibration curves were verified for each cytokine. When available, duplicate values were 
compared and the coefficient of variation calculated. None of the values obtained were above the 
upper limit of the calibration curve. Many values were recorded near or below the limits of 
detection. The results have been analysed however and this is discussed in the relevant sections.   
 
2.2.6 Sweat test and analysis (Chapters 3,6) 
 
Sweat tests were performed using the Macroduct (R) Sweat Collection System and were 
performed in accordance to the manufacturer’s instructions [257].  
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A selected area on the patient’s forearm was cleaned and 2 electrodes with Pilogel (pilocarpine 
gels) discs installed were attached to the forearm with velcro straps, coloured to indicate positive 
and negative. The electrodes were attached to the Webster Sweat Inducer, which activates 
iontophoresis, for 5 minutes. The electrodes were then removed and a Macroduct Sweat collector 
firmly attached to the stimulated skin site, where the positive electrode had been attached. The 
sweat was collected along the spiral tubing; a blue indicator dye allows this to be visualised. When 
the collection was complete, tubing was severed from the Macroduct base and the sweat specimen 
was collected into a universal container tube and sent to the Biochemistry lab at RBH, for analysis 
of the sweat chloride concentration. This process was performed on both arms, and the mean of 
both measurements taken as the value for the patients’ sweat chloride concentration [258]. 
Very few technical problems were encountered. On several occasions insufficient sweat was 
collected, requiring a repeat of the test. 
 
2.2.7 CFTR mutation analysis (Chapters 3,4,6) 
 
CFTR gene mutation analysis was not repeated if it had previously been performed for clinical 
reasons and the information was available.  
 
Blood samples were taken from patients and were sent to the Kennedy Galton Genetics Lab and 
analysed for the presence of any genetic mutations known to cause CFTR dysfunction. Analysis 
was performed using the Devyser CFTR- Core Kit, which includes a panel of the 36 most common 
mutations found in the European population [259].   
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2.2.8 Airway potential difference measurements (Chapters 3,4,6) 
 
This section describes the methodology for measurement of airway potential difference. 
 
2.2.8.1 Nasal measurements  
 
Equipment: 
 
The solutions; Ringers solution, Ringers Amiloride solution and Zero Chloride Amiloride (ZCl/ 
Amiloride) solution, were prepared at the Eastbourne Hospital Pharmacy and supplied in 50 ml 
glass bottles in batches (composition in Appendix A). At the RBH they were stored at 4oC. 
 
• Stock Ringers solution   
• Stock Ringers Amiloride solution   
• 2 x Stock Zero Chloride Amiloride  
• 11 x19G needles  
• 4x 50 ml, 2 x 5ml ,1 x 2ml, 1 x 1ml syringe 
• 2.25mg/2ml vial pack Isoprenaline 
• Marquat Dual-Channel Nasal Probe – Length 80cm; Diameter 2.5mm (Ref: I0202US)  
• Alaris pump x 4  
• 1 x 2ml syringe and 2x 5ml syringes  
• Alaris microtubing (MFX2259)  
• 3- way tap x 3 (3 for tubing circuit, 1 on catheter)  
• T-piece connector x 4   
• Laptop computer with PD software (Logan Research Ltd)  
• LR4 millivoltmeter (Logan Research Ltd)  
• Silver-silver chloride electrodes (Biosense Medical) x 2  
• Electrode cream (Signacreme, Parker laboratories)  
• Dental drill system including sterile single use dental burr  
• Sleek (tape)  
• Steristrips  
• Micropore tape 70%  
• Alcohol Skin Swab (Steret
 
or equivalent)  
• Sterile single pack yellow pipette tip  
• Small forceps  
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• Chin rest  
• Cardboard disposable tray / bowl  
• Paper towels  
Equipment Preparation 
 
Preparing the solutions and tubing circuit is illustrated in Figure 2.2-4. 
 
 
 
Figure 2.2-4 Schematic diagram showing the set-up of NPD equipment, as described in the following 
paragraph (image courtesy of Dr Michael Waller) 
 
The solutions were allowed to warm to room temperature, then drawn up into 50ml syringes and 
the syringes labeled to identify the contents. To prepare the ZCl and Isoprenaline (ZCl/Iso) 
solution, 0.11ml of Isoprenaline (2.25mg/2ml) measured in a 1ml syringe, was added to a 50ml 
syringe of ZCl/ Amiloride solution and shaken to mix to a final concentration of 2.5 mcg/ml. This 
solution was used within 2 hours of adding the isoprenaline to ensure it did not deactivate. The four 
syringes were placed in syringe drivers in the order in which they were to be perfused. A t-piece 
was attached to the end of each of the solution syringes, and the t-pieces connected to each other 
with three 3-way taps. 
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Setting up the computer equipment 
 
The Voltmeter was attached to a laptop computer via the USB connection. 2 electrodes were 
attached to the Voltmeter with the red port connected to the recording (nasal) electrode and the 
black port connected to the reference (skin) electrode. The Voltmeter, followed by the computer, 
were switched on and the Logan Software programme opened. Initially the scale of the graph was 
changed to -80 on the x axis, and the programme set to ‘run’.  
Off set 
 
Both electrodes were placed in a sterile container filled with electrode cream, and the trace 
monitored until the values were stable and <+/- 5mV. If the recording was outside this range, a new 
set of electrodes were chosen and measured. When satisfactory, the offset was recorded, and the 
‘offset correction’ option chosen from the menu to reset the trace to zero. 
 
Preparing the nasal catheter 
 
For each patient a new, Marquet double lumen catheter was used. 2ml of electrode cream 
(SIGNACREME® electrode cream) was injected into the catheter through the luer-lock port through 
the channel marked with a yellow band until a steady flow of cream was seen exiting the catheter. 
A 5 ml syringe, half filled with electrode cream, with the plunger removed, was connected to the 
yellow band marked port. The recording (nasal) electrode was then inserted into this 5ml syringe. 
The offset was rechecked to test the electrical circuit of the nasal catheter in the Electrode Cream 
and corrected if >0.5mV. The reference electrode was then secured in the syringe using adhesive 
tape. 
 
Performing measurements 
 
A proforma was used to record information during the procedure. This included both pre- and post-
procedure electrode offsets, skin PD measurement, subject’s clinical status, any unexpected 
events or problems, and the timings that the solutions changed and the corresponding PD values. 
 
Measuring Skin PD 
 
The subject’s skin was cleaned with an alcohol wipe, and a shallow skin abrasion made using a 
sterile, single-use dental drill burr. A piece of sleek was placed over the reference electrode (skin), 
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and a small hole made in the tape overlying the circular hole in the electrode. This was then placed 
exactly over the abraded skin site. A small syringe was filled with electrode cream, attached to a 
21G needle, inside a yellow pipette tip. Electrode cream was then injected through the hole in the 
sleek, providing contact between skin and the electrode. 
 
The catheter, ready primed with conducting cream, was placed on the patients’ fingertip and the 
value for the skin, displayed on-screen, was documented. This confirmed the integrity of the 
electrical circuit and that skin contact was adequate. Skin measurements generally lie between -30 
and -60 mV, and if skin PD was <30mV the circuit was reviewed and the forearm skin preparation 
process repeated. Patients with CF have a typically more negative skin PD. 
 
Measuring nasal PD 
 
The patient rested on a chin rest to help maintain head stability during the procedure. With the 
head in neutral position, the catheter was inserted slowly along the nasal floor, with the blue 
marker on the catheter pointing to the left side of the operator to ensure that the recording port was 
in contact with the floor of the nostril. The site with the highest (most negative) PD, after testing 
both nostrils, was chosen to be the measuring site, and the length of the catheter into the nasal 
cavity and which nostril used was documented. For subsequent measurements in the same 
subject, the same site was used. The electrode was held in place using steristrips, and the head 
was positioned downwards prior to starting the perfusion of the solutions.  
 
The syringe pumps and the computer were disconnected from the main electricity supply, and 
powered by battery to reduce electrical interference. Perfusion of the first solution was commenced 
at a flow rate of 4ml/minute. The solutions perfused were: 
 
• Ringers solution until the trace was stable (minimum 30 seconds) 
• Ringers + Amiloride (minimum of 3 minutes and the trace was stable) 
• ZCl + Amiloride solution (5 minutes) 
• ZCl + Amiloride with Isoprenaline solution (5 minutes) 
  
When the solutions were changed, the PD value displayed on the screen was documented and the 
Voltmeter switch moved from O/P to CAL to O/P to place a mark on the screen. The solution was 
stopped and the 3-way tap switched to allow the next solution to run. A typical trace of a healthy 
control and CF patient were illustrated in Chapter 1 Figure 1.3-1.  
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Problems encountered:  
 
Equipment failure: Equipment failures predominantly involved the presence of bubbles in the 
electrode cream in the catheter circuit which interrupted the electrical circuit and caused disruption 
to the trace (frequent). Other problems included displacement of the nasal catheter during the 
procedure either due to poor securement or the patient moving secondary to coughing or talking 
(occasional).  
 
2.2.8.2 Adaptation of PD measurements for lower airway 
 
All measurements were performed with patients under a general anaesthetic (GA) administered by 
Dr Brian Keogh, Consultant Anaesthetist RBH. The bronchoscopy was performed on all occasions 
by Professor Jane Davies (Professor of Paediatric Respirology and Experimental Medicine, 
Imperial College) and LAPD measurements by either myself, or my colleague Dr Michael Waller. 
 
Equipment list 
• Flexible Bronchoscope  
• Biopsy forceps (Disposable biopsy forceps, Olympus, FB-231D) x 1 per bronchoscopy  
• Stock Ringers and Zero Chloride Solutions, in 50 ml pre-prepared bottles.0.22micron filter, 
vial of Isoprenaline sulphate 2.25mg/2ml, 1ml syringe, green needle, 50ml syringes, syringe 
to syringe transfer bung, bungs and worksheet as prepared by pharmacy.  
• 5ml syringe containing (solid) 1ml 4% Agar in 3M Potassium Chloride. 
• Alaris syringe pump x 2  
• Silver-Silver chloride Skin electrode (Biosense Medical) labelled with study ID number  
• Silver-Silver chloride measurement electrode (Biosense Medical)  
• 18G Abbocath-T x 2  
• T-piece connector x 3  
• White (19G) needle x 2  
• 2ml syringe and 5ml syringe  
• Signacreme  
• Dental drill system including sterile single use dental burrs  
• Sleek (tape)  
• 70% Alcohol Skin Wipe (Steret or equivalent)  
• Sterile single packet Yellow pipette tip  
• Green needle (21G)  
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• Laptop with PD software (Logan Research Limited)  
• LR4 millivoltmeter (Logan Research Ltd)  
 
Solutions: 
 
Ringers and Zero Chloride (ZCl) (no amiloride) solutions are prepared and stored as per Appendix 
A.  
 
Equipment Preparation  
 
Figure 2.2-5 shows a schematic representation of the LAPD set up as it was used in the gene 
therapy Multidose Trial. 
 
 
Figure 2.2-5: Schematic diagram of the LAPD set up, (image courtesy of Dr Gwyneth Davies) 
 
The day prior to the procedure:  
 
• 2 x 50ml Ringers Solution bottle and 1x 50ml ZCl were placed in the fluid warmer at 37oC; 
this meant that the solutions were cooling down during the set-up reducing micro-bubble 
formation.  
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• The agar syringe was made. 0.4mg of agar powder was added to 10 ml of potassium 
chloride solution and gently heated to ensure it dissolved. 5 ml syringes, with the plunger 
remover, were filled carefully with 2 ml of agar, ensuring that it was present in the hub of the 
syringe and absent of air bubbles. These were left to set overnight. 
 
The day of the bronchoscopy: 
 
• All solutions were removed from the warmer and 50 ml of both Ringers solution and the 
ZCl solution were drawn up into a 50ml syringe. 
• ZCl/Iso was made up; as described for NPD measurements.  
 
Circuit 
 
A t-piece was attached to the end of the Ringers solution syringe and primed with the solution. Any 
bubbles trapped in the t-piece were displaced by gently tapping the tubing. A second t-piece (2), 
also primed was attached to the first t-piece, and t-piece 1 clamped off. The rubber bung of the t-
piece (1) was pierced with a 19G needle whilst gently purging the syringe allowing the needle to fill 
with Ringers solution. When a meniscus of fluid was visualised on the top of the needle hub it was 
attached to the agar filled syringe. Approximately 2ml of SIGNACREME® electrode cream (Parker, 
USA) was added on top of the Agar in the syringe. A third t-piece (3) was attached to the ZCl 
solution syringe, and primed carefully to ensure no bubbles were present. The ‘off’ bung of the 3-
way tap was placed on the t-piece (2) and the rubber bung pierced with a 19G needle and filled 
with Ringers solution as before. The primed t-piece (3) was then connected to this needle and 
clamped off. The syringes were then placed carefully in the pumps and the circuit was secured to 
the side of the pump with sleek tape.  
 
For the PD catheter, the sheath surrounding a disposable cytology brush was used, into which an 
18G Abbocath catheter was inserted roughly 4mm. The green end of the Abbocath was attached to 
the remaining port of the t-piece (2) followed by purging the Ringers solution from the infusion 
pump to prime the Abbocath and the PD catheter. 
 
Setting up the computer 
 
The only difference between the set up for NPD (section x) compared to LAPD is the selection 
scale of the y axis on the graph was selected to -40mvol.   
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Offset 
 
A second 18G Abbocath was inserted into the end of the PD catheter (to preserve sterility of the 
latter) and the needle removed and disposed of. Ringers solution was purged to the end of the 
Abbocath until a meniscus was seen at the green open end. The measurement electrode (Red 
port) was placed in the syringe containing electrode cream above the agar, and both the reference 
(skin) electrode and the green end of the Abbocath were placed in a Universal container containing 
Signacreme. The offset was measured and corrected for as described above.  
 
Performing measurements 
 
A proforma was used to record information during the procedure; including pre- and post-
procedure electrode offsets, the skin PD value, comments about the general appearance of the 
airways and the side chosen from which to perform the measurements. The same side was used 
both pre- and post- dosing. The timings that the solutions changed and the corresponding PD 
values were documented, in addition to any unexpected events. 
 
Measuring Skin PD 
 
Performed as above for NPD measurements 
Measurements in the airway 
 
LAPD measurements were performed as listed below.  
 
• The bronchoscope was introduced  
• The lung with least inflammation and mucus was chosen to perform the PD measurements 
to maximise contact between the electrode and bronchial epithelium.  
• The PD catheter was inserted into the bronchoscope and the tip of the catheter rested 
against the lower airway mucosa.  
• Ringers solution was connected and perfused onto the mucosa at a flow rate of 100ml/hour. 
Measurements were taken at 4 locations at the level of the carina: anterior, posterior, right 
lateral and left lateral.  
• Ringers solution was run through the catheter at each location until a stable measurement 
was recorded, (minimum 20 seconds).  
• The bronchoscope was repositioned to a distal site (approximately 5th generation bronchi).  
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• Ringers solution was perfused onto the mucosa until values were stable (minimum 20 
seconds).  
• The solution was changed to ZCl/Iso.  
• The stop clock was started for 300 seconds  
• At 300 seconds, ZCl/Iso was stopped, the sheath withdrawn, and purged with 2ml of 
Ringers solution to eliminate the ZCl/Iso solution from the catheter.  
• The procedure was repeated at 2 further locations in the distal bronchus in the same lung. 
• The offset of the electrodes was rechecked, and documented, to ensure there had been no 
significant drift in the voltage measured.  
• Bronchial brushings and biopsies were performed at the end of the procedure as described 
in Chapter 4. 
• A single dose of two appropriate antibiotics was administered following the procedure to 
limit any potential adverse effects.  
• When woken from the GA, patients were monitored for a minimum of 4 hours before 
discharge.  
 
A typical LAPD trace from a subject with CF is illustrated in Chapter 4 Figure 4.4-2, along with 
examples of traces that were difficult to analyse due to problems encountered.  
 
Problems encountered  
 
Loss of electrical contact due to visible bubbles, or micro-bubbles in the circuit: on several 
occasions the electrical trace was lost as evidenced by a sudden change in the PD measurement. 
On these occasions the catheter was purged with the solution that was currently running to 
dislodge the bubbles until contact was regained. If no contact was regained the trace was 
discontinued. 
Agar syringes dislodged: On 2 occasions the agar disconnected from the syringe. The syringe was 
immediately replaced with a spare and the procedure was continued. Agar syringes were made at 
least 18 hours before the procedure to allow time for them to solidify completely, and several were 
made at one time to provide a replacement if required.  
Medical concerns: If the subject encountered any medical problems (desaturations, hypercarbia or 
haemoptysis) during the procedure, it would be discontinued and only restarted if considered to be 
safe by all medical members present. One patient experienced an episode of hemorrhage following 
the endobronchial brushing, which resolved spontaneously but the procedure was discontinued.  
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Saving airway PD data 
 
Files were saved to the computed in a Logan prop.binary data file which was ‘DataDumped’ to 
create a compatible text file which was used for the data analysis.  
 
2.2.8.3 Analysis of airway PD measurements 
 
Nasal PD measurements  
 
The nasal PDs were analysed as according to the UKCFGTC analysis of NPD measurement SOP. 
The text files containing the PD values were transferred to an Excel worksheet for further analysis. 
The values were then converted into a graph so that the trace could be visualised.  
 
Measuring the phases of NPD in Excel: 
 
The transition point between the NPD phases was mostly clearly visible due to the marker places 
on the trace by the operator at the time of the procedure. If this was not obvious, the time written in 
the proforma was used. 
 
Baseline/ Ringers:  The time at which the Ringers phase was completed was visualised. The 
values for the 20 seconds preceding the transition were averaged to provide a basal value.  
 
Amiloride response: To determine the voltage after perfusion of amiloride, the same process was 
repeated as for the Ringer's phase. The amiloride response is the Ringers value - the Ringers 
amiloride value 
 
ZCl/ Amiloride: This value was measured at 300 seconds from the changeover point.  
 
ZCl/ Amiloride + Isoprenaline: same process was repeated as for the ZCl/ Amiloride phase.  
 
Total chloride response: ZCl/ Amiloride response + ZCl/ Amiloride + Isoprenaline response 
 
 
All delta values (the amiloride response and the both the ZCl phases), values were calculated from 
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the start of each specific NPD phase but before 30 sec, therefore excluding any electrical artefact 
that occurred in the PD trace during the changeover of solutions and the influence of the 
subsequent perfusate on the epithelium. 
 
Lower airway PD analysis  
 
This is described in Chapter 4  
 
2.2.9 Statistics 
 
Data were analysed using Prism 6 statistical software (GraphPad Software Inc, CA, USA). The 
specific statistical tests used in each chapter are described in the relevant sections.  Normality of 
the data was determined using the Kolmogorov-Smirnov test. Where data were non-parametric, 
paired comparison pre treatment and post treatment values were analysed using the Wilcoxon 
matched-pairs Signed Rank Test. Comparison between active and placebo groups was assessed 
with Mann-Whitney U test (normality not assumed due to small data size). Correlation between 
outcome measures was evaluated in these data sets using non-parametric spearman rank 
correlation. The null hypothesis was rejected at p<0.05.  
 
Where multiple sets of data were compared to each other, the non-parametric Kruskal-Wallis test 
was used. The Dunn multiple comparison test was performed to determine whether the post-hoc 
tests were significant.  
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3 Gene Therapy Multi Dose trial  
 
3.1 Introduction 
 
Alongside the development of small molecular therapies for CF, there have been significant 
advances in gene therapy for CF, which aims to correct the underlying genetic abnormality itself 
[260]. The UK CF gene therapy consortium (GTC) conducted a gene therapy Multidose Trial, 
designed to assess for the first time whether the administration of repeat doses of lipid-mediated 
gene therapy to the lungs of patients with CF results in a clinical benefit, rather than, as in other 
gene ‘therapy’ trials, whether WT-CFTR can be expressed in the airway. The primary outcome was 
relative change in FEV1, but the opportunity was also taken to explore CFTR surrogates including: 
LAPD measurements performed on a subgroup of patients in this trial both pre- and post- gene 
therapy dosing. The Multiple dose trial provided the unique opportunity for this thesis both to 
evaluate LAPD measurements as a marker of CFTR function in subjects with CF and to further 
explore the relationship between CFTR protein function and airway disease.     
  
This introduction provides a summary of the recent advances in gene therapy in CF leading up to 
the Multidose Trial. This chapter describes the trial in detail and provides context for Chapter 4, 
which describes the LAPD-focused study and the correlation between these measurements and 
the markers of airway inflammation, in order to address the underlying hypothesis; that here is a 
direct relationship between CFTR function as manifest by sodium and chloride transport and 
airway health. 
 
3.1.1 Gene therapy for CF  
  
CF is considered to be an appropriate target for gene therapy as it is a single gene disorder, and 
the airways, which carry the majority of disease burden, are relatively accessible for topical non-
invasive drug delivery. Furthermore the CF airways are thought to be unaffected at birth suggesting 
that there is a potential therapeutic window. Gene therapy can be achieved by either gene 
replacement therapy, or by gene editing techniques. The latter involves correction of genetic 
defects in-situ, via DNA or RNA editing, and is an emerging therapeutic avenue in CF [261]. This 
introduction focuses on gene replacement, in which the aim is to transfer a functioning copy of 
CFTR into the airway epithelium, which is transported into the cell nucleus, allowing transcription of 
the therapeutic gene. The airway however, has developed physical and immunological barriers as 
defence mechanisms (described in section 1.1), in addition to cellular barriers to cell entry and 
 86 
access to the nucleus, all of which must be overcome in order for gene therapy to be successful. 
Vectors are required to assist the entry of DNA in to the airway epithelial cell, of which the most 
extensively used in trials to date are either genetically modified viruses, or non-viral vectors such 
as liposomes. 
 
3.1.1.1 Clinical trials in gene therapy in CF  
 
Viral vectors  
  
Viruses were considered suitable vectors as they have naturally evolved to evade many host 
defences and achieve effective cell entry. Early studies focused on the use of adenovirus (AV) and 
adeno-associated viruses (AAV). The first clinical trial in gene therapy in CF in 1993 used an AV-
vector coupled with WT-CFTR, which was instilled on the nasal surface of 3 CF patients [262]. 
CFTR mRNA and protein were undetectable, however NPD measurements demonstrated a return 
towards normal baseline and chloride response, providing ‘proof of concept’, which then led to a 
number of larger trials. The majority of these delivered gene therapy to the nasal mucosa as a 
surrogate for the lower airways for safety reasons in addition to the technical advantages in drug 
delivery and tissue sampling. Changes in NPD measurements, presence of CFTR mRNA and 
CFTR protein, have been used most commonly as evidence of successful gene transfer [263-265]. 
Together these trials demonstrated that the products were safe and well tolerated, and provided 
variable evidence of successful gene transfer, typically in the order of 20-25% correction of the 
chloride defect. 
 
The first study looking at the response to repeat AV-mediated gene therapy administered 5 doses 
to 6 CF patients [266], demonstrating a partial chloride defect correction in some subjects. 
However, there was less correction of the defect with each subsequent administration, thought to 
be due to the development of a host immune response to the vector preventing gene transfer on 
subsequent doses, although no patients developed antibodies to CFTR itself. This has 
consequently been shown to be a major limitation to the use of the early viral vectors [267-270]. As 
CF is a life-long condition, unless gene therapy is able to target stem cells, it must be repeatedly 
delivered in order to produce a long-term clinical benefit.  The feasibility of stem cell based therapy 
has been explored, however to date both in vitro and animal models have not been promising. As 
the target cells (bone marrow) are not easily accessible, delivery of CFTR must be systemic, and 
studies have demonstrated that this has limited success in trans-differentiation into the airway 
epithelium [271]. In gene therapy, there has only been 1 trial using a viral vector, designed to 
assess clinical improvement. The initial safety arm of the study demonstrated that some subjects 
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showed a small but significant improvement following 3 doses of nebulised AAV mediated CFTR 
cDNA 30 days apart, however these results were not replicated in the larger phase IIb study [268, 
272]. 
 
Non viral vectors  
  
Trials of non-viral vectors commenced as a response to the immune response to viral vectors 
limiting the effectiveness of repeated gene transfer. The most extensively trialed agents currently 
are cationic liposomes, which achieve cell entry by endocytosis across the cell membrane. Initial 
non-viral vector studies looked at nasal administration in small numbers of CF patients. These 
showed evidence of CFTR expression, including partial correction of the chloride defect detected 
by NPD lasting from 3 days up until a month in some patients. Administration was well tolerated 
without adverse effects and significantly, the delivery of 3 doses at 4 weekly intervals did not 
produce an immune response or result in reduced efficacy with subsequent doses, thus supporting 
its role in further trials for long-term treatment of CF [175].   
  
The first clinical trial administering lipid-DNA complex to pulmonary mucosa compared the 
responses of 8 patients receiving nebulized doses of the cationic lipid (GL67) coupled to CFTR 
under the control of a cytomegalovirus (CMV) promoter, followed one week later by a nasal dose, 
with 8 patients receiving lipid alone [194]. Results revealed approximately 25% restoration of 
chloride channel function which persisted for 3 weeks, accompanied by a significant reduction in 
sputum inflammatory cells, and reduced bacterial adherence on epithelial cells obtained by 
bronchial brushing. Side effects of the active treatment included a transient drop in respiratory 
function, and mild flu like symptoms that had resolved by 48 hours. Similar to previous trials, no 
reduction in sodium transport in NPD measurements was seen [194]. In vitro studies have shown 
that change in chloride secretion can be achieved following CFTR correction in a minority of cells 
whereas correction of Na+ hyperabsorption requires normal CFTR function in almost all cells [273]. 
It is currently unknown whether correction of sodium transport, in addition to chloride is required for 
clinical benefit [274].  
 
3.1.2 UK Gene Therapy Consortium 
  
The GTC was founded in 2001 with the aim of sharing expertise and to coordinate the 
development of gene therapy for CF in the UK, linking scientists and clinical sites in Edinburgh, 
Oxford and London. There have been two focuses: working towards the gene therapy Multidose 
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Trial (Wave 1), and the development of a modified lentiviral vector for clinical trials (Wave 2); 
discussed under future work (Section 3.5).  
 
3.1.2.1 Gene therapy Multidose Trial (Wave 1)   
  
The GTC has been working towards performing a large clinical trial with the aim of delivering 
multiple doses of lipid-mediated gene therapy over a long enough period to produce clinical benefit, 
delivered via a nebulizer to the airways of patients with CF. 
 
The gene therapy product was optimised prior to the trial to ensure that it was the most effective, 
safe and well tolerated available. The side effect (a flu-like inflammatory response) was thought to 
be due to an innate immune response to the un-methylated CG dinucleotide (CpG) motifs present 
in the plasmid DNA. A CpG-free plasmid was developed which was shown in preclinical models to 
eliminate the inflammatory response [275]. In addition, the CMV promoter utilised in previous trials, 
which had a rapid onset of action but silenced quickly, was changed to a humanised promoter 
coupled with the elongation factor 1a promoter (hCEFI), to increase the quantity and duration of 
gene expression. The final product is called pGM169, which was shown to provide efficient gene 
transfer into both human airway cells and animal models, without provoking an immune response 
on repeat administration [276, 277]. 
 
Pilot study:  
 
A single-dose safety pilot trial was performed with several aims; to confirm safety following a single 
dose of gene therapy, to assess for evidence of successful gene expression, to determine the dose 
for progression into the Multidose Trial, and assess the duration of gene expression. Patients 
received a single dose of nebulised pGM169/GL67A GT and/or a dose instilled onto the nasal 
mucosa (nasal dose). Three volumes of airway doses were evaluated; 5ml, 10ml or 20ml and 
measurements of safety and gene transfer and expression were recorded at 1,2,6,14 and 28 days 
following the dose. Safety assessment included clinical observations and physical examination, 
adverse event recording, spirometry, HRCT, and serum inflammatory markers. Gene expression 
was evaluated using PD measurements in the nasal and lower airway mucosa and detection of 
transgene mRNA from cell brushing. The 5 ml dose was shown to be optimal; with less systemic 
inflammatory response and reduction in pulmonary function than seen at larger doses whilst 
demonstrating changes in CFTR molecular surrogates [278]. 
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Run-in Study:  
 
The GTC performed a ‘Run-in’ study; a 3 year multicentre trial, conducted to identify which 
outcome markers best assessed any clinically relevant response to gene therapy, and which 
patients to take part in the Multidose Trial [279]. 192 patients with stable CF (aged>10 and 
FEV1>40% predicted) were enrolled. Spirometry and LCI were performed, sputum and blood 
samples were taken for assays assessing inflammation, and radiographic images were obtained at 
4 time points over the first 12-18 months, then at 6 monthly intervals. FEV1 % predicted was 
chosen as the primary outcome, as it was shown to be the assay requiring the fewest patients for 
adequate statistical power, and is the most acceptable outcome measure in CF to regulatory 
agencies. Amongst other measures, CT chest, quality of life questionnaire and LCI were included 
as secondary outcomes. Suitable patients were identified as >12 years old, with FEV1 50-90%. 
These parameters were chosen as patients with lower lung function have inflamed airways with 
large volumes of mucus, obstructing contact between gene therapy and the epithelium [280]. In 
patients in whom FEV1 was already >90%, it is difficult to demonstrate an improvement.  
  
3.2 Gene Therapy Multidose Trial – Method  
 
3.2.1 Aim of the trial  
  
To assess for the first time whether administration of repeat doses of lipid-mediated gene therapy 
to the airways of patients with CF results in a clinical benefit.  
 
3.2.2 My role in the trial  
 
The Multidose Trial had been running for 4 months prior to my commencing this MD(Res). As one 
of 2 clinical research fellows at the RBH site I took on a pivotal role in the everyday running of the 
trial, including; 
 
• Lead for recruitment of the paediatric patients at the RBH 
• Assisted in setting up the UK wide Participant Identification Centres (PICs).  
• Consented both adult and paediatric patients,  
• Provided medical care and assessment.  
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• Either myself, or my colleague, performed all NPD measurements, nasal brushings, and 
blood sampling, 
• I was part of the team who performed the LAPD measurements.  
• I helped amend the trial protocol and patient information sheets (PISs), wrote SOPs 
• As a team of two, we assessed and graded all of adverse events (AEs) from the London 
site.  
• Following the completion of the clinical trial visits I assisted in the analysis of the MBW 
traces for LCI, trial data entry and monitoring the quality of data input.  
• I jointly analysed all LAPD traces and assisted in developing methods to analyse and 
interpret the results as part of a group consisting of Professor Eric Alton, Professor Jane 
Davies, and Dr Michael Waller.  
 
3.2.3 Study personnel   
 
The Chief Investigator was Professor Eric Alton. Trial visits took place in London, at the RBH, and 
in Edinburgh, at the Royal Hospital for Sick Children or the Western General Hospital. The clinical 
team in London, consisting of 2 trial doctors, 3 nurses, 2 physiologists and a clinical trial 
coordinator and was led by Professor Jane Davies. The clinical team in Edinburgh; consisting of 2 
trial doctors and a clinical trial coordinator was led by Dr Alistair Innes. The scientists and 
laboratory technicians at London and Oxford were led by Professor Uta Griesenbach and Dr Steve 
Hyde, respectively.  
  
3.2.4 Subjects and recruitment  
  
The trial ran from June 2012 to May 2014 and recruited patients aged >12 years with CF, defined 
in Section 2.1. Patients who had taken part in the ‘run in’ study, and who were eligible were invited 
to take part. Following this, potentially eligible patients receiving their medical care from any of the 
3 trial sites, were identified from clinic lists and electronic records. In December 2013, PIC sites 
were included and patients from any of the collaborating sites across the UK could also be referred 
by their local team to participate. Subjects were approached by telephone or during a clinic visit 
and followed up by telephone. Interested subjects attended an initial visit to find out more about the 
trial. Consent (and assent if the patient was a child) was performed by one of the clinical trial 
doctors and the subject was enrolled if they fulfilled the inclusion criteria as shown in Table 3.2-1 
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Inclusion criteria 
CF confirmed by sweat testing or genetic analysis 
Males and females > 12 years old 
FEV1 between 50 and 90% inclusive (Stanojevic reference equations) 
Clinical stability at screening 
All patients were required to take effective contraception for duration of the trial 
and 3 months after 
Withhold DNAse for 24 hours before and 24 hours after the GT dose 
Written informed consent obtained 
Permission to inform GP of participation in study 
Exclusion criteria 
Infection with Burkholderia cepacia complex organisms, MRSA or M abscessus 
Significant nasal pathology including: 
polyps, clinically significant rhinosinusitis, severe epistaxis (nasal cohort only) 
Chloride secretory response on nasal PD of >5mV (nasal cohort only) 
Acute upper respiratory tract infection within the last 2 weeks 
(entry can be deferred) 
Previous spontaneous pneumothorax without pleurodesis 
(bronchoscopy subgroup only) 
Current smoker 
Significant comorbidity including: 
Significant renal impairment (serum creatinine > 150 micromol/l) 
Moderate/severe CF liver disease (varices or sustained-ALT/AST>100IU/l) 
Significant coagulopathy (bronchoscopic group only) 
Receiving 2nd line immunosuppressant drugs such as: 
methotrexate, cyclosporine, intravenous immunoglobulin preparations 
Pregnant or breast feeding 
 
Table 3.2-1: Inclusion and exclusion criteria for subjects participating in the Multidose Trial. These were 
applicable to all subjects in the trial unless it is indicated specifically that it is only relevant to patients in 
either of the subgroups. 
 
3.2.5 Ethics and MHRA approval  
  
This trial was approved by the Gene Therapy Advisory Committee 
(GTAC184/http://www.clinicaltrials.gov/ct2/show/NCT01621867) and the Medicines and Healthcare 
products Regulatory Agency. It was sponsored by Imperial College London and managed by the 
Imperial Clinical Trial Unit. Funding for the study was obtained from the NIHR/MRC EME board.  
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3.2.6 Study design  
 
The study design and protocol were devised by the GTC's strategy group. This was a randomised, 
double blind placebo-controlled study designed to assess the clinical efficacy and tolerability, and 
gene expression of repeated doses of gene therapy. Randomisation was on a 1:1 basis, stratified 
for centre, age and FEV1% predicted. An overview of the trial is illustrated in Figure 3.2-1 
 
 
 
Figure 3.2-1: Overview of gene therapy Multidose Trial – nasal subgroup red, bronchoscopy sub group 
green. Reproduced with permission from Dr Michael Waller 
 
All patients were recruited to receive 12 doses of nebulised gene therapy or placebo 28 (+/-5) days 
apart (lasting 48 weeks in total). Investigations were performed prior to the first dose, prior to select 
doses and again on completion on the trial (See Figure 3.2-2). 
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3.2.6.1 Mechanistic Subgroups  
 
Patients seen at the RBH only, were invited to join either one or both subgroups; the nasal (n=24) 
and bronchoscopy (n=24), which were designed to look for evidence of gene expression. The 
randomisation of patients in the subgroups was 2:1 in favour of active treatment. The results of the 
nasal subgroup are being reviewed by my colleague Dr Michael Waller (CRF) and will not be 
covered in detail in this thesis, however mention will be included where appropriate.  
 
Nasal subgroup:  
 
In addition to the nebulised ‘lung’ dose of gene therapy, these patients received a 2ml nasal dose 
of gene therapy administered via a nasal spray. Participants underwent NPD tests at the regular 
time intervals for assessment of CFTR function, in addition to nasal brushings pre- and post-dosing 
and following completion of the trial to asses for the presence of CFTR DNA and vector specific 
mRNA.  
 
Bronchoscopy subgroup:  
 
Patients underwent two LAPD tests to assess bronchial epithelial CFTR function; these were 
performed pre-dosing and after completion of the trial. Brushings were taken on both occasions for 
measurement of CFTR DNA and vector specific mRNA levels. Endobronchial biopsies were 
performed to assess remodelling, lipid accumulation and inflammation.   
  
3.2.6.2 Randomisation  
 
Electronic randomisation was performed as soon as possible after the patient passed screening 
using the InForm system (a web-based data entry system provided by Imperial College). Relevant 
patient details were entered by a member of the trial team to generate a 4 digit randomisation 
number corresponding to a blinded randomised arm of the trial.   
 
3.2.6.3 Study visits   
 
An overview of the all the visits is provided in Table 3.2-3. All visits and investigations were 
performed within the timeframe as defined in the protocol and documented in Table 3.2-2. If this 
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was not possible, a discussion took place with the CI as to whether to adjust the timeframe. The 
timing of tests performed for safety monitoring was not adjusted.   
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Visit Time frame Description 
Pre-dosing 
All subjects 
Introductory 
(optional) N/A Confirmation of subjects eligibility 
    Consent obtained 
    Baseline measurements 
Screening 
(compulsory) N/A Re-confirmation of subjects eligibility 
    Baseline measurements 
Subgroups only 
Nasal NPD: performed on any visit Confirmation of subjects eligibility  
  Brushings >7 days pre 1st dose NPD performed 
Bronchoscopy If pre-screening:  Confirmation of subjects eligibility  
  > 7 days pre-screening Bronchscopy performed  
  If post-screening:   
  > 7 days prior to 1st dose   
Dosing  
All subjects 
All dosing visits  
Dose 1: <28 days from 
screening                   
 
Other doses: 28 days +/- 5 
days referenced to dose 1 
Clinical stability confirmed 
 
Dose given over 40 minutes with a 
minimum of 30 minutes observation 
before discharge 
  (Extended to +/- 7 days in exceptional circumstances) 
 
Doses 4/7/10   Specified additional tests performed  
Subgroups only 
Nasal   Additional nasal dose of gene therapy administered  
Follow up  
All subjects 
Follow up 1 14 days (+/-2) referenced to final dose Post dosing measurements  
Follow up 2 
28 days (+/- 2) referenced to 
final dose 
Post dosing measurements 
Subgroups only 
Nasal Performed at follow up 1 and 2  NPD performed 
  Nasal brushings after 2nd NPD   
Bronchoscopy 
27-36 days following the last 
dose ensuring after follow up 
Bronchoscopy performed  
     
 
Table 3.2-2: An overview of the study visits in the Multidose Trial.  
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3.2.6.4 Dosing protocol  
 
Patients normally taking RhDNase (Pulmozyme) were asked to withhold treatment for 24 hours 
prior to each dose and for 24 hours after due to concerns over potential degradation of the CFTR 
genomic DNA.   
 
20 minutes pre-dosing, patients received 200mcg of inhaled salbutamol via metered dose inhaler 
and spacer (unless there was a contraindication) to limit any potential bronchoconstriction induced 
by the hypotonic gene therapy formulation. Patients were provided with a nasal clip, and 5 ml 
doses of the product: pGM169/GL67A or placebo (0.9% saline) was delivered via an AeroEclipse 
breath-actuated nebuliser in specially designed negative pressure cubicles. The active product and 
the placebo were delivered in identical bottles to prevent un-blinding. Nebulisation was performed, 
with patients receiving 8 cycles consisting of 3 minutes ‘on’ and 2 minutes ‘off’ (40 minutes in 
total).  
 
Nasal subgroup:  A single spray to each nostril of the nasal dose was administered, by the patient, 
at the beginning and at the end of the ‘off’ period, a total of 6 times. The patient held their head 
forward by 45o, placed the nasal spray nozzle in the nostril, and lifted the bottle to a 45o angle. 
Whilst breathing in slowly through the nose, the subject depressed the bottle to generate a spray.  
 
1g of paracetamol (dose adjusted for weight if <16 years old) was given immediately post dose and 
again 6 hours later, to mask any potential flu-like symptoms due to the active product which might 
cause un-blinding. Patients were observed for 30 minutes post-dose, either in the dosing cubicle or 
whilst wearing a facemask in the study bedroom, and reviewed by a doctor and pulse oximetry 
performed prior to discharge. 
 
3.2.6.5 Adverse events and safety reporting  
 
AEs were collected on all patients at every trial visit by one of the doctors. These were graded 
according to their severity and their relationship to the study drug. AEs were discussed cross-site 
to ensure consistency in grading and serious AEs were immediately reported to the trial sponsor 
and relevant bodies.  
 
3.2.6.6 Long-term follow up  
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All patients, including those who had withdrawn after commencing dosing, continue to be followed 
up for a total of 2 years after finishing dosing, at their scheduled clinical appointments.  
 
3.2.7 Outcome measures  
 
The outcome measures included as part of the trial are listed in Table 3.2-3. This chapter 
describes in detail only those relevant and those utilised as outcome measures in the study 
described in Chapter 4.  
 
Clinical efficacy Safety 
Relative change in lung function * Clinical examination 
Lung Clearance Index * Transcutaneous oxygen saturations 
Chest CT scan * Serum inflammatory markers* 
Exercise capacity (bike test) Renal and hepatic function 
Frequency of respiratory exacerbations                                                  
Activity monitor 
Endobronchial histology* (bronchoscopy 
subgroup only) 
Serum calprotectin* Immune response markers 
Quality of life questionnaire Gas transfer 
Change in sputum weight*  
Sputum culture and inflammatory markers*   
 
Table 3.2-3: List of the outcome measures included as part of the MDT. All patients underwent all 
investigations at the time points illustrated in Figure 3.2-2 unless indicated for a subgroup only. Investigations 
documented with a * are of particular relevance to this thesis  
 
Figure 3.2-2 provides a summary of all study investigations performed at individual time points. 
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Figure 3.2-2: Summary of the study investigations at individual time points of the Multidose Trial. INT – 
Introductory visit; SCN- Screening visit; FU – Follow up visit; AAFB- Acid fast and Alcohol Fast Bacilli 
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3.2.7.1 Outcome measures of airway health  
 
Spirometry (see Section 2.2.2) 
 
FEV1 % predicted was performed at screening to determine the subjects' eligibility for enrollment 
into the study, and on dosing visits to ensure that they met the fitness criteria to dose (Appendix B). 
Spirometry was always performed prior to dosing, and the values were converted to Stanojevic 
reference ranges [281].     
  
Lung HRCT scan  
 
All subjects underwent a total of 3 HRCT scans, pre and post dosing to assess efficacy of the 
treatment, and pre-dose 4, as a safety measure. HRCT scans were performed on a 64-channel 
multi detector scanner (Sensation 16 or 64; Siemens Medical Solutions, Erlangen, Germany). 
Females were required to have a negative urine pregnancy test on the day of the CT scan. 2 
dosing proformas were used: a volumetric (inspiration) scan comprising thin sections (1.25mm) 
throughout the lung (used pre- and post-dosing), and an interspersed (expiration) scan with 
1.25mm at 10mm intervals in order to reduce radiation exposure (used pre dose 4).  
 
Scoring:  
 
The scans were anonymised and scored by two independent radiologists who were blinded to 
subject identification and whether the CT was performed pre or post gene therapy dosing. Scans 
were analysed and graded as follows: 
 
o Extent of bronchiectasis  (scored 0-3 per lobe and the value averaged),  
o Bronchiectasis severity and wall thickness  (0-4 per lobe and the value averaged), 
o Evidence of mucus plugging (scored 0-2 per lobe and the value averaged),  
o Tree in bud pattern (scored 1-5 per lobe and the value averaged)  
o Gas trapping (scored as a %) [282].  
 
LCI (See Section 2.2.3) 
  
Tests were performed on all patients at 2 separate occasions pre dosing, prior to doses 4, 7, 10 
and at follow up 1 and 2.   
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To ensure quality control of data analysis at both clinical sites the following measures were put in 
place:  
   
• A proportion (13.8%) of the LCIs were analysed at both sites, across a full range of patients 
with different LCI values, with tests taken from each time point to determine the inter-
observer variability. The 95% limits of agreement were -0.04 to 0.04 LCI units.  
 
• Due to the blinded nature of the trial, the majority of the traces were analysed following the 
completion of the trial, with the exception of those obtained pre dosing, and performed in 
batches related to the visit to prevent longitudinal un-blinding of the observer.  
  
Inflammatory markers: 
 
Inflammatory markers were assessed in the serum, the sputum from all subjects in the trial who 
were able to expectorate, and from endobronchial biopsies in subjects participating in the 
bronchoscopy subgroup. 
 
Serum inflammatory markers  
 
Blood samples were taken at each visit for both clinical and research assays. Samples were sent 
to the trial-site hospital laboratory for assessment of FBC, CRP, ESR, renal and liver function tests, 
and for the bronchoscopy subgroup only, coagulation prior to the procedure. At the time points 
indicated in Figure 3.2-2 blood was tested for anti-nuclear and anti-double stranded DNA 
antibodies in the Clinical Microbiology Laboratory, RBH and lymphocytes were removed from the 
whole blood and sent to the University of Pennsylvania for assessment of anti-CFTR T-cell 
responses. On one occasion blood was taken for the extraction of genomic DNA for CFTR 
genotyping and saved for polymorphism analysis of possible modifier genes; the latter has not 
been analysed to date.   
 
Serum was frozen and stored for subsequent cytokine analysis described below. This was 
performed by the London GTC research technicians.  
 
IL-6  
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Serum IL-6 was measured on the Beckman Access 2 immunoassay analyser, according to 
manufacturers guidelines (Beckman Coulter, High Wycombe, Buckinghamshire, UK) 
 
Calprotectin:  
 
The measurement of calprotectin in the serum samples was performed by an in-house calprotectin 
ELISA (intra-assay coefficient of variation = 5.6%; unpublished data). Calprotectin antibodies were 
gifted by Erling Sundrehagen, Oslo, Norway. Incubation was carried out in a damp box. Microtitre 
plates (Immulux HB, Q88 Dynex Technologies, Chantilly, VA, USA) were coated overnight at 4°C 
with 100 μl of anti-calprotectin (mouse anti-human) monoclonal antibody at 2.5 μg/ml in coating 
buffer (KPL/Insight Biotechnology). Plates were blocked with 1% bovine serum albumin (BSA) for 1 
hour at 37 °C and washed four times with 0.05% Tween-20. Duplicate samples of 100 μl were 
added to the plate in 1:60,000 dilutions for sputum in PBS and 1:500 for serum (50% fetal calf 
serum in PBS). Positive controls of calprotectin (Immundiagnostic, Oxford Biosystems, Oxford, UK) 
were included. Human recombinant calprotectin (Cambridge Biosystems, Cambridge, UK) was 
used to produce 1.56–100 ng/ml standard curves. The samples: anti-calprotectin (chicken anti-
human) polyclonal antibody at 1:5000 dilution; 100 μl of alkaline phosphatase-conjugated donkey 
anti-chicken IgG (Jackson ImmunoResearch, Suffolk, UK) at 1:5000 
dilution were added to wells in three cycles of incubation at room temperature for 1 hour on a 
platform vibrator (450 rpm) followed by washings. Finally, 100 μl of BluePhos® Microwell 
Phosphatase Substrate System (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, USA) 
was added to each well. Plates were incubated in the dark at 600 rpm until the blue colour 
developed, and reached an absorption of 620 nm on a Biotek plate reader. Sample concentrations 
were calculated using the five-parameter logistic (5PL) non-linear regression curve-fitting model 
[283]. 
 
Sputum inflammatory markers  
 
Sputum samples were obtained where possible at the visits illustrated on Figure 3.2-2. The 
samples were collected over 24 hours into 50ml Falcon tubes and weighed. If the patient was 
unable to expectorate sputum spontaneously, induced sputum was performed with 7% hypertonic 
saline only at screening and at follow up. Freshly expectorated samples were stored on ice for a 
maximum of 2 hours and processed as described below. If still no sample was obtained, a cough 
swab was performed for microbiological culture. Samples were analysed for microscopy, culture 
and sensitivity (MC&S), total cell counts (counts/g), neutrophil count (%), concentration of IL-8 
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(ng/ml), concentration of calprotectin (µg/ml), extracellular DNA (µg/ml), quantification of lipid 
droplets and sputum solid content (%). Only the methodology of the outcome measures that were 
used in this thesis are described below. 
 
Sputum processing 
 
Whole sputum was transferred into a sterile Petri dish. The sputum plugs were identified and 
separated out using forceps into a pre-weighed falcon tube and treated with freshly prepared 0.1% 
dithiotreitol (Sigma-Aldrich, Dorset UK) in Dulbecco’s phosphate buffered saline (D-PBS), at a ratio 
of 4ml:1g. Each aliquot was briefly vortexed, rotated for 15 minutes at 4oC before dilution in an 
equal volume of D-PBS and filtered through a pre-moistened gauze to remove solid debris. The 
sample was centrifuged at 1200rpm for 10 minutes at 4oC to produce the sputum sol phase, and 
the supernatant, which was transferred to cryovials for storage at -80oC.  The cell pellet was re-
suspended in 0.9% D-PBS for analysis of total cell counts.  
Cell counts 
 
Cells were isolated from solubilised sputum as described above, and approximately 105  sputum 
cells were cytospun (5 minutes at 500 rpm) onto cytoslides (Thermo Shandon Ltd, Cheshire, UK) 
(six slides per subject). Slides were air dried and fixed for 10 minutes in 4% formalin (Sigma-
Aldrich, St Louis, M0, USA) and subsequently stored at – 20 °C until further use. For total and 
differential cells counts, cells were fixed for 10 minutes in cold methanol (Fisher Scientific, 
Loughborough, UK), dried and stained with May–Grunwald– Giemsa (MGG quick stain; Bio-Optica, 
Milan, Italy) using routine histological procedures and neutrophils, lymphocytes, macrophages and 
eosinophils quantified. Cells were counted on random fields until 300 neutrophils were counted, 
and adjusted for sample volume to provide cells/g sputum.   
  
IL-8  
 
The measurement of IL-8 in the sputum samples was performed using IL-8 Human ELISA and is 
described in Section 2.2.5.1.   
Calprotectin  
 
The measurement of calprotectin in the sputum samples was performed using the same in-house 
ELISA as described above for measurement of serum calprotectin.  
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Endobronchial biopsies: 
 
Two endobronchial biopsies were taken per patient per bronchoscopy, obtained from 
approximately the 5th generation, using one set of disposable cup forceps (Olympus, FB-231). One 
biopsy was frozen in 2-methylbutane-cooled liquid nitrogen at –196 °C and the other immediately 
fixed in 10% formal saline.  
 
The formalin-fixed samples were processed using a Tissue Tek Sakura VIP processor and 
embedded in paraffin wax blocks. 3 micron sections were then cut from these blocks for 
haematoxylin and eosin (H&E) staining. For H&E staining, slides were thawed at room temperature 
for 30 minutes, and then placed in Harris’ s haematoxylin for 1 minute. Subsequently, they were 
differentiated in acid alcohol for 5 seconds and washed in tap water for 5 minutes. They were then 
counterstained with eosin for 30 seconds and cover-slipped using an aqueous mountant. These 
slides were scored independently by two blinded pathologists using a semi-quantitative scoring 
system from 0 to 6 for goblet cell hyperplasia, basement membrane thickening, presence of 
chronic inflammatory cells (lymphocytes and plasma cells), neutrophils, eosinophils and 
seromucinous gland hyperplasia, except for seromucinous gland hyperplasia which was scored as 
absent (0)/present (1).  
  
The frozen biopsy sample was later analysed for the presence of lipid-laden macrophages using a 
semi-quantitative scoring system. This was required as a safety outcome to ensure that excessive 
lipids from the vector were not accumulating in the airway. 
 
3.2.7.2 Methodology for outcome measures of gene expression  
CFTR DNA and mRNA  
Epithelial cell brushings  
Sample collection 
 
Nasal brushings were performed in subjects in the nasal subgroup following their final NPD 
measurements both pre-dosing, and on completion of the trial. Samples were taken from both 
nostrils (described in Section 2.2.4) 
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Lower airway brushings were taken from patients in the bronchoscopy subgroup following LAPD 
measurements. 10 bronchial samples were taken per patient per bronchoscopy using disposable 
cytology brushes (Olympus, BC-202D-5010). At the sampling site, the bronchial wall was brushed, 
and the bronchoscope removed from patient. The clinician performing bronchoscopy held the 
bronchoscope and sheath of cytology brush and wire brush beyond distal tip of scope. The wire 
brush was protruded further than the plastic sheath. A designated person held the wire (not the 
plastic casing) and cut the wire so they are left holding the brushing sample, taking care not to 
touch the brushings. The wire and sheath were retracted and removed through the bronchoscope. 
The site of the bronchial brushings was recorded and the procedure repeated as required. 
Processing samples 
 
Upper and lower airway samples were separately pooled and assessed for cell count and the 
presence of pGM169-specific and endogenous CFTR DNA and mRNA. This was performed using 
TaqMan (Life Technologoes, Paisley, UK) real time quantification PCR instruments and supplies 
[284]. These assays were run by Consortium researchers in Oxford according to the relevant SOP 
developed in that lab. Data were counted as percentage of pGM169-specific to endogenous CFTR 
numbers. If pGM169 was detected but below the linear detection range, or the quantification of 
endogenous CFTR signal was negative; the sample was scored as Positive But Not Quantifiable 
(PBNQ). Samples that were negative for endogenous CFTR were recorded as Not Determined 
(ND), and those negative for pGM169 but positive for endogenous CFTR were valued as zero. 
Results are presented as differences between post- and pre-treatment.  
 
NPD measurements (described in Section 2.2.8.1) 
 
Measurements were performed at the times illustrated in Figure 3.2-2; 3 pre-dosing, during, and 
twice post-dosing, most commonly coinciding with the follow up visits. As all NPD measurements 
were performed by myself or my colleague, it was necessary that the traces performed during the 
dosing period were not visible to the operator or the patient in case clear variations from an 
‘expected CF trace’ led to un-blinding. This was achieved by a method designed for this trial in 
which an external member of the team with no clinical contact with the patients was trained to 
monitor the trace in real-time. They informed the operator when stability was obtained during the 
Ringers and Amiloride phases and if there was a sudden loss of contact between the catheter and 
the nasal epithelium. The final 2 stages were timed for 5 minutes each.  
 
The validity of this 2-operator (blinded) technique was reviewed by Dr Waller, who showed that it 
did not impair the quality of the NPDs [196]. 
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3.3 Statistical analysis  
 
A total patient number of 120 was chosen to provide 90% power to detect a 6% difference between 
groups calculated as the mean change from baseline at a 2-sided 5% significance level.  
 
Statistical analyses were performed according to a predefined plan devised by the trial statistician 
(Gordon Murray) and approved by the Trial Steering Committee. Statistics were performed using 
Prism (Version 5.0c for Mac OSX) and/or IBM SPSS Statistics (Version 22.0). Outcome between 
groups was compared with ANCOVA model, stratified for the following factors; gender, study site 
(London or Edinburgh), baseline FEV1 and whether the subject was in a subgroup. A post hoc 
analysis was performed on all major endpoints, comparing the results between 70-90% (high) and 
50-70% (low) starting FEV1 predicted.  
 
The results are displayed as adjusted mean differences and 95% confidence intervals (CIs). 
Bronchial and nasal biomarkers were assessed with a Mann-Whitney U test. The null hypothesis 
was rejected at p<0.05.   
 
  
3.4 Results   
 
3.4.1 Patient data  
  
Patients were recruited between June 12, 2012 and June 24, 2013. 140 subjects were randomised 
into the trial to receive either the active product; n=78 or the placebo; n=62. 4 withdrew without 
receiving a dose leaving 136 patients (the intention to treat population); active n=76 and placebo, 
n=60. 116 subjects received ≥ 9 doses, active n=62 and placebo n=54. The reasons for 
discontinuing the trial were similar in both groups. Figure 3.4-1 illustrates patient numbers from 
enrolment to completion of the study.  
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Figure 3.4-1: Consort diagram illustrating patient numbers from enrolment to completion of the study. 
  
3.4.2 Subject characteristics  
 
Baseline characteristics were similar between the two groups as illustrated in Table 3.4-1. The 
mean (SD) age of subjects in the active group was 26 (13) compared to 23.6 (10.8) in the placebo. 
The mean (SD) FEV1 % predicted in the active group was 69.0 (9.9) compared to 69.9 (11.1)%. 
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  Placebo Active 
Subjects 54 62 
Age (years) mean (SD) 26.0 (13.0) 23.6 (10.8) 
   <18 17 (31%) 23 (37%) 
   >18 37 (69%) 39 (63%) 
Sex   
   Female 25 (46%) 31 (50%) 
   Male 29 (54%) 31 (50%) 
Centre distribution number   
   Edinburgh 24 (44%) 22 (35%) 
   London 30 (56%) 40 (65%) 
Height (cm) mean (SD) 165.0 (10.6) 163.6 (10.9) 
Weight (kg) mean (SD) 61.6 (15.6) 61.0 (15.7) 
FEV1 (% predicted) mean (SD) 69.0 (9.9) 69.9 (11.1) 
Body-mass index (kg/m2) mean (SD) 22.4 (4.4) 22.4 (4.5) 
Mutation class   
   F508del/F508del 26 (48%) 31 (50%) 
   F508del/class 1-6 22 (41%) 23 (37%) 
   Not F508del/class 1 1 (2%) 3 (5%) 
   Heterozygous/ homozygous class 3-6 2 (4%) 2 (3%) 
   F508del/ Unknown class 3 (6%) 3 (5%) 
 
Table 3.4-1: Baseline and demographic characteristics of subjects in the Multidose Trial  
 
3.4.3 Primary outcome measure 
 
Out of 116 subjects fulfilling predefined per protocol criteria, pre and post treatment measurements 
of % predicted FEV1 were available for 114 patients (active 60, placebo 54). Of the two that were 
not available for follow up, 1 subject was excluded due to clinical deterioration and the other 
withdrew due to time commitments. At 12 months, a significant ANCOVA-adjusted treatment effect 
was demonstrated in the active group compared to the placebo group; 3.7% (95% CI 0.1- -7.3), 
p=0.046. The relative changes demonstrated between the 2 groups were -0.4% (95% CI -2.8 - 21) 
in the active group compared to -4.0% (95% CI -6.6 - -1.4) in placebo. The treatment effect was 
evident from 1 month onwards, as seen in Figure 3.4-2, which illustrates the time course of FEV1 % 
predicted values in patients in response to both active and placebo.   
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Figure 3.4-2: Time-course of the change in FEV1 % predicted value in response to placebo or gene therapy 
(pGM169/GL67A). Error bars show the standard error of the mean  
 
To determine if a responder subgroup existed the patients were divided into pre-defined groups 
and analysed according to sex, age, CFTR mutation (F508del homozygous vs other), chronic 
infection with PA, severity of disease as according to starting FEV1%, CT findings, concurrent 
medication and AEs considered to be associated with trial medication. This revealed a trend, 
though not a significant difference between subjects with more severe disease (FEV1 49.6-69.2%) 
demonstrating a greater response than those with less severe disease (69.6-89.9%); +6.4% (95% 
CI 0.8 - 12.1%) compared to +0.2% (-4.6 - 4.9) (p=0.065). This is illustrated in Figure 3.4-3. 
 
Figure 3.4-3: Primary outcome stratified by baseline FEV1. Time course of the primary outcome response 
stratified by baseline FEV1 at trial entry. (a) Severe group, baseline FEV1 49.6–69.2% predicted; and (b) 
milder group, baseline FEV1 69.6–89.9%, showing a trend towards a larger effect in the severe patents 
(P=0.065). Error bars indicate standard error of the mean. 
 109 
Following the observation that baseline FEV1 appeared to have an influence on the magnitude of 
the treatment effect based on the primary outcome, other outcome measures were analysed for 
this effect. Many of the assays reflected the effect that had been seen for the primary outcome, 
demonstrating that the more severe group of patients showed approximately double the treatment 
effect compared with the values in the whole, unstratified group. This resulted in an absolute 
improvement (vs. stabilisation) in many of the assays. Of note, in those with less severe FEV1 at 
trial entry, biomarkers associated with smaller airways, in particular LCI, still showed a trend 
towards improvement, favouring the active group. These benefits seen in the severe subgroup 
were not related to an increased number of antibiotic courses during the trial, as the number of 
courses taken was comparable in both groups of disease severity. 
  
3.4.4 Secondary outcome measures results  
 
A significant treatment effect was also demonstrated for FVC (p=0.03), and change in extent of gas 
trapping seen on HRCT scans (p=0.048) but not for other measures of lung function including LCI, 
imaging, or quality of life assessments. Whilst the study was not powered to detect differences in 
other outcome measures, a trend was seen across the parameters taken together in favour of 
active treatment over placebo, which did not reach statistical significance. These are illustrated in 
Figure 3.4-4, which summarises the primary and secondary trial outcomes, in response to placebo 
and active treatment.  
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Figure 3.4-4: Forest plot showing secondary outcome responses to placebo or the active product 
(pGM169/GL67A). Data are mean (SD) or mean (95% CI) unless otherwise indicated.  
  
There was no difference between those in the active and placebo groups between the numbers of 
oral antibiotic course received (p=0.3) or i.v courses (p=0.33), which was used as a surrogate 
measure of pulmonary exacerbations, although the trial was not powered to demonstrate it. 
 
3.4.5 Adverse events 
 
No statistical different was found between the total numbers of adverse events recorded between 
the placebo and treatment groups (p=0.68) with a mean of 19.1 per patient throughout the trial in 
the placebo group compared to 21.1 in the active group. 
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3.4.6 Inflammatory markers 
 
 
3.4.6.1 Serum: 
 
Serum samples were collected in all patients. No differences were detected in the level of 
inflammatory markers in the serum between the active and placebo group. A comparison of the 
changes in serum CRP/ ESR and WCC are illustrated in Figure 3.4-4 and changes in other 
markers of inflammation are illustrated in Figure 3.4-5. 
 
3.4.6.2 Sputum: 
 
Out of the expected 232 sputum samples, 169 (63%) were not available because patients did not 
expectorate sufficient sputum for processing. No differences were detected in the level of 
inflammatory markers in the sputum between the active and placebo group (Figure 3.4-5) 
 
 
 
Figure 3.4-5: Forest plot showing the change in sputum and serum inflammatory mediators to placebo or the 
active product (pGM169/GL67A) 
 
There were no clinically relevant changes in sputum microbiology including: Aspergillus fumigatus, 
Mycobacteria, HI, PA and SA	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3.4.6.3 Endobronchial biopsies:  
 
Out of the 50 possible biopsies, 39 (78%) were analysed. The remaining 11 biopsies were not 
analysable because of poor sample quality (n = 10) or because the patient withdrew from the trial 
(n=1), as illustrated in Figure 3.4-6, with no difference between the active and placebo groups.  
 
 
Figure 3.4-6: Histological assessment of bronchial biopsies. All data are expressed as the change from post 
to pretreatment. A positive number indicates an increased score following treatment. Dots represent scores 
for individual biopsies. The horizontal bar indicates the median. a) goblet cell hyperplasia; b) basement 
membrane thickening; c) numbers of lymphocytes; d) numbers of neutrophils; e) numbers of eosinophils; and 
f) seromucinous gland hyperplasia. 
 
 
3.4.7 Outcome markers of gene expression 
 
3.4.7.1 Molecular CFTR results  
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As expected, in the nasal group vector specific DNA was detected in all 15 of the patients who had 
received the product. There was evidence of cross contamination in some samples, however 
significantly more was detected in the active group compared to placebo. In the lower airway, the 
level of vector specific DNA was significantly increased in the patients who had received the active 
product (12/14) compared to none in the patients in the placebo group (0/7) (Figure 3.4-7) 
(p=0.001). This demonstrated that the product made contact with both the nasal and bronchial 
epithelium and was still present at approximately 28 days post-dose. The specific mRNA levels 
were below the limits for detection for both groups in both the upper and lower airway.   
 
 
 
Figure 3.4-7: Comparison of change in vector specific DNA between active and placebo group post dosing. 
Positive But Not Quantifiable = PBNQ, LOQ = limits of quantification, pGM169/GL67A = active product. The 
horizontal line illustrates the median 
 
3.4.7.2 Nasal subgroup  - NPD measurements  
 
24 subjects were in the nasal subgroup. 1 patient was excluded prior to the final analysis as the 
pre-dosing traces were post-hoc considered to demonstrate a total chloride secretory response ≥ 5 
mV. Overall, 75/106 (70.8%) of ZCl, and 70/106 (66.0%) of ZCl/Iso recordings were considered 
interpretable. No signifiant changes were demonstrated in either the baseline values, amiloride or 
chloride secretory responses in either group, illustrated in Figure 3.4-8. However, as in previous 
trials a number of patients in the active group showed changes in chloride values towards non-CF 
values.  
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Figure 3.4-8: Comparison between change in chloride secretion in NPD between active and placebo groups 
post dosing. a) change in voltage in response to perfusion of ZCl solution and b) change in voltage in 
response to perfusion of ZCl/Iso solution. The horizontal lines indicate the median. 
 
3.5 Discussion of primary and secondary outcome measures 
  
The gene therapy Multidose Trial is the first trial designed to assess the clinical efficacy, safety and 
tolerability and gene expression, following repeat doses of non-viral CFTR gene therapy in patients 
with CF. The primary outcome demonstrated a statistically significant treatment effect with relative 
change in FEV1% predicted in the active group 3.7% higher than in the placebo group (p=0.046) 
(relative changes of -0.4% and -4.0% respectively). Changes in secondary outcome measures 
showed a trend towards supporting this finding; however only differences in FVC and the 
percentage change in gas trapping detected by HRCT reached statistical significance. No clinically 
important AEs attributable to the active treatment were seen. The results of the mechanistic 
outcome measures are discussed in the next section along with the results from the LAPD 
measurements. 
 
These results are encouraging, however the treatment effect was largely due to decreased FEV1 in 
the placebo group associated with stabilisation of lung function in the active group. A reduction in 
FEV1 in a placebo group has been demonstrated in other clinical trials in CF but here was higher 
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than that recorded in the CF registry of 1-2%/year [129, 285, 286]. The strict entry criteria for entry 
into the trial may have resulted in patients being at optimal health, and subsequently normalising 
over the forthcoming 12 months. In addition, the CF registry may underestimate the rate of annual 
decline as annual patient data is generally collected at a time of patient stability, thus not reflecting 
real-life variations.  
 
The largest improvement in FEV1 was seen in patients with more severe disease. This is likely to 
be due to patients with more severe disease having more obstructed distal (small airways) and the 
product predominantly being delivered to the proximal (larger airways) compared to those with 
milder disease. Preliminary studies, which were performed to assess drug deposition in the airway 
using similar sized particles to the gene therapy product, demonstrated almost twice the deposition 
in the larger airways in patients with more severe disease, thus supporting this theory. 
Correspondingly a trend towards a greater improvement in LCI (distal airway) was seen in those 
with mild disease compared to severe. 
 
Whilst this trial demonstrated stabilisation of FEV1, gene therapy is unlikely to be included in 
patient’s clinical care due to already high treatment burden on patients and large treatment cost in 
CF. Further work in this field involves to try and improve the efficacy of gene transfer. Using the 
non-viral vector this involves studies reviewing the frequency of dosing, and potentially assessing 
the effect of a combination of gene therapy with a CFTR potentiator. The GTC is currently working 
on a 'wave 2' project which focuses on the development of a novel viral vector. This project is 
looking at lentiviral vectors as that they appear to evade the immune system, allowing a prolonged 
expression profile, however they are inefficient at transducing airway epithelial cells. The 
consortium have pseudotyped the lentivirus with envelope proteins (F and HN) derived from the 
Sendai virus (SIV) in order to increase its ability to transfect airway cells, showing that the F/HN-
pseudotyped simian immunodeficiency viral vector (F/HN-SIV) can be delivered repeatedly and 
safely to murine lower airways without loss of expression, and that it also transduces human air-
liquid interface (ALI) cultures generating stable, long term gene expression [287]. Extensive safety 
testing must be carried out prior to human clinical trials, as therapy that integrates the imported 
gene into the host cell DNA risks insertional mutagenesis and possible activation of a proto-
oncogene, as seen in patients who received gene therapy for Severe Combined Immune 
Deficiency (SCID), who subsequently developed leukaemia [288].  
 
This chapter has set the scene for Chapter 4, which focuses on the bronchoscopy subgroup and 
the LAPD outcomes. This subgroup provided the opportunity to explore the relationship between 
CFTR ion function in the lower airway with measures of disease severity and inflammation at 
baseline and the changes in these parameters following gene therapy. 
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4 Relationship between lower airway potential difference measurements and airway 
disease 
4.1 Introduction 
 
LAPD measurements were chosen as an outcome measure in the Multidose Trial to evaluate 
CFTR function, and provide proof of successful gene transfer. LAPD measurements are 
infrequently performed, and to date, no studies have compared these measurements to markers of 
disease severity. As LAPD measures the ion channel function of CFTR in bronchial epithelium, the 
direct site of disease pathology, these measurements are likely to correlate with markers of airway 
disease. 
 
The hypothesis of this study stated that increased expression of CFTR, as measured by LAPD, 
would provide a protective effect on disease progression and would have an inverse association 
with markers of airway disease. The secondary hypothesis was that improvements in airway PD 
measurements following repeat dosing of CFTR gene therapy would directly correlate with an 
improvement in clinical markers of airway disease.   
 
Evaluating the relationship between LAPD measurements and markers of airway disease 
 
4.2 Study aims:  
 
• To compare LAPD measurements with functional and structural markers of airway health in 
patients with CF  
 
• To establish the relationship between changes in LAPD and those in clinically relevant 
markers after repeated dosing with CFTR-gene therapy  
 
Objectives: 
 
• To measure LAPD in patients with CF prior to starting gene therapy, and compare the 
parameters derived from this with the baseline measurements of inflammation which were 
collected in these patients as part of the MDT 
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• To measure LAPD in patients with CF after repeat doses of lipid-mediated gene therapy 
and compare the changes in these parameters with the changes in inflammatory markers  
 
4.3 Study design 
 
Data from patients taking part in the bronchoscopy subgroup of the gene therapy Multidose Trial 
were included in this study (inclusion criteria are listed in Table 3.2-1). Patients underwent a 
bronchoscopy prior to commencing gene therapy during which LAPD measurements were 
performed, and again on completion of the trial after the follow up measurements had been 
obtained (27-32 days post last dose).  LAPD was used as a functional assessment of CFTR. Other 
measurements analysed are listed below, and were obtained at the time points as described in 
Chapter 3.  
 
Measurement of CFTR  
 
• Functional assessment 
o LAPD measurements  
• Molecular assessment 
o Bronchial brushings for detection of vector specific CFTR DNA and mRNA 
 
Measurements of airway disease and inflammation 
 
• Spirometry 
• LCI 
• Serum markers of inflammation 
o CRP/WCC/ESR/Calprotectin/ IL-6 
• Sputum markers of inflammation 
o Total cell count/ neutrophils/ calprotectin/ IL-8 
• Endobronchial inflammation (assessed from endobronchial biopsy) 
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4.4 Methods 
 
The methodology for obtaining the outcome measures are described in Section 3.2.7. LAPD 
measurements were performed as described in Section 2.2.8.2. 
 
4.4.1 LAPD analysis  
  
Professor Davies and myself analysed the basal values at the carina and in the distal bronchi. The 
chloride secretion, measured by the change voltage following perfusion of ZCl/Iso solution, was 
analysed by Professor Alton.  As it is currently unknown whether the mean voltage measured, or 
the most negative voltage measured, is the most clinically useful parameter, both of these values 
were documented for the basal measurements at the carina, basal measurements in the distal 
airway and the values for chloride secretion.   
 
4.4.1.1 Basal measurements  
  
Each of the group of traces measured at the carina, and the separate traces measured distally (1-
3); pre- and post- gene therapy, received an individual random number (generated with Excel 
random number generator). Every trace was analysed individually, with the operator blinded to the 
subject, treatment group, the timing of the trace, and to all other traces from that subject.   
 
Analysis of the trace was performed in conjunction with the timings that were documented on the 
pro-forma at the time of measurement.  Typical traces of the basal measurements obtained at the 
carina, and the distal basal measurements and the response to ZCl/Iso solution are illustrated in 
Figure 4.4-1 and Figure 4.4-2 respectively. 
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Figure 4.4-1: Typical traces of basal LAPD measurements at the carina – the 4 different locations (either 
anterior/ posterior/ right and left, measured in any order) are marked with the arrows 1-4 with the flat 'stable' 
trace representing the measurement. The final value is the mean voltage across this time. 
 
Figure 4.4-2: Typical LAPD trace in the distal airway of a CF subject – the 1st black arrow indicates the distal 
basal measurement (a mean of the values over 20 seconds of stability), the 1st red arrow where the Ringers 
solution was stopped, and the 2nd red arrow when perfusion of the ZCl/Iso solution was commenced. The 2nd 
black arrow indicates the final measurement after 300 seconds of ZCl/Iso perfusion (again a mean of the 
values over 20 seconds of stability. This shows no change in the voltage of the trace, consistent with absent 
chloride secretion, characteristic of CF.   
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4.4.1.2 Carina  
  
Using the time and location documented on the pro-forma, the parts of the trace corresponding 
with the anterior/ posterior/ right lateral and left lateral tracheal measurements were identified. The 
stable period for each location was identified on the graph, and the mean value over this period 
taken as the final value. Measurements were unacceptable if the period of stability was <10 
seconds or the trace was unsteady (rising or falling), illustrated in Figure 4.4-3.   
 
 
 
Figure 4.4-3: Examples of analysis of measurements performed at the carina. a) an acceptable 
measurement with the black arrow indicating the period of stability over which the values were averaged b) a 
measurement that was too unsteady to analyse, the black arrow illustrates this period, in which there is a 
downwards trend in the trace 
 
4.4.1.3 Distal airway  
  
Basal value: This was taken as the period of trace stability during the Ringers phase prior to 
changing the solution. The mean value for approximately 20 seconds preceding the transition was 
taken as the basal value. Measurements were unacceptable if the period of stability was <10 secs, 
the trace was thought to be rising or falling, or the trace was lost (Figure 4.4-4). There were no 
traces where the distal basal period was too short or unsteady, however on occasions the trace 
was lost and the measurements were subsequently abandoned.  
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Figure 4.4-4: Examples of analysis of distal basal measurements performed at the carina. Arrow 1 indicates 
where Ringers solution was discontinued 2, where ZCl/Iso was started. a) illustrates an acceptable 
measurement and b) where the trace was lost (marked with the red arrow 3) and the measurement was 
abandoned 
 
4.4.1.4 Chloride secretion  
  
The bronchial potential recordings (1-3) from the same patient at the same time point were pre-
grouped and the group assigned a random number. Traces were analysed as a group with the 
operator blinded to the subject, treatment group and whether the traces were performed pre- or 
post- dosing. The traces were printed and assessed visually. The values were obtained by 
meaning the data points in the stable segment of the trace.   
  
The time for ZCl solution to reach the epithelium after commencing the perfusion of the fluid 
through the circuit was 50 seconds. Following perfusion of the ZCl/Iso solution the voltage either 
remained similar, became more negative (upwards), became more positive (downwards), or 
displayed both upward and downward deflection phases. Traces were initially assessed for 
acceptability and were accepted only if:  
  
The time of any change in the trace occurred >50 seconds after commencing the ZCl/Iso solution 
(allowing the solution to pass through the catheter) and <80 secs, allowing approximately 30 
seconds for drug interaction.  If a deflection occurred outside these time points it was thought to be 
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more likely to as a result of external factors e.g. electrical interference secondary to the circuit 
change, dislodgement of mucus or localised debris, or electrode drift.  
   
Traces were excluded if:   
 
• The trace at 50-80 seconds was unstable   
• The trace deflected both upwards and downwards (depolarisation and hyperpolarisation)  
 
Examples of these are illustrated in Figure 4.4-5:  
 
 
 
 
Figure 4.4-5: Examples of traces that were excluded where a) the trace was unsteady 50-80 seconds after 
perfusion of the ZCl/Iso solution and b) the trace deflected both upwards and downwards. The black arrow 
illustrates the basal measurement, the 1st red arrow where the Ringers solution was discontinued, and the 
2nd red arrow when ZCl/Iso solution was commenced 
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If the trace fulfilled the acceptability criteria, the delta ZCl/Iso was calculated by subtracting the 
mean measurement after 300 seconds of perfusion of ZCl/Iso from the mean of the stable part of 
the trace between commencing ZCl/Iso perfusion and 50 seconds.   
  
When calculating the change in values (basal values and measure of chloride secretion) between 
pre and post dosing visits:   
 
• mean difference = mean post dose value - mean pre-dose value  
• most negative = most negative post dose value - most negative pre dose value.   
  
4.5 Statistics 
 
The bronchoscopy subgroup was included in the main trial as observational and opportunistic 
studies that were underpowered to show a statistical difference.  
 
The analysis of the trial data of special interest for this thesis was performed by myself, using 
Prism Version 6 software (GraphPad). The outcome between active and placebo groups was 
assessed with Mann-Whitney U test (normality not assumed due to small data size). Correlation 
between outcome measures was evaluated using non-parametric spearman rank correlation. The 
null hypothesis was rejected at p<0.05 
 
4.6 Results 
 
4.6.1 Bronchoscopy subgroup demographics 
 
Figure 4.6-1 illustrates the profile of subjects recruited into the bronchoscopy subgroup. The 
bronchoscopies for 4 patients; 2 active and 2 placebo, were performed outside the timeframe, due 
to ill health and subject availability. The values for the 2 subjects in the active arm were omitted 
from the final analysis, and the patients on placebo arm were included on the basis that 0.9% 
saline would be unlikely to influence bronchial electrophysiology. There were paired pre and post 
dosing bronchoscopy LAPD measurements in 17 patients (active 10, placebo 7).  
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Figure 4.6-1: Summary of the patients in the bronchoscopy subgroup  
 
 
The patient demographics are summarised in Table 4.6-1.  
 
  Placebo Active 
  Bronchoscopy MDT 
 
Bronchoscopy MDT 
   Subgroup Subgroup 
Number (n) 7 54 16 62 
Age (years) mean (SD) 28.9 (13.4) 26.0 (13.0) 21.5 (10.5) 23.6 (10.8) 
Sex     
   Female n (%) 4 (57) 25 (46) 10 (62.5) 31 (50) 
   Male  n (%) 3 (33) 29 (54) 6 (37.5) 31 (50) 
FEV1 (% predicted) 
mean (SD) 67.0 (10.5) 69.0 (9.0) 71.4 (8.8) 69.9 (11.1) 
Mutation class     
   F508del/F508del 3 (42.8) 26 (48) 10 (62.5) 31 (50) 
   F508del/Other  4 (57.2) 28 (41) 6 (37.5) 31 (50) 
 
Table 4.6-1: Summary of patient demographics in the bronchoscopy group and the entire MDT. The age/ 
sex/ FEV1% predicted and genetic mutation of patients in the placebo and active group are documented. 
Data are mean (SD) or n (%) unless otherwise stated.   
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4.6.2 Adverse events related to bronchoscopy visits  
 
There was one serious adverse event considered by the DSMB likely related to a bronchoscopy 
visit which was the patient being admitted to their local hospital with a respiratory exacerbation 
within 24 hours of the procedure.    
  
4.6.3 Results of primary outcome (FEV1 % predicted) measure in patients in the 
bronchoscopy subgroup  
 
As this was a small subgroup it was not expected that significant treatment effects would be 
observed, however a treatment effect was seen for the primary outcome measure with the active 
group demonstrating a significant improvement in FEV1% compared to the placebo group; 14.2 % 
p<0.01. The relative changes demonstrated between the 2 groups were +3.35% in the active group 
compared to -11.16% in the placebo group illustrated in Table 4.6-1. These discrepant findings 
compared to the main trial group are discussed below.  
 
 
 
 
Figure 4.6-2: FEV1% predicted response to active product and placebo in bronchoscopy subgroup, 
demonstrating a greater improvement in the group on active treatment (p<0.01).The horizontal line illustrates 
the median  
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4.6.4 LAPD measurements  
 
Total number of traces for analysis were 67 (both traces with basal measurements performed at 
the 4 locations at the carina (once per procedure), and traces performed distally including basal 
values and response to ZCl/Iso (performed 3x per procedure). The number of acceptable traces for 
analysis of the basal measurements in the carina and distal bronchi were 98.5% and for the 
analysis of chloride secretion was 64.7%.   
  
4.6.4.1 Pre-dosing measurements 
 
Basal carina and distal measurements: All pre-dosing measurements on subjects who progressed 
to dosing were included in this analysis (n=22).  
 
Delta ZCl/Iso: Only the measurements taken from subjects in which there are paired pre and post 
treatment data were used in this analysis (n=17). The results for the measurements recorded pre-
dosing; basal carina values, distal basal values and the chloride secretion measured by delta 
ZCl/Iso values, for each individual, are summarised graphically in Figure 4.6-3. Both the mean, and 
the most negative delta ZCl/Iso values are illustrated. Each patient is represented by the candidate 
number on the x-axis. The individual traces are displayed as data points, with the horizontal bar 
indicating the mean and the SD. In graph c and d, the scale is adjusted to account for both positive 
and negative changes in the PD.  
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Basal carina measurements 
 
  
 
 
 
 
 
 
Basal distal measurements 
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Mean delta ZCl  
 
 
 
 
 
Most negative delta ZCl  
 
Figure 4.6-3: Pre dosing LAPD measurements. These graphs display the pre-dosing LAPD values for each 
patient obtained at a) the carina (4 measurements at the left lateral/ right lateral/ anterior and posterior 
locations) b) distal basal values (3 different locations at approximately 5th generation bronchi) and c) the 
mean change in voltage in response to ZCl/Iso and d) the most negative change in voltage in response to 
ZCl/Iso.  
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The mean and most negative basal values at the carina were compared with corresponding values 
taken in the distal airways, illustrated in Figure 4.6-4, showing no difference between the 
measurements and the anatomical site using; p=0.07 and p=0.1 (Wilcoxon matched-pairs signed 
rank test).  
 
 
Figure 4.6-4: Comparison of basal values at the carina and the distal airway demonstrating no significant 
difference when comparing a) the mean values and b) the most negative values. The horizontal line indicates 
the median. 
 
 
The measurements at the carina for individual patients were found not to correlate with the distal 
basal values either when comparing the mean values (r = 0.19 p=0.42) or the most negative values 
(r= 0.22 p=0.33) (Figure 4.6-5) 
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Figure 4.6-5: Comparison between measurements made at the carina and at the distal bronchi. a) 
comparison of the mean values at the carina with the mean distal value and b) the most negative values at 
the carina compared to the most negative distal values. 
 
4.6.4.2 Comparison of LAPD measurements between active and placebo groups  
 
LAPD measurements following treatment with active product and placebo were compared. Both 
the mean values and the most negative values for the different parameters were compared. No 
difference was seen between the change in voltage (mV) between the active (n=10) and placebo 
(n=7) groups at the carina (comparison of mean values p=0.40 and most negative values (p= 0.23) 
(Figure 4.6-6) or the distal basal measurements (comparison of mean values p=0.94 and most 
negative values p> 0.9) (Figure 4.6-7). The basal LAPD measurements are thought to largely 
reflect sodium transport via ENaC, with a lower (less negative value) seen in non-CF. A change in 
these values has not previously been reported following gene therapy.   
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Figure 4.6-6: Comparison between the change in basal measurements in the carina between active and 
placebo groups post dosing. a) mean values and b) most negative values. A more positive change is 
considered to beneficial and towards non-CF values. The horizontal line indicates the median  
 
 
 
 
 
 
Figure 4.6-7: Comparison between the change in distal basal measurements between active and placebo 
groups post dosing. A more positive change is considered beneficial and towards non-CF values a) mean 
values and b) most negative values. The horizontal line indicates the median  
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The change in voltage following perfusion of ZCl/Iso (chloride secretion) was compared between 
those who had received active product versus those who had received placebo (Figure 4.6-8). A 
more negative value is associated with improved chloride secretion, consistent with improved 
CFTR function. A significant difference was demonstrated between the mean values of all 
interpretable traces from each patient (p=0.03) (Wilcoxon matched-pairs signed rank test). The 
active group had a median change of -1.3mV (range +4.0 to –5.8mV) compared to +3.1mV (range 
+9.3 to –1.2mV) in the placebo group. Comparison of the most negative values did not reach 
statistical significance (p=0.08), with a median delta ZCl/Iso change of – 2.8mV (range +4.0 to – 
16.8mV) in the active group compared to median +2.6 mV (range + 9.3 to – 1.2mV) in the placebo 
group. 6 out of 10 active-treatment patients had values more negative than the largest placebo 
response.  
 
 
 
 
Figure 4.6-8: Comparison between basal delta ZCl/Iso at distal locations between active and placebo groups 
post dosing. A more negative change (indicating chloride secretion) is considered to beneficial and towards 
non-CF values. a) mean values (p=0.03) and b) most negative values (p=0.08). The horizontal line indicates 
the median.   
 
4.6.5 Relationship between LAPD measurements and markers of disease severity and 
inflammation 
 
4.6.5.1 Relationship at baseline 
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Physiological outcome measures  
 
For all comparisons the mean measurement, and the most negative value from all traces have 
been used. The basal reading at the carina, the distal basal value and delta ZCl were compared to 
the FEV1% predicted and LCI values performed on the screening visit. The results are displayed in 
Figure 4.6-2. 
 
LAPD measurement Outcome 
Position Value FEV1% LCI 
   r p value r p value 
Carina Mean 0.22 0.33 -0.35 0.12 
  Most negative 0.28 0.21 -0.32 0.16 
Distal basal Mean 0.35 0.1 0 0.98 
  Most negative 0.43 0.04* 0.08 0.72 
Delta ZCl Mean -0.08 0.77 -0.44 0.09 
  Most negative -0.1 0.7 -0.25 0.35 
 
Table 4.6-2: Correlation between LAPD values and markers of disease severity measured by FEV1% and 
LCI performed on the screening visit. Both the r (Pearson correlation coefficient) and p value are tabulated, 
with those that are statistically significant indicated with a *  
 
A significant correlation was seen between the most negative basal measurements obtained in the 
distal airway when compared to FEV1%, suggesting that those with more severe disease (lower 
FEV1) had a higher (more negative) basal measurement, reflective of underlying ENaC over-
activity secondary to loss of CFTR modulation of this ion channel. Whilst it didn’t reach statistical 
significance, there was a close association between the mean basal distal measurement and 
FEV1% predicted Figure 4.6-9.  
 
No correlations were detected between any of the other parameters derived from LAPD 
measurements and FEV1 or LCI.   
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Figure 4.6-9: Correlation between patient’s baseline FEV1% predicted and a) mean distal basal value, 
revealing a trend in correlation, which was not significant (p=0.1) and b) the most negative distal basal value 
which was significant (p=0.04) 
 
Measures of inflammation in serum and sputum 
 
At baseline, there was no correlation between any parameters derived from LAPD measurements and any 
measure of inflammation in the serum and sputum  
Table 4.6-3). As none of the correlations were significant, correction for multiple comparisons was 
not applied.  
 
a) 
LAPD 
measurement Serum 
Position Value CRP WCC ESR Calprotectin IL6 
    r p  r p r p r p  r p  
Carina 
Mean 0.12 0.66 0.15 0.59 -0.04 0.86 -0.01 0.97 -0.21 0.38 
Most 
negative -0.04 0.9 0.12 0.67 -0.16 0.5 -0.13 0.58 -0.3 0.2 
Distal 
basal 
Mean 0 1 -0.43 0.11 0.11 0.63 -0.03 0.9 0.03 0.89 
Most 
negative -0.02 0.95 -0.4 0.14 0.12 0.6 0 1 0.02 0.94 
Delta 
ZCl 
Mean -0.18 0.5 0.67 0.11 -0.11 0.63 0.18 0.45 -0.16 0.49 
Most 
negative -0.02 0.93 0.44 0.1 0.03 0.91 0.24 0.3 -0.03 0.9 
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b) 
LAPD 
measurement Sputum 
Position Value TCC Neutrophils Calprotectin IL8 
    r p r p r p r p 
Carina Mean -0.14 0.67 -0.38 0.22 -0.02 0.94 -0.3 0.4 
  Most negative -0.09 0.79 -0.29 0.35 -0.03 0.92 -0.31 0.38 
Distal 
basal Mean 0.18 0.59 0.18 0.57 -0.48 0.11 -0.52 -0.39 
  Most negative 0.19 0.57 0.06 0.85 -0.48 0.11 0.12 0.26 
Delta 
ZCl Mean 0.06 0.86 0 1 0.01 0.98 0.32 0.37 
  Most negative 0.21 0.53 0 0.99 -0.07 0.82 0.33 0.36 
 
Table 4.6-3: Correlation between LAPD values and measures of inflammation in a) serum b) sputum. Both 
the r (Pearson correlation coefficient) and p value are tabulated, with those that are statistically significant 
indicated with a *.   
 
4.6.5.2 Relationship between change in LAPD measures and measures of airway disease 
following gene therapy 
 
As there was only a significant treatment effect in mean chloride secretion (delta ZCl/Iso), only 
these values were compared with changes in outcome measures reflecting disease status and 
inflammation.   
 
Physiological outcome measures  
 
An increase in FEV1% and decrease in LCI is consistent with an improvement in disease. No 
correlation was demonstrated between the change in chloride secretion and either change in 
FEV1% predicted (r=0.24, p=0.52) or change LCI (r=0.04, p=0.92) between pre and post dosing 
values in the active group (Figure 4.6-10) 
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Figure 4.6-10: Relationship between change in chloride secretion pre and post dosing (with a more negative 
value considered to be beneficial) in the active group and a) FEV1% predicted (increase is beneficial) and b) 
LCI (decrease is beneficial) showing no correlation between either parameter. 
 
Measures of inflammation in serum and sputum 
 
As discussed (Chapter 3), there was no significant change levels of inflammation in serum and 
sputum samples pre- and post- gene therapy, and no correlation was shown between the change 
in these parameters and the change in chloride secretion Table 4.6-4.  
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LAPD 
measurement Serum 
Position Value CRP White Cell Count ESR Calprotectin IL6 
    r p  r p  r p  r p  r p  
Delta 
ZCl Mean 0.07 0.9 0.07 0.9 0.1 0.8 0.03 0.95 0.08 0.84 
  Most negative 0.11 0.84 0.1 0.81 0.1 0.81 0.22 0.58 0.27 0.49 
                        
                       
LAPD 
measurement Sputum 
Position Value Sputum weight 
Total Cell 
Count Neutrophils Calprotectin IL-8 
    r p  r p  r p  r p  r p  
Delta 
ZCl Mean -0.4 0.75 0.6 0.35 0.21 0.77 -0.2 0.78 0.2 0.92 
  Most negative -0.4 0.75 0.5 0.45 0.36 0.63 -0.1 0.95 0.2 0.92 
 
Table 4.6-4: Relationship between change in chloride secretion pre and post dosing in the active group and 
secondary outcome measures revealing no significant correlations: Both the r and the p value for each 
comparison are documented.   
 
Relationship between change in LAPD measurements and change in CFTR cDNA  
 
I analysed only those patients receiving active treatment. There was no statistically significant 
correlation between vector- specific DNA measured from the bronchial epithelium with the total 
chloride secretion (delta ZCl/Iso) measured in response to active treatment (r=-0.02, p=0.98) 
(Figure 4.6-11) 
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Figure 4.6-11: Graph plotting the correlation between bronchial cDNA and LAPD choride response following 
active treatment  
 
4.6.6 Analysis of variability of LAPD measurements 
 
4.6.6.1 Intra-subject variability  
 
Within measurements coefficients of variation (CV)%: For all subjects, the mean intra-subject CV% 
for baseline measurements taken pre-dosing at the carina and distal airway respectively were 
31.37% and 35.7%.  
  
Between measurement CV%: For the 7 patients who had received the placebo, I calculated the 
between measurement intra-subject CV% by comparing the values obtained pre-dosing with those 
obtained post dosing (approximately 12 months apart). The CV% between mean values at the 
carina was 31.7%, and between most negative values 25.2%. The CV between mean distal basal 
values was 21.5% and between the most negative values was 27.8%.  
 
The intra-subject variability was thus comparable for both between measurements performed at 
the same time point and within measurements performed on different occasions.   
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4.6.6.2 Variability and disease severity  
 
The airway of CF patients with severe disease is characterised by patchy inflammation and mucus 
deposition. It was thought that more severe disease might affect the variability of the LAPD 
measurements, with mucus disrupting the contact between the catheter and the epithelial surface, 
and localised inflammation affecting epithelial cell integrity heterogeneously throughout the airway. 
To assess this, I determined whether the CV of LAPD measurements was related to FEV1 and LCI 
as measures of disease severity. 
 
Within measurements: Neither the CV% of the measurements taken at the carina or the distal 
basal measurements were found to correlate with the FEV1% predicted or LCI value (Error! 
Reference source not found.) 
 
CV (%) site  
Disease severity 
FEV1(% predicted)  LCI 
  r p  r  p  
Basal 
carina 0.03 0.91 -0.01 0.97 
Distal basal  -0.05 0.85 -0.24 0.38 
 
Table 4.6-5 Correlation between markers of disease severity measured by FEV1% and LCI and the within 
measurement CV% of basal measurements performed at the carina and in the distal airway. Both the r 
(Pearson correlation coefficient) and p value are tabulated 
Between measurements: The CV% of the mean an most negative measurements taken pre and 
post dosing at the carina and the distal basal measurements in the 7 patients in the placebo group 
were compared to markers of disease severity (FEV1% and LCI) taken at the screening visit. There 
was no correlation between the CV% of the mean or most negative values at the carina or the 
distal basal measurements and FEV1% and LCI  
 
CV (%) site  
Disease severity 
FEV1(% predicted) LCI 
  r p  r p  
Basal 
carina -0.57 0.2 -0.26 0.66 
Distal basal  -0.36 0.44 0.37 0.5 
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Table 4.6-6: Correlation between markers of disease severity measured by FEV1% and LCI and the between 
measurement CV% of basal measurements performed at the carina and in the distal airway. Both the r 
(Pearson correlation coefficient) and p value are tabulated, 
 
These results suggest that the variability of LAPD measurements is not dependent on the disease 
status of the patient.   
 
Using this variability data; power calculations (GraphPad StatMate 2) revealed that in order to 
determine a difference basal values of 10mV a sample size of 16 patients in each group (32 in 
total) (95%CI) would be required. For a difference in chloride secretion of 5mV (95% CI), a sample 
size of 14 patients in each group (28 in total) would be required.  
 
4.6.7 Relationship between NPD and LAPD measurements 
  
The relationship between the NPD and LAPD measurements of subjects (n= 5) who participated in 
both subgroups was reviewed by Dr Waller in his PhD thesis. There was no relationship between 
the basal values. A significant correlation was identified at baseline between the nasal and 
bronchial chloride response. Although the numbers were small, this suggests that patients with 
residual chloride secretion have so in both airway sites. Following gene therapy only 5 patients had 
matching NPD and LAPD measurements. A trend was suggested between improved chloride in 
both nasal and bronchial epithelium however the numbers were too small to draw firm conclusions 
[196].  
 
4.7 Discussion  
 
This chapter focused on the LAPD results obtained from the subjects in the bronchoscopy 
subgroup of the Mutlidose Trial. To our knowledge there are no studies that have compared CFTR 
ion transport function in the lower airways with markers of disease severity and inflammation, or 
assessed its use as a functional endpoint assay for novel therapies in CF aiming to correct the 
basic defect. Analysis of the pre-dosing LAPD measurements demonstrated a correlation between 
a higher (more negative) distal basal LAPD measurement and a lower FEV1 % predicted, but not 
with other outcome measures. Treatment with gene therapy resulted in a small but statistically 
significant improvement in lower airway chloride secretion, however this did not correlate with 
improvement in FEV1 % predicted or other markers of disease severity or inflammation. Finally, it 
was shown that the variability of LAPD measurements was high, but not dependent on disease 
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severity. These results are discussed in more detail below, but must be interpreted with caution 
because the numbers are small and the magnitude of the changes in chloride transport are not 
large. 
4.7.1 Pre dosing LAPD measurements 
 
These results replicated previous studies, showing near zero (mean -0.6mV) chloride secretion in 
CF subjects; indicating that the technique was reliable and that subjects were representative of the 
disease group [195]. However, in contrast to the published literature, the basal measurements at 
the carina were not higher (more negative) than those taken distally, which may be due to the small 
sample size. As expected, no correlation was found between carina and distal measurements on 
an individual basis, likely reflecting the variability in expression CFTR throughout the lung. In the 
proximal airway structures CFTR chloride channel is thought to be expressed at low levels [289]. In 
the distal airway, the highest levels of CFTR expression have been demonstrated in the respiratory 
bronchioles as compared with proximal bronchioles (two fold) and alveoli (five fold) [290]. 
 
4.7.2 LAPD response to gene therapy 
 
No treatment effect was observed in the change in basal values at the carina and the distal 
airways. This was expected because, as previously discussed, correction of the basal values 
(reflecting sodium hyperabsorption) is thought to require CFTR correction in almost all epithelial 
cells, which was not anticipated from delivery of lipid-mediated gene therapy. The small but 
statistically significant treatment effect change in chloride secretion of -4.4mV (more negative value 
towards non-CF values, indicated successful gene transfer. These results were not accompanied 
by increased vector specific mRNA in the active group, as the levels were below the limits of 
detection, (Chapter 3) however, previous studies have suggested that PD measurements are more 
sensitive than measurement of vector mRNA to detect evidence of gene transfer [284]. 
 
The difference between the change in chloride secretion between both groups was largely as a 
result of the placebo group becoming more positive (+3.1mV) compared to the active group who 
only had a modest increase in chloride secretion of -1.2mV. This was a small patient group (active 
= 10, placebo = 7) and it is possible that in this size group, variations in only a few measurements 
may alter the interpretation. Looking at the individual responses, 6 out of 10 active-treatment 
patients had values more negative (towards non-CF values) than the largest placebo response.  
 
There are inherent limitations in LAPD measurements, which affect the interpretation of these 
results. It is a technically complex procedure, resulting in a high variability in the measurements, 
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with a within CV in the distal airway of 37% (discussed below). During the procedure, only a small 
area of the bronchial epithelium is being assessed. In subjects with CF, the presence of mucus and 
airway secretions prevents even distribution of the drug throughout the airway, and PD 
measurements may record that had a lesser degree of transfection, thus underestimating the 
response.  
 
It is also important to consider that the improvement seen in FEV1 % in the active group (reported 
in Chapter 3) may not be a direct result of gene therapy and successful gene transfer, but a non-
specific reaction to the plasmid complex itself, especially in the light of the mRNA results and the 
lack of electrophysiological changes detected in the nasal subgroup. This would be unexpected, as 
liposome alone has shown no evidence for producing physiological improvements in the airways of 
non-CF or CF subjects, and plasmid DNA is more commonly associated with deleterious effects. 
Furthermore, there was no evidence of lipid accumulation in the airways of subjects on active 
treatment. Due to ethical reasons it was not possible to administer a CFTR plasmid/liposome 
complex as the placebo due to its unknown effect on the lung when multiple doses are delivered 
and 0.9% saline was used instead, therefore a direct comparison is not possible.  
 
In order to evaluate whether the change in chloride secretion reported in the lower airway was a 
true treatment effect of lipid-mediated gene therapy, further studies in larger groups of patients are 
required. Using larger or more frequent doses and/or performing LAPD measurements in more 
sites would increase detection of CFTR restoration. Ultimately, it may be that the lipid- based 
vector does not result in adequate levels of gene expression to be detected by LAPD 
measurements 
 
 
4.7.3 Relationship between CFTR function and disease severity 
 
Interestingly, this study revealed that at baseline, the most negative distal basal measurement 
correlated with more severe disease measured by FEV1 %. No correlation was seen between the 
distal basal measurements and LCI or inflammatory mediators and there was no relationship 
between chloride secretion in the distal airway or measurements at the carina and disease severity 
or inflammation. 
 
As the group size was small, it is difficult to draw firm conclusions from these results, however the 
correlation between the most negative distal basal measurements and FEV1 is a new finding. This 
supports studies that showed a correlation between more negative basal NPD values and larger 
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amiloride response with worse respiratory disease [245]. The basal hyperpolarisation (more 
negative values) of the bronchial mucosa reflects disinhibition of ENaC (caused by absent CFTR 
function), causing increased sodium absorption. The correlation between distal basal LAPD and 
FEV1 was not seen with LCI. As FEV1 is thought to represent airway damage in the proximal 
airways, compared to LCI, which detects disease in the distal airways (much more distal than the 
LAPD measurements), the correlations that we saw would be anticipated. However, confirmation of 
the relationship between FEV1 and basal distal measurements is required in a larger group, 
particularly since this was not seen in proximal measurements 
 
The Multidose Trial demonstrated a significant improvement in FEV1 in both the trial group as a 
whole, and in the smaller bronchosopy subgroup, accompanied by a trend towards improvement in 
other outcome measures of disease. The change in FEV1 was an unexpectedly larger difference 
than that demonstrated in the trial as a whole; and as the baseline demographics of the subgroup 
were comparable to that of the overall trial, it is most likely to be a chance finding due to the small 
numbers in the group. As chloride secretion was the only electrophysiological measurement to 
demonstrate a treatment effect, changes in this parameter were compared to changes in outcome 
markers of disease and inflammation revealing no significant correlations. 
 
The lack of correlation between chloride transport and disease severity both at baseline and 
following CFTR restoration may be due to several, not mutually incompatible, reasons, either due 
to the limitations of the outcome measures, the patients or potentially because chloride ion channel 
transport does not directly correlate with airway disease:    
 
• LAPD measurements may be too insensitive to perform correlation studies. The variability 
in measurements was high, and may not allow subtle comparisons to be made with a 
feasible number of patients (estimated 32 or 28 subjects required in total to reveal a 
significant difference in basal and chloride measurements respectively).  
 
• The inclusion criteria for the trial required FEV1% to lie between 50 and 90% thus 
automatically excluding those at the edge of the spectrum of disease severity in whom a 
correlation may be most evident.   
 
• There are also limitations in interpreting the outcome markers of disease severity. Many of 
these measures are insensitive, non-specific, and are time dependent measures which may 
influence the results. FEV1 measurements also have some variability from test to test, with 
short term variability reported in the literature as (SD) 6.3%, and dependent upon many 
variables including time of day, mood and tiredness [291]. The variability of inflammatory 
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biomarkers in sputum is reported to be high, and how these markers relate to disease 
severity and longitudinal changes in lung function is still being explored [292].  
 
• It is known that a variety of other factors influence both CFTR function and disease severity 
e.g. age, genotype, infectious status, pancreatic sufficiency status, modifier genes, 
environmental influences, tobacco and air pollutants.   
 
• As considered above, the treatment effect in FEV1 may not have been a direct response to 
gene therapy, but instead to the plasmid complex, although unlikely this cannot be 
excluded. 
 
• It may be that chloride secretion is not the principal force in determining the severity of 
airway disease. The correlation between basal distal values and FEV1 implicate ENaC 
hyperactivity in disease pathogenesis, likely by increased sodium absorption causing 
mucus dehydration and increased viscosity. The extent to which ENaC contributes to 
disease is an ongoing debate [293, 294]. Furthermore, CFTR dysfunction in immune cells 
(Section 1.2.3.3) may play a larger role in disease progression than expected, and/or a 
dysregulated inflammatory response as explored in the next chapter. A combination of 
these influences, rather than chloride secretion alone may lead to airway damage. 
Supporting this theory are results from studies exploring the efficacy of Ivacaftor, which 
produced large changes in FEV1 but only minimal (approximately 35%) improvement in 
chloride response. 
  
Despite being the largest data set of traces to date, the numbers are still small, and to truly assess 
for a correlation between CFTR function measured by LAPD measurements and disease severity, 
more directed and larger trials are required although practically this will be hard to achieve.  
  
4.7.3.1 Variability of LAPD measurements  
 
The pre-dosing within-subject variability of LAPD measurements (basal carina, basal distal and 
delta ZCl/Iso) was shown to be higher than that demonstrated in NPD measurements, (between 9 
and 15% for NPDs performed on different days) likely reflecting the complexity of the procedure 
and the increased presence of mucus and inflammation on the surface of the bronchial epithelium 
[295, 296]. It was thought that the variability of measurements may increase in subjects with more 
severe disease. Inflammation in the nasal epithelium is known to cause a ‘blunted’ PD response, 
characterised by a lower basal value and a flatter responses to the perfusion Ringers Amiloride 
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and ZCl solutions [192]. This was not demonstrated, with no correlation seen between CV% and 
disease severity as measured by patient’s baseline FEV1 % predicted and LCI measurements, 
although it must be stressed that the numbers are small. These results were replicated in the group 
of patients who had been randomised to receiving the placebo with a similar variability calculated 
between the measurements obtained pre dosing with those performed approximately 12 months 
later, where again no correlation was seen between the variability of measurements and disease 
severity. This may be because in comparison to NPD measurement, in LAPD, the catheter is 
placed under direct vision, thereby improving the chance of better contact between the device and 
the epithelium.   
 
Despite this, there is still a large inherent variability in the measurements. In this study, both the 
mean values, and the most negative PD values were recorded for each parameter, as it is 
unknown which provides the most useful readout measurement. Averaging the PD measurements 
reduces the variability between measurements performed at different sites, however it has been 
shown that this may underestimate CFTR function [297, 298]. The most negative PD measurement 
is thought to reflect sodium transport more than CFTR, therefore may miss a chloride response 
[299]. In this study, both measurements have revealed different information, suggesting that both 
should continue to be analysed. LAPD measurements can used to successfully discriminate 
between non-CF and CF subjects, however it does not appear to be sensitive to small changes in 
CFTR expression in vivo, and alternative assays are required [195].  
 
 
4.7.4 Limitations  
 
There are limitations to this study, most of which have been mentioned. The practical difficulties 
involved in performing LAPD measurements, and the necessarily invasive technique means that 
the numbers in this study are small.  
 
4.8 Summary and future work  
 
Ultimately, this study showed that there was an improvement in both FEV1 and LAPD chloride 
secretion (thought to indicate successful transfer of CFTR to the airway epithelium) following 
multiple doses of gene therapy, however there was not enough evidence to support the hypothesis 
that increased expression of CFTR, as measured by LAPD measurements, has a direct, inverse 
association with markers of airway disease, and that changes following repeat dosing of CFTR 
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gene therapy correlated with an improvement in clinical markers of airway disease. Pre-dosing, 
distal basal measurements were shown to correlate with disease severity as measured by FEV1% 
predicted, but not LCI, as would be expected given the location of the measurements, but no 
correlation was seen with other values. The small but significant change in chloride secretion did 
not correlate with changes in outcome markers of designed to measure inflammation or disease 
severity.  
 
In order to fully establish whether a relationship exists between LAPD measurements and CFTR 
function, it would be useful to perform more measurements to see if the results are replicated in a 
larger group, or with an intervention known to produce a big increase in ion transport.  It would be 
particularly useful to treatment with ivacaftor, which has been demonstrated to restore CFTR 
function in the skin (sweat chloride concentrations halved), the nasal epithelium, and to produce a 
significant clinical benefit.   
 
 
Since this study failed to confirm an effect of dysregulated chloride and sodium transport on CF 
airway disease, in the next chapter I have gone on to explore an alternative pathophysiological 
mechanism of disease, related to dysregulation of the immune response, as a prelude to the final 
results chapter exploring the other limb of the hypothesized bidirectional relationship between 
CFTR and inflammation, namely the effects of inflammation on CFTR.  
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5 CFTR function and the inflammatory response to bacterial challenge of nasal epithelial 
cells cultured at an air-liquid interface  
5.1 Introduction 
 
CF lung disease is characterised by recurrent bacterial infection and chronic airway inflammation 
resulting in an uncontrollable vicious cycle, ultimately causing severe airway damage. Previous 
results in this thesis have suggested that dysregulated chloride and sodium transport are not 
directly related to CF airway disease. As a consequence, I have explored an alternative 
mechanism in this chapter. There is growing evidence to suggest that the CFTR defect itself 
causes a dysregulated immune response, which contributes to disease progression, however to 
date the results from studies exploring this field are inconclusive. My predecessor at the 
Department of Gene Therapy, Dr Ives, undertook a study to further investigate the effect of CFTR 
dysfunction on the immune response by comparing the inflammatory response to bacterial 
challenge of CF cells with cells from subjects with non-CF CSLD (PCD) and healthy controls. This 
work provides pilot data for the study described in this chapter.  
 
This section first provides a detailed review of the studies exploring the role of CFTR in immune 
regulation and an overview of the proposed mechanisms. This is followed by a description of the 
work preliminary work leading into the rationale and aims of this study.  
 
 
5.1.1 CFTR and inflammation 
 
It has been suggested that CFTR dysfunction alters the inflammatory response in one or more of 
several possible ways including; by stimulating an inflammatory response in the absence of 
infection, by stimulating an inflammatory response disproportionate to the level of the pathogen 
and failure actively to resolve the inflammatory response [300]. Infection and inflammation are hard 
to dissociate. This section provides an overview of the studies which have sought to establish the 
relationship between CFTR, infection and inflammation in human studies, cell culture systems and 
animal models followed by a review of the proposed mechanisms.  
 
5.1.1.1 Clinical studies 
 
Children with CF have been shown to have higher levels of pro-inflammatory cytokines, and 
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neutrophils in BAL than controls, even in the absence of apparent infection [301]. The ratio of 
neutrophils and IL-8 in BAL, in the presence of bacterial infection was significantly higher in 
subjects with CF than controls, disproportionate to the bacterial load [302, 303]. In addition, there is 
in vivo evidence of reduced quantities of anti-inflammatory molecules such as IL-10 and lipoxins in 
the CF airway compared to controls [304, 305]. However, the evidence is conflicting as other 
studies have demonstrated that BAL obtained from CF infants in the absence of infection had an 
inflammatory profile similar to those of control subjects, suggesting no inflammation without 
infection [306] [307] and in another study that some CF infants who have never had lung infection 
have no detectable inflammatory response [112].  
 
 
There are several possible confounding factors. Firstly, inflammation and infective microbes are 
not evenly distributed throughout the lung. The levels detected in a BAL samples from a single 
region cannot be generalised to other lung segments [308], and infections may be missed [309]. 
BAL analyses were only performed at a single time point. An infection occurring before the study 
and successfully cleared could have accounted for the increase in inflammatory mediators. In 
addition, whilst microbial culture has been considered to be the ‘gold standard’ for the detection of 
microbes, it is estimated that only 1% of bacteria can be cultured [310]. As more sensitive 
detection techniques have been developed, such as 16S rRNA PCR pyrosequencing there is 
growing awareness that previously unidentified bacteria and microorganisms are present, which 
could be contributing to the inflammatory profile [311].  
 
5.1.1.2 Cell culture  
 
In vitro studies comparing healthy and CF cell cultures provide a useful model to explore the 
inflammatory profile of cells lines as both the quantity and exposure time to infection can be 
controlled, however, interactions between epithelial and immune cells are difficult to study, a 
weakness of these studies.  
Basal levels of inflammatory cytokine release:  
 
In primary respiratory epithelial cells, it was shown that IL-8 is produced in higher quantities in CF 
than in wild-type cells at basal conditions [103, 312, 313] [314], with an associated increase in 
activity of the transcription factor, NF-kB. Further studies have confirmed this, with evidence of 
increased NF kB activation, IL-8 production and other inflammatory mediators in CF airway 
epithelial cells at baseline compared to control [315]. However, other studies have showed no 
difference in the levels of cytokines between CF and non-CF cells when un-stimulated and even 
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reduced levels of IL-8 at baseline in CF airway epithelia leaving the results currently inconclusive 
[316].  
 
Bacterial stimulation:  
 
In vitro models exploring the inflammatory profile of CF cells following bacterial exposure have also 
produced variable results with some studies demonstrating a difference between CF and non-CF 
cells, others revealing a difference only under specific conditions whilst other studies have 
demonstrated none at all. These are summarized Table 5.1-1 
 
 
Table 5.1-1A review of the in vitro studies designed to review whether CF cells are hyperinflammatory 
following stimulation. 
Reference  Method  Result 
Difference between CF and controls 
J Clin Invest 
1995;96:2204–2210 
IL- 8 measured in immortalized 
airway epithelial cells and CF 
epithelial cells following exposure to 
PA gene products.   
PA gene products evoked a 4 fold higher 
IL-8 response in the CF cell line 
compared to its corrected cell line 
J Allergy Clin Immunol 
1999;104:72–78 
Immunofluorescence and ELISA for 
IL-8 and 10 were used to compare 
the cytokine profile of CF and non-
CF bronchial epithelial cells in 
culture.  
NonCF cells secreted IL-10, with no  IL-8 
or IL-6.  CF cells did not secrete IL-10 but 
produced more IL-8 and IL-6. 
Iimmunofluroescence data correlated  
Am J Physiol Lung 
Cell Mol Physiol 
2001;280:L493–502 
Cytokine response to PA measured 
in 2 pairs of human epithelial cell 
lines; CF and non-CF.  
CF cell line more IL-8, IL-6 and GMCSF 
than non-CF, with the difference between 
the 2 increasing over time 
Becker et al cytokine 
secretion by CF 
airway epithelial cells 
2004 
Non-CF and CF bronchial epithelial 
cells were cultured at an ALI. The 
cytokines measured at baseline, and 
when activated with TNFα, a 
synthetic TLR-2 agonist, SA and PA. 
Neither groups expressed IL-10 or 
RANTES. CF cells produced more IL-8 
post TNFα and synthetic TLR-2 and SA 
exposure.  No difference following PA at 
baseline, but more in CF cells in the 
presence of human serum.  
Am J Physiol Lung 
Cell Mol physiol 
288:L471-L479,2005 
In vitro activation of NF-kappaB and 
IL-8 levels were measured in CF 
and non-CF cells in response to PA 
Elevated levels of NF-kB activation in CF 
cells, not in non-CF, at baseline and a 
transient increase following PA 
stimulation. IL-8 mRNA only higher in CF 
cells later. 
No difference between CF and controls 
Am J Respir Cell Mol 
Biol 1998;19:210–215 
IL-8 levels measured in non-CF, CF 
and CF cells corrected with CFTR at 
baseline and stimulated with TNFα 
or RSV infection 
 IL-8 response in both. No difference 
between the groups at baseline or 
following stimulation. 
Am J Physiol 
1999;276:C700–C710 
Chemokines measured in CF and 
non-CF airway epithelia at baseline 
and in response to TNFα and IFN-λ 
No difference in IL-8 or MCP-1. CF cells 
expressed less RANTES than non-CF 
cells which was restored when cells were 
corrected with CFTR.  
Am J Respir Cell Mol 
Biol 1999;20:1073–
1080 
Cytokines and specific mRNA were 
compared in CF and non-CF cell 
culture at baseline and followingIL-
1B stimulation. 
CF cells that were engineered to express 
the WT-CF gene secreted more IL-8 than 
the CF cell.  !!
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Limitations in cell modeling systems likely contributed to these inconsistent results. Acquiring the 
cells by mechanically detaching them from their environment likely produces an inflammatory 
response, which may interfere with further measurements of the inflammatory mediators in 
experimental conditions. As the cells have been removed from the internal environment, they are 
not exposed to circulating cells and mediators, which may affect their responses.  
 
• Cell suspension models do not accurately reflect in vivo conditions as the basolateral 
surfaces are exposed to the stimulus, rather than just the apical surface as in the intact 
airway, and they have a short life span therefore cellular activity may deteriorate over the 
course of the experiment.   
 
• Cell culture systems provide a more accurate model of in vivo conditions (described in detail 
below) however they also have limitations. Firstly, a range of cell modeling systems are 
used in the studies, which have been shown when in direct comparison to produce different 
and variable results [317]. Also, when using immortalized cells, clones of cells are derived 
from a mixed population of primary cells, therefore the isolated clone represents only a 
subpopulation of the primary culture that may or may not have the same characteristics as 
the principle cell-type of origin. The process of culturing and passaging cells can also alter 
the expression of cell-specific characteristics, such as cell polarity, tight junction formation, 
mucus secretion and cilia formation [318]. Genetic and environmental factors likely have an 
effect on the tissue cultures and influence the inflammatory response, which is difficult to 
measure.  
 
Whilst cell-modeling tools are useful, they do not accurately reflect the complexity of the airway 
environment and interpretation must take this into account. 
 
5.1.1.3 Animal studies  
 
Studies using xenografts have examined the inflammatory profile of the CF airway, using human 
fetal tracheal grafts in severe combined immunodeficiency (SCID) mice. These studies 
demonstrated that uninfected CF human fetal tracheal grafts have higher intraluminal 
concentrations of IL-8 at baseline and increased subepithelial leukocytes compared with non-CF 
grafts. Bacterial challenge with PA initiated intense damage to the mucosa in the CF airway graft 
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compared to the non-CF graft, leaving it vulnerable to further bacterial infection [319].  
 
Murine models have demonstrated that following the instillation of PA-impregnated agar beads, 
CFTR-deficient mice have significantly higher concentrations of inflammatory mediators in BAL 
fluid, and greater mortality than controls, despite an identical infecting bacterial load [320]. Similar 
to in vitro models, not all murine models have shown this relationship, with some subsequent 
studies demonstrating similar levels in both groups [321]. More recently, studies in newborn CF-
ferrets have indicated that defects exist in both innate immunity and inflammatory signaling. BAL 
obtained both immediately at birth and following first bacterial exposure during birth showed 
disturbances in inflammatory mediators, with higher TNF-α and IL-8 in CF ferrets compared to 
controls, and disturbance in cellular signaling pathways controlling immunity and inflammation 
(including the complement system and macrophage function) [322]. Studies in the CF pig have 
revealed that despite the fact that they develop spontaneous lung infections soon after birth, the 
levels of neutrophils a hypothesis theory that infection must be present to stimulate the 
inflammatory response; however the CF pig has not yet been explored to see if the response to 
infection is exaggerated [15].  
 
5.1.1.4 Proposed mechanisms – leading to exaggerated inflammatory response 
 
It has been proposed that defective CFTR alters several pathways that result in a dysregulated 
immune response. The mechanism of this is currently not known and there are several proposed 
hypotheses:  
 
Epithelial cells with impaired CFTR function are hyperinflammatory.  
 
• Increased activation of the NF-kB pathway; possibly as a result of abnormal CFTR function 
affecting ASL composition and volume, concentrating pro-inflammatory factors which leads 
to altered cell signaling and enhanced production of NF-kB. This factor translocates into the 
nucleus and increases the transcription of pro-inflammatory cytokine genes (including IL-8, 
TNF-α, IL-6 IL-1B), which ultimately increase airway neutrophilia In addition, impaired 
CFTR function results in hyper-polarised membrane potentials, which potentially leads to an 
increase in intracellular calcium ions that effect NF-kB signaling, particularly on exposure to 
pathogens [323].   
 
• Defective CFTR affects fatty acid and cholesterol metabolism, resulting in a higher production 
of products that promote inflammation (arachidonic acid and leukotriene B4) and decreased 
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levels of anti-inflammatory lipids [324]. 
 
• Abnormal intracellular ion transport caused by impaired CFTR function results in an 
accumulation of ceramide in the airways, inducing cellular apoptosis. There is subsequent 
deposition of DNA in the airways, which increases the adhesion of PA and promotes a 
downstream signaling cascade leading to chronic inflammation [325].  
 
• Accumulation of mis-folded or unfolded CFTR protein in the endoplasmic reticulum (ER) in 
patients with CF, causes stress-induced cell death which results in an increase in 
inflammatory signaling pathways to repair tissue damage [300]. 
 
 
Epithelial cells with impaired CFTR function have impaired resolution of the immune response. 
• There is a defect in lipoxin-mediated anti-inflammatory activity in the cystic fibrosis lung, 
with lipoxin concentrations in the airway fluid shown to be significantly lower in subjects with 
CF compared to other inflammatory lung conditions [304]. This is postulated to be due to 
reduced 15-lipoxygenase 2 expression; the gene that encodes for an enzyme involved in 
converting arachidonic acid into anti-inflammatory lipoxins [324].  
• A study of murine alveolar macrophages showed that lack of CFTR function resulted in 
abnormal TLR4 localisation, which resulted in an increase in pro-inflammatory pathways 
(modulated by increased NF-kB) and a decrease in the degradation of the TLR which 
affects the down-regulation of the pro-inflammatory state [326]. 
 
• It has been proposed that interferon (IFN) signalling is blunted, which interferes with 
eradication of bacteria, and increases susceptibility to viral infection [326]. 
 
 
Currently there is inconclusive evidence to determine whether CF airways generate excessive 
inflammation for a given bacterial load, and whether the airway epithelium dysregulates pathways 
thus contributing to the excessive inflammation which characterises CF lung disease. Alternative 
models for exploring the role of CFTR function in regulating the inflammatory response are 
required. 
. 
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5.1.2 Previous work performed in the Departments of Gene Therapy and Paediatric 
Respiratory Medicine 
 
This study compared the inflammatory phenotype of nasal epithelial cells from subjects with CF 
with those from patients with PCD. PCD shares a similar pathology of impaired MCC and airway 
neutrophilia to CF, but cells have no genetic CFTR defect, and presumed normal CFTR protein 
function. Comparison of the two cell types potentially allows differentiation between the secondary 
effects of chronic infection and inflammation on MCC and epithelial cells with that of specific CFTR 
dysfunction. The hypothesis for this study was that the cells from subjects with CF, with absent 
CFTR function, would produce higher levels of pro-inflammatory cytokines following bacterial 
stimulation than those from subjects with PCD or healthy controls.  
 
Epithelial cells were obtained by nasal brushing samples from patients with CF and PCD who were 
attending respiratory clinic at the RBH and age/sex matched healthy controls. The samples were 
infected with known concentrations of the common respiratory bacteria SA, PA or HI and 
supernatant surrounding the cells was removed at 1 and 24 hours and later analysed using IL-8 
Human ELISA Kit (Life Technologies) to quantify the level of this pro-inflammatory cytokine. This 
ELISA was also used in the pilot studies for the main experiment and the methodology is described 
in Section 2.2.5.1.  
 
Results in 38 subjects, CF (10), PCD (10) and controls (18) surprisingly demonstrated that the 
levels of IL-8 in the supernatant from cells from subjects with PCD cell were significantly lower 
(P<0.05) at 24 hours than CF and controls, which were similar (Figure 5.1-1)  
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Figure 5.1-1: Inflammatory response (IL-8) of nasal epithelial cells in suspension infected with PA 
demonstrating a smaller inflammatory response in patients with PCD than CF or controls at 24 hours 
(p<0.05). Data presented are mean (pg/ml) and range of values for each subject group at 1 hour and 24 
hours after exposure to PA 
 
These results did not support the hypothesis that cells with reduced/absent CFTR function produce 
an exaggerated pro-inflammatory response to infection; the epithelial cells from subjects with PCD 
appeared to mount a blunted inflammatory response when exposed to bacterial stimuli, opposite to 
that seen in-vivo [327]. It is likely that these unexpected results were due to limitations of the cell 
suspension model; discussed above.  
 
The study described in this Chapter is a development of the pilot study in which cells cultured at an 
air-liquid interface (ALI) were chosen to test the hypothesis, as they better replicate in vivo 
conditions than cells in suspension.  
 
5.1.2.1 Cells cultured to an ALI 
 
Cells obtained from subjects by brushings, are cultivated in a controlled environment (described 
below in detail). The result is a confluent cell monolayer where medium is only supplied to the 
basal chamber and the apical surface of the cells is exposed to air, which mimics the conditions 
found in the airway. Cells can either be cultured to this ‘basal’ level, or can be further cultivated to 
allow cells to differentiate towards a ciliated epithelial phenotype that resembles the human 
respiratory epithelium in vivo. These cells have normally motile cilia, secrete mucus, and develop 
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stable transepithelial electrical resistance thus providing a robust experimental tool. For 
experiments that use in vitro models to explore cell response to bacterial stimulation, ALIs have the 
advantage that it is possible to apply bacteria only to the apical surface as would occur naturally in 
the airway. The disadvantage of allowing final stage for ciliogenesis to occur is that this stage of 
cell culture takes approximately 21 days and is frequently unsuccessful due to failure of the cells to 
propagate. This lengthens the time scale of studies and increases the risk of cell infection thus 
reducing the yield of successful cell cultures. It is unknown whether cells cultured to the basal level 
produce a comparable inflammatory response to bacterial stimulation as ciliated cells and whether 
these can be used as a surrogate tool.  
 
 
This present study was designed to enhance understanding of the relationship between CFTR 
function and the response to bacterial challenge of nasal epithelial cells, utilising cells cultured at 
an ALI as a better representative of in vivo conditions than cells in suspension.  
 
The hypothesis was that cells from subjects with CF, with absent CFTR function, would produce 
higher levels of pro-inflammatory cytokines following bacterial stimulation than those with PCD or 
healthy controls. 
 
5.1.3 Study aims: 
 
• To define the relationship between CFTR function and inflammation by comparing the 
inflammatory response to bacterial challenge of CF nasal epithelial cells cultured at an ALI 
to those of wild-type and non CF CSLD, in this case PCD 
Objectives  
 
• To culture cells at an air-liquid interface from subjects with CF, PCD and controls and 
expose the cell cultures to common respiratory bacteria 
• To collect supernatant from the cell cultures at regular time intervals (1, 4, 24 and 72 hours) 
following bacterial stimulation, and measure the quantity of pro-inflammatory cytokines in 
the supernatant 
• To compare the inflammatory profile of the supernatant obtained from CF, PCD and 
controls at all time points 
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This study was designed and performed by myself assisted by Dr Amelia Shoemark, Senior 
Scientist, RBH, London. All of the data analysis and statistics were performed by myself. 
 
5.2 Methods 
 
5.2.1 Overview of study design 
 
Nasal brushings were obtained from subjects with CF, PCD and healthy volunteers. These cells 
were cultured at an ALI interface to a ciliated cell phenotype until 4 wells from the same subject 
had differentiated. These were infected with either one of the common respiratory disease causing 
organisms; SA, PA, HI or phosphate buffered saline (PBS) (control). After 1 hour, the organisms 
were killed with local application of antibiotics (streptomycin, penicillin and gentamicin) and 
supernatant from all of the samples was collected at 1 hour, 4 hours, 24 hours and 72 hours 
following the initial infection. The supernatant was frozen at -80oC, and later analysed using the 
MSD platform, designed to detect the presence and quantity of inflammatory mediators in tissue 
supernatant. The inflammatory response elicited from each group to each bacterial stimulus was 
compared.  
 
5.2.2 Pilot study 
 
Prior to commencing the study described above, it was necessary to establish the experimental 
parameters. This included: 
 
• The most appropriate cell lineage:  
- To determine whether cells cultured to the basal stage elicit the same inflammatory response 
as the fully ciliated phase, and therefore if basal cells could be used as a quick surrogate for 
planning the main study. 
• The optimal bacterial concentration:  
- To be both sufficient to stimulate a cytokine response detectable by standard laboratory 
assays, and also be successfully killed by antibiotics to ensure that the period of bacterial 
exposure to the cells could be controlled. 
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These matters were addressed in a pilot study, consisting of 3 experiments described below in 
section 5.2.4. 
 
5.2.3 Laboratory methodology 
 
The following section describes the elements of the methodology common to both the pilot and 
main experiment, based on approved departmental protocols.  
 
5.2.3.1 Nasal brush biopsies 
 
Nasal brushings were obtained as described in Section 2.2.4.  
 
5.2.3.2 Cell culture  
 
Airway Liquid Interface (ALI) cell cultures were grown as according to the RBH NHS Trust Electron 
Microscopy Unit - PCD diagnostic service standard operating procedure. 
 
Equipment 
 
Recirculating class II safety cabinet with HEPA filter  
Vacuum pump  
37ºC CO2 Incubator with sealable door and HEPA filter 
Laboratory fridge freezer  
Nikon Eclipse TI inverted microscope with 40x lens 
Small incubator (for warming media)  
Balance (sensitive to 0.01g) 
A list of the reagents, including calibration material is included in Appendix A.  
 
Culturing basal cells:  
 
The cytology brush was agitated in 1ml of BEGM until all the material was removed and the BEGM 
was transferred to a collagen coated well  (12 well plate). The cell cultures were incubated at 37oC, 
5% CO2. Every 2-3 days the BEGM was changed and the confluence of the basal cell layer 
visualised under the microscope and documented. When 80-90% confluence had been reached 
the cells were expanded into a flask.  
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Flasks:  
 
To expand the wells into a tissue culture flask (T25), the BEGM was removed from the well using a 
vacuum pump. 1ml of Hanks Balanced Salt Solution with calcium and magnesium (HbSS-Ca-Mg) 
was added and incubated for 5 minutes at 37oC, it was then removed and 0.5ml of Trypsin/ EDTA 
added to the well and incubated for 3 minutes. Both of these steps facilitate detaching the cells 
from the well. The cells were gently pipetted off the trypsin and transferred into 10ml BEGM in a 
15ml tube. This was spun at 1100rpm at 19oC for 5 minutes, the supernatant removed, the pellet 
resuspended in 1 ml BEGM and added to a collagen coated T25 flask containing 4ml BEGM. 
Flasks were fed every 2-3 days and confluency assessed. When 80-90% confluence was attained 
(at least 4 days) it was split into transwell supports. 
 
 
Transwell supports:  
 
A 12 well plate with 4 transwell inserts was placed in the fume hood, exposed to UV light. 5ml of 
HbSS Ca-Mg was added to the T25 flask for 5 minutes (37oC) which was replaced by 1.5ml of 
Trypsin/EDTA, incubated for 3 minutes, and then transferred into a 15 ml tube with 10ml BEGM. 
This was centrifuged at 1100 rpm for 5 minutes at 10oC. Supernatant was removed and the pellet 
resuspended in Air Liquid Interface (ALI) media to make 330,000 cells/ml. 0.25ml (roughly 83,250 
cells) were transferred into the wells on the plate (usually 4). 1 ml of ALI media was added to the 
basolateral side of each well. Every 2-3 days the apical liquid and basolateral liquid were replaced 
with 250μl and 1 ml of ALI media respectively. The change in colour of the media was noted, and 2 
feeds after the media changed from pink to orange (on average 7-10 days) they were transferred to 
air liquid interface (ALI).  
 
ALI cultures:  
When 100% confluence was achieved, the apical fluid was removed using the vacuum pump and 
the basolateral fluid replaced with 700μl ALI media. This was repeated every 2-3 days. The colour 
of the media was noted as change from pink to orange indicated cells were successfully 
metabolising ALI media. Cilia start to emerge from day 12 of ALI onwards and are visible under the 
microscope at day 21 of ALI. 
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5.2.3.3 Common problems encountered 
 
Infection:  Cells became infected either from the original source or contamination from apparatus. 
To try and avoid this, penicillin, streptomycin, gentamicin and amphotericin were added to the 
media (BEGM and ALI). When wells became infected they were removed immediately and 
disposed of in Virkon to prevent cross contamination.  
 
Failure to propagate: A minimum number of 82,000 cells are required for basal cells to propagate 
on the 12 well plate. Insufficient numbers meant that samples failed to develop for splitting into 
flasks. 
 
Failure to ciliate: Samples can fail to ciliate for several reasons. Either a mixed cell population can 
develop despite the use of selective growth media, or they appear to grow ‘tired’ during the process 
and fail to successfully ciliate.  
 
5.2.3.4 Bacteria 
 
Growth of bacteria 
 
Bacteria known to be a common cause of infection in patients with CF and PCD were considered 
for the study. PA SA and HI were chosen as they are the most common infecting organisms [328]. 
 
The bacteria (PA: PA01 lab strain, and HI and SA: clinical strains) were stored at -20oC on beads. 
4 days prior to experimental use, 2 beads were placed in 10ml of Tryptone Soya Broth (TSB) and 
agitated overnight at 37oC. Following this, each strain was subcultured 3 times on appropriate 
agar: SA and PA on Colombian horse agar and HI on chocolate agar. 24 hours prior to the 
experiment, a single colony of each bacteria was used to inoculate a separate container of 10mls 
of TSB. These were cultured overnight and agitated at 37oC to provide the bacterial culture.  
 
Concentration of bacteria 
 
The concentration of bacteria was measured using optical density at a wavelength of 600nm 
(OD600). OD is measured in a photometer where light is emitted by a source and detected and 
quantified on a photoelectric cell. A sample of the bacterial culture is placed between the light 
source and the cell in a cuvette, causing the light to scatter, so that the electrical signal is weaker 
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than with a cell-free cuvette. The weaker electric signal is converted to an extinction or OD value, 
which can be used to estimate the concentration of the bacteria, as illustrated in Figure 5.2-1.  
 
 
Figure 5.2-1 Typical setup of an absorbance measurement in a photometer, illustrating a) a control sample 
with a cell-free cuvette, and b) bacteria in the cuvette, causing the light to scatter resulting in a weaker 
electrical signal 
 
Method:  2 ml of each bacterial solution suspended in TSB was spun at 3000g for 10 minutes at 
4oC to retrieve a pellet. The pellet was re-suspended in PBS and the OD600 determined using 
UNICAM UVI (ultraviolet visible instrument). The OD600 was adjusted to the required OD600 by 
addition of PBS. It is known from the literature that an OD600 of 0.1 equates to approximately 1 x 
108 cfu/ml of PA, however the OD required to obtain approximately the same concentration of 
cfu/ml of SA and HI is not as well established. This was addressed in the pilot study, Experiment 2 
(5.2.4.2). 
 
5.2.4 Pilot Study – methods 
 
5.2.4.1 Experiment 1 
 
This experiment was performed to determine whether cells cultured to the basal stage elicit the 
same inflammatory response as the fully ciliated phase, and therefore if basal cells could be used 
as a surrogate for fully ciliated ALIs. 
 
Method 
 
5 sets of cell cultures were selected for this experiment, selected from samples that were initially 
grown for clinical purposes but subsequently found not to have a diagnosis of CF or PCD and no 
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longer required. 3 sets of the cell cultures contained fully differentiated ciliated cells, and 2 
consisted of predominantly basal cells (determined by visual inspection). These were derived from 
4 different donor subjects; with the 3 sets of ciliated cells from 3 different donors, and the basal 
cells both from the same, 4th donor, due to the availability of cell cultures available. 24 hours prior 
to the experiment, all cells were fed with ALI media which had been made without the normal 
addition of antibiotics or steroids, to prevent any artificial suppression of the inflammatory 
response.  
 
The bacteria were prepared as described above. PA/SA and HI were reconstituted in PBS and the 
concentration adjusted to produce concentrations of each at both OD600 =1, and OD600 = 0.1. 
 
Start 
 
The cells were infected with 200μl of bacteria or PBS (control). Not all sets of cell cultures had 4 available 
wells therefore infection of the cells was adjusted as illustrated in  
Table 5.2-1. 
 
 
Cell 
Number 
Cell type 
Well 1 Well 2 Well 3 Well 4 
Bacteria 
Conc 
OD600 
Bacteria 
Conc 
OD600 
Bacteria 
Conc 
OD600 
CONTROL 
1 Ciliated HI 1 SA 1 PA 1 PBS 
2 Ciliated HI 0.1 SA 0.1 X n/a PBS 
3 Ciliated X n/a X n/a PA 0.1 PBS 
4 Basal  HI 1 SA 1 PA 1 PBS 
5 Basal HI 0.1 SA 0.1 PA 0.1 PBS 
 
Table 5.2-1: Layout of the wells, cell type and bacteria in each group of cell cultures 
 
1 hour 
 
200μl of supernatant was sampled from the apical region, divided into 4 x 50μl cryovials and frozen 
at -80oC. 700μl of supernatant from the basolateral region was frozen in a cryovial at -80oC. 700μl 
of ALI media without steroids, but with antibiotics, was added to the basolateral region of all the 
cells. 200μl of ALI media with the addition of antibiotics was added to the apical section of the 
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basal cells. 200μl of PBS containing antibiotics was added to the apical section of the ciliated cells. 
All cells were placed in the incubator at 37oC. 
4 hours 
 
Supernatant was collected and stored as at 1hour. 10μl of supernatant from each well infected with 
bacteria, was removed and plated onto the appropriate agar and incubated overnight at 37oC. 
These were examined at 24 hours to look for evidence of bacterial growth. 
24 hours 
 
Supernatant was collected and stored as before. 10μl of supernatant was only removed from the 
samples in which bacterial growth had been documented at 4 hours. These were incubated over 
night and examined at 24 hours to look for evidence of bacterial growth. 
72 hours 
 
Supernatant was collected and stored as before. 10μl of supernatant was only removed from the 
samples in which bacterial growth had been documented at 24 hours. These were incubated over 
night and examined at 24 hours to look for evidence of bacterial growth. The cells were examined 
under the (Axiovert inverted microscope, Zeiss) microscope to observe cellular integrity and ciliary 
beat frequency as a marker of cell damage.  
At a later date, the samples of supernatant were thawed and analysed using an IL-8 Human ELISA 
Kit (Life Technologies) following the manufacturers instructions (Section 2.2.5.1). The standard 
curve range, 15.6-1000ρg/mL for this ELISA is comparable to the dynamic range of IL-8 detection 
on the MSD platform, 0.12-10000 ρg/mL (sensitivity >0.12 ρg/mL), which will ultimately be used in 
the main experiment.  
 
Results 
 
• Cell lineage and sample site 
o Basal cells did not produce an inflammatory response detectable within the 
standard ELISA range. 
o Levels of IL-8 measured in the supernatant sampled from the basolateral segments 
were significantly lower than that from the apical segments. 
• Bacterial concentration 
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o Elevated IL-8 levels were detected in the apical supernatant of ciliated cells 
following infection by all bacteria at both concentrations (OD600 =0.1 and OD600 =1) 
as illustrated in Figure 5.2-2, however the response produced following stimulation by 
PA was greater than that produced by HI and SA 
 
 
 
Figure 5.2-2: IL-8 response following infection with a) higher concentration of the all bacteria OD600 =1 PA, 
SA, HI and control, and b) a lower concentration of PA only (OD600 =0.1 PA) and control and c) a lower 
concentration of SA and HI (OD600 =0.1 SA/ HI) and control 
 
 
o Following infection with all of the bacteria at the lower concentration (OD600 0.1), cilia were 
visualised to be beating in the well and no holes in the monolayer or visible damage to the 
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cells had occurred at 72 hours. Infection at the higher concentration of bacteria (OD600=1) 
showed more cilial damage, and dead cells had detached and were floating in the apical 
media at 72 hours. 
o No growth of either PA, HI or SA were visualised on the agar plates at 1,4,24 or 72 hour 
points at either concentration  
 
Discussion 
 
Cells cultured to the basal stage did not produce a sufficient inflammatory response to be 
detectable within the limits of the IL-8 ELISA kit (15.6-1000pg/ml). The ciliated cell cultures showed 
a rise in levels of IL-8 following stimulation with PA at bacterial concentrations OD600=0.1 and OD 
600= 1, therefore these fully differentiated ciliated cultures were selected for all subsequent 
experiments. At both concentrations there was no bacterial growth on the agar plates following 
antibiotics, indicating successful bacterial killing. As there was significant evidence of cell damage 
following inoculation where OD600 =1, a lower concentration was considered preferable. A value of 
OD600=0.5 was chosen for subsequent experiments, to maximise the inflammatory response and 
limit cell damage.  
 
There was less of an increase in IL-8 following bacterial stimulation by HI and SA compared to 
when the cells were infected with PA. In the methodology, we had reconstituted each bacteria to 
either OD = 0.1 or OD = 1, however this did not account for the different cell density of the bacteria. 
It is known that for PA OD600=0.1 contains approximately 1x108 cfu/ml (reference), however this 
has not been established for HI and SA. As HI and SA are larger than PA, it is likely that for a 
similar OD600.there are less cfu/ml, which may explain the reduced inflammatory reaction response 
to these 2 bacteria. Alternatively, PA may induce a different inflammatory profile to the other 2 
bacteria. An experiment was required to determine the OD600 for each strain required to acquire the 
same number of cfu/ml for each bacteria.  
 
5.2.4.2 Experiment 2 
 
This was performed to determine the OD of HI and SA, and compare to the known OD of PA. 
Bacteria cultures were prepared as described (5.2.3.4). 1ml of each bacterial broth suspension 
was spun at 3300 rv/minute for 5 minutes to retrieve a pellet, which was re-suspended in 1ml of 
PBS. The OD600 of this bacterial suspension was measured, and adjusted by the addition of PBS to 
obtain a 1ml sample of each bacteria where OD600=0.1. This 1ml sample was distributed in 8 
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aliquots, with 100μl added to 900μl of PBS in the first aliquot and subsequent serial dilution. 2 x 
10μl from each aliquot were applied to designated sections of the appropriate agar plate for each 
bacteria, and the plates were incubated at 37oC. At 24 hours, the numbers of cfu grown for both 
samples at each dilution for all of the bacteria were counted.  
 
Results 
 
Table 5.2-2 documents the results for the number of cfu grown for each bacteria at each serial 
dilution. This demonstrates that the OD for HI is approximately 10 logarithms higher than PA, and 
SA 10 logarithms higher again. These results replicate the published studies which have shown 
that OD600 =0.1 for PA contains approximately 1x108 cfu/ml. 
 
Dilution PA 1 PA 2 HI 1 HI 2 SA 1 SA 2 
1 + + + + + + 
2 + + + + + + 
3 + + + + 137 118 
4 + + 104 120 13 17 
5 80 + 17 13 2 3 
6 38 10 8 2 0 0 
7 1 2 3 1 0 0 
8 2 0 1 0 1 0 
 
Table 5.2-2- Number of cfu grown for each bacteria (PA, HI and SA) at each serial dilution  
 
Discussion 
 
To obtain a similar number of cfu of HI and SA to PA, x10 and x100 the initial volume of these 
species is required respectively compared to PA. This can be spun down to retrieve the pellets, 
which could then be reconstituted in the same volume (200μl) of PBS to produce a comparable 
cfu/ml. It would not be possible to measure the OD of these bacteria at this concentration as it 
would lie above the optimal range (OD >0.8 leads to less accurate results). Instead, for future 
experiments, the amount of bacteria required to make a 1ml suspension with an OD of 0.1 was 
calculated, then the volume of bacterial solution taken was scaled up accordingly.    
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5.2.4.3 Experiment 3 
 
It was necessary to determine the most appropriate way to collect the supernatant. In experiment 1 
the cells had been covered with PBS for the 72 hour duration of the experiment to maximise the 
collection the inflammatory mediators, however cells cultured at ALI rely on the apical surface of 
the cells being exposed to air to replicate in vivo conditions.  
 
Experiment 3 was performed to assess 2 issues:  
 
• Whether leaving the cells uncovered from the 4 hours onwards (allowing for bacterial killing with 
antibiotics from 1 hour to 4 hours), and adding 200μl of PBS for 10 minutes prior to sample 
collection would collect comparable inflammatory mediators to the covered cells.  
• Whether the 3 species, with the OD600 adjusted to provide the same number of cfu/ml, would 
produce a comparable inflammatory profile detectable by standard lab assays. 
 
Method 
 
2 cell cultures were utilised for this experiment, again initially grown for clinical purposes but 
subsequently found not to have a diagnosis of either CF or PCD. Bacteria were prepared as 
described in Section 5.2.3.4 and the OD600 adjusted to ensure that each sample had equivalent to 
5x108 cfu/ml. 3 wells from both cell cultures were infected with 200μl of each of bacteria and 1 with 
200μl of PBS (control). 
 
This experiment was performed as described for Experiment 1 with the following exceptions. At 4 
hours, following the collection of the supernatant, 200μl of PBS with antibiotics was added to the 
apical surface of sample 1, and sample 2 was left uncovered. At the subsequent time points (24 
and 72 hours) 200μl of PBS were added to the apical section of sample 2, and agitated for 10 
minutes prior to collecting and storing the sample.  
 
Results 
 
• Uncovered cells vs covered cells 
• IL-8 detectable levels at these concentrations comparable to those in experiment 1 
• A comparable level of IL-8 was detected following bacterial infection with all 3 bacteria. 
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• SA colonies grew on plate for Sample 1 at 4 and 24 hours.  
 
Discussion 
 
ALI cells left uncovered yielded similar quantities of inflammatory mediator to the samples that had 
remained covered between experimental time points. As uncovered conditions better replicates in 
vivo conditions, this method was carried forward to the main experiment. When the concentrations 
of the bacterial suspensions were adjusted to provide a similar concentration of cfu/ml, comparable 
levels of IL-8 were obtained with different organisms. SA colonies were visualised on the agar plate 
at the 4 and 24 hour time points, indicating microbial killing by the antibiotics was unsuccessful. 
The decision was made to reduce the concentration of SA to half of that previously used.  
 
 
Having established the optimal cell lineage, conditions, sampling sites and bacteria concentration 
from the pilot study, we went on to perform the main study, described below in detail. For this 
study, the MSD platform was chosen to analyse the concentration of inflammatory cytokines, as 
compared to standard ELISA. The MSD platform offers an increased dynamic range (for IL-8: 0.17-
10000 pg/mL compared to 15.6–1,000 pg/mL respectively), improved sensitivity, and reduced 
sample and reagent requirements. Furthermore, it provides the opportunity to measure multiple 
cytokines simultaneously.  
 
5.3 Main experiment – methods 
 
An overview of the experiment is illustrated in Figure 5.3-1. Nasal brushings were performed 
(section 2.2.4) on subjects with PCD, CF and healthy controls. Respiratory ciliated cells were 
cultured at ALI as previously described (Section 5.2.3.2). In total 51 subjects were recruited to 
participate in the study. Of these, 13 (25.5%) sets of ALI cell culture were successfully cultivated to 
produce 4 wells of ciliated epithelial cells: healthy controls (5), CF (4), and PCD (4). All CF subjects 
were F508del homozygous. The subjects with PCD all had ultra-structural defects associated with 
PCD; 2 had outer dynein arm defect (ODA) and 1 outer and inner dynein arm defect (IDA), 1 a 
transposition defect.  
 
To ensure that the cells were a similar age and to account for both the time period involved in 
collecting samples, and the ALIs reaching ciliated stage at different times, the experiment was 
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performed in 3 stages. Each stage utilised cells from either the CF or PCD group, and included a 
healthy control sample. 24 hours prior to the experiment, all cells were fed with ALI media which 
had not had antibiotics or steroids added to prevent any artificial suppression of the inflammatory 
response. 
 
Bacteria were prepared as described in section 5.2.3.4 to produce samples containing 5x108 cfu/ml 
of PA and HI and 2.5x108 cfu/ml of SA.  
 
 
 
Figure 5.3-1: An over view of the main experiment comparing the inflammatory response to bacterial 
challenge of CF nasal epithelial cells cultured at an ALI to those from patients with PCD and controls  
 
 
 
 
Cell cultured to an ALI!
Fed overnight with ALI media without abx or steroids!
START!
3 wells exposed to bacteria and one PBS (control)!
(PA, SA, HI)!
Incubated at 37oC!!
1 hour!
Supernatant from apical & basolateral region collected, stored in single at 
-80oC!
Cells fed with ALI media with antibiotics!
Incubated at 37oC!
4 hours!
Supernatant collected as above!
Supernatant from each well infected with bacteria plated onto agar!
ALI media added to basolateral region, apical segment left uncovered!
Incubated at 37oC!
24 hours!
PBS added to apical segment and agitated for 10 minute!
Supernatant collected and stored as above!
Supernatant only removed & plated if bacterial growth documented at 4 hours!
ALI media added to basolateral region, apical segment left uncovered!
Incubated at 37oC!
72 hours!
PBS added to apical segment and agitated for 10 minute!
Supernatant collected and stored as above!
Supernatant only removed & plated if bacterial growth documented at 24 hours!!
Supernatant!analysed!using!MSD!plate!for!quan5ty!of!pro6inﬂammatory!
cytokines!!
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Start 
 
The cells were infected with either 200μl of bacteria or PBS (control) applied to the apical cell 
membrane. 
 
1 hour 
 
200μl of supernatant was sampled from the apical region, divided into 4 x 50μl cryovials and frozen 
at -80oC. 700μl of fluid from the basolateral region was frozen at -80oC in a cryovial. 700μl of ALI 
media without steroids, but with antibiotics, was added to the basolateral region, and 200μl added 
to the apical section of the cells. All cells were incubated at 37oC. 
 
4 hours 
 
Supernatant was collected and stored as before. 10μl of supernatant from each well infected with 
bacteria, was removed and plated onto the appropriate agar. Plates were incubated overnight at 
37oC and examined at 24 hours to look for evidence of bacterial growth. 700μl of ALI media without 
steroids, but with antibiotics, was added to the basolateral region. The apical sections were left 
uncovered.  
 
24 hours 
 
200μl of PBS were added to the apical section of the wells and agitated for 10 minutes. 
Supernatant was collected and stored as before. 10μl of supernatant was only removed from the 
samples in which bacterial growth had been documented at 4 hours. 
 
72 hours 
 
200μl of PBS were added to the apical section of the wells and agitated for 10 minutes. 
Supernatant was collected and stored as before. 10μl of supernatant was only removed from the 
samples in which bacterial growth had been documented at 24 hours. 
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5.3.1 Sample analysis  
 
The samples were thawed and the cytokine profile measured using a Human ProInflammatory 9-
plate Tissue Culture Kit (Meso Scale Discovery (MSD) platform) (K15007B-1), designed to quantify 
the presence of GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, and TNF-α in tissue culture 
supernatant. The methodology for this was described in detail in Section 2.2.5.2. 2 of the samples 
were run twice on the MSD platform to assess the repeatability of the results.  
 
As in the previous studies (both the cell suspension and the pilot experiments), IL-8 analysis had 
been performed using a Human ELISA Kit (Life Technologies) (as previously described), 4 
samples from the cell suspension experiment were also analysed on the MSD plate; 2 of which 
were reported to have low levels of IL-8 and 2 which had high levels. This was performed to see if 
both analysis platforms produced similar results, thus allowing the results from both experiments to 
be compared.  
 
 
5.3.2 Data analysis 
 
The results were analysed using Prism 6 software (GraphPad Software Inc, CA, USA). As data 
were non-parametric, the Kruskal-Wallis test was used to compare the 3 patient groups at each 
time point, with post hoc Dunn’s comparison test for multiple statistical comparisons. The null 
hypothesis was rejected at p<0.05. 
 
5.4 Results 
 
5.4.1 Assessment of successful bacterial killing 
 
Bacterial growth was only detected on 3 plates in total. 2 of these were SA at 24 hours and at 72 
hours from the same cell culture, and the remaining 1 was SA from another cell culture at 24 hours, 
however this was not grown again at the 72 hour point.  
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5.4.2 Inflammatory profile in supernatant 
 
Data from all cytokines were analysed, however the results displayed below focus on IL-6, IL-8, 
TNF-α and IFN-γ as they are considered to be the most clinically relevant inflammatory mediators 
(ref) and the others did not display a significant bacterial response. 
  
5.4.2.1 Baseline cytokine levels 
 
To determine whether there was a difference in baseline cytokines between the 3 groups, the level 
of the cytokines IL-6, IL-8, TNF-α and IFN-γ detected following 1 hour exposure to PBS (control) 
were compared. The results are illustrated in Figure 5.4-1 
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Figure 5.4-1: Supernatant cytokine profile at baseline. a) IL-6 b) IL-8 c)TNF-α d) IFN-γ. Cytokine 
concentrations are illustrated as pg/ml with data from each patient expressed as a single data point. There 
was no statistical difference in the levels between the control groups, CF and PCD. The horizontal line 
indicates the median value of the group. 
 
Comparison of the patient groups using the Kruskal-Wallis test demonstrated no statistical 
difference in baseline levels of the cytokines (Figure 5.4-1). This was replicated with all other 
cytokines measured on the MSD panel 
 
 
 
Co
ntr
ol CF PC
D
0
20000
40000
60000
80000
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
Co
ntr
ol CF PC
D
0
20
40
60
80
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
Co
ntr
ol CF PC
D
0
10
20
30
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
Co
ntr
ol CF PC
D
0
5000
10000
15000
20000
C
on
ce
nt
ra
tio
n 
(p
g/
m
l)
a)# b)#
c)# d)#
 173 
5.4.2.2 Level of cytokines following bacterial stimulation 
 
Following this, the level of cytokines detected at 1, 4, 24 and 72 hours in each patient group 
following bacterial stimulation with HI, PA and SA were compared. The level of cytokine measured 
is displayed as a ratio to the control group, where the cells from the same subject were exposed to 
only PBS. The results are illustrated in Figure 5.4-2 - Figure 5.4-5. For each set of graphs, the time (x 
axis) represents the period of time (hours) after cells had been exposed to the bacteria (or control) 
before the supernatant was collected. The y axis measures the level of cytokine detected when a) 
the cells were unstimulated (control cells exposed only to PBS), and in response to bacterial 
stimulation by b) HI c) PA and d) SA. The values for each group are expressed as median and 
IQR. 
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IL-6 response to bacterial stimulation 
 
 
 
Figure 5.4-2: Levels of IL-6 (pg/ml) 
 
Figure 5.4-2 illustrates that the cells mounted an inflammatory response, measured by levels of IL-6 
increasing 2-3 fold, in all 3 patient groups to HI and PA and to a much lesser extent SA (NB: scale 
only to 100 compared to 10,000) at the 4 hour and 24 hour time points. The response detected at 
72 hours was more variable. Comparison of the levels of IL-6 using the Kruskal-Wallis test, and 
Dunn’s multiple comparison test demonstrated no significant difference between the levels 
detected between any of the patient groups, at any time points.  
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IL-8 response to bacterial stimulation 
 
 
Figure 5.4-3: Levels of IL-8 (pg/ml)   
 
Figure 5.4-3 shows no consistent rise in IL-8 was detected following exposure to any of the 
pathogens, which did not replicate the findings from the pilot study, in which an IL-8 response was 
demonstrated.   
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IFN- γ response to bacterial stimulation 
 
Figure 5.4-4: Levels of IFN- γ (pg/ml) 
 
 
Figure 5.4-4: Levels of IFN- γ (pg/ml) shows no consistent rise in IFN- γ was detected following 
exposure to any of the pathogens. 
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TNF-α response to bacterial stimulation 
 
 
Figure 5.4-5: Levels of TNF-α (pg/ml) 
 
 
Figure 5.4-5 demonstrates that there is a considerable rise in levels of TNF-α at 4 hours in all 
patient groups following exposure to all pathogens to a comparable extent, though this level did not 
increase from the 24 hour time point onwards. No significant difference was detected at 4 hours 
between TNF-α levels between the 3 patient groups. 
  
The other 5 cytokines measured using the 9-plate pro-inflammatory cytokine kit did not display a 
significant response to bacterial exposure in any patient group.  
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5.4.2.3 Comparison of IL-8 levels measured on the Human ELISA Kit (Life Technologies) with the 
MSD) platform 
 
The cell suspension samples that had been recorded to have ‘low’ and 'high' levels of IL-8 when 
analysed with the Life Technologies Human ELISA kits, also measured 'low' and 'high' levels 
respectively when analysed by the MSD platform (Table 5.4-1) indicating that the experiments 
could be interpreted along side each other.  
 
IL-8 level  
MSD plate concentration (pg/ml) 
(Life technologies ELISA) 
Low 42.9 
Low 44.2 
High 15675 
High 2986 
 
Table 5.4-1: Comparison of IL-8 measurements with the Life Technologies ELISA Kit utilised in the cell 
suspension experiment and with the MSD platform   
 
5.5 Discussion 
 
The hypothesis stated that the cells from subjects with CF, with reduced/ absent CFTR function, 
would produce higher levels of pro-inflammatory cytokines than the other groups. The aim of this 
study was to define the relationship between CFTR function and inflammation by comparing the 
inflammatory response to bacterial challenge of CF nasal epithelial cells cultured at an ALI to those 
of wild type and non CF CSLD. This is the first study to simultaneously assess the inflammatory 
profile of epithelial cells obtained from subjects with CF, with those from patients with PCD and 
healthy controls. The level of inflammatory cytokines produced by epithelial cells from all 3 groups 
was measured at baseline, showing no difference between the groups, and then in response to 
bacterial stimulation by common respiratory pathogens over several time points. Cells from all 
groups showed elevated IL-6 levels, and a rise in TNF-α at 4 hours in response to bacterial 
stimulation, however there was no difference in the levels of elevated cytokines between the 
groups. An inflammatory response was not detected for other cytokines.  
 
The pilot study revealed unexpected results, with CF and control primary cells in suspension 
demonstrated a three and five fold increase respectively in levels of IL-8 following exposure to 
respiratory pathogens compared to uninfected cells from the same subjects at 24 hours, whilst 
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PCD cells mounted a blunted inflammatory response. In the subsequent experiments undertaken 
by myself, the epithelial cells were cultured at an ALI, to better replicate in vivo conditions, prior to 
bacterial exposure. There was no significant difference in the levels of any of the inflammatory 
cytokines between PCD (4), CF (4) and healthy controls (5) at baseline. Some of the agar plates 
grew SA after the 24 hour collection of the supernatant, indicating that bacteria had not been 
successfully eradicated. This may have affected the inflammatory response due to unknown levels 
of continued bacterial stimulation by SA, however the cytokine responses were comparable to that 
seen with the other bacteria, so have been included in the analysis. There was an increase in the 
inflammatory cytokines IL-6 and TNF-α following pathogen exposure in all patient groups, 
illustrating an inflammatory response to the infectious stimuli. The levels of TNF-α peaked at 4 
hours, whilst the IL-6 response was longer and consistently elevated for all patient groups, 
exposed to all 3 bacteria for up to 24 hours. There was no difference in the levels of either IL-6 or 
TNF-α at any of the time points between the 3 patient groups. A response was not detected for the 
other pro-inflammatory cytokines, which was a surprise, particularly for IL-8 given that a response 
had been detected in the pilot study.  
 
There are several reasons that may explain the main study not replicating the positive findings of 
the pilot; both sample sizes were small, and so perhaps under-powered to show a true effect. 
Additionally different analysis platforms were used in the two experiments, and although the MSD 
platform provides improved sensitivity and dynamic range, it is possible that these kits were not 
comparable. Lastly, the cell populations used in the pilot study were not retested in the main study, 
so it is possible that the results reflect two cell lineages that could not be compared. 
 
In the main study, the lack of inflammatory response across the range of cytokines could reflect 
either: no cytokine response elicited at this level of bacterial exposure, or the response was 
undetectable within the limits of the MSD platform and experimental methods. In order to establish 
the cause, further experiments refining the concentrations and conditions are required.  A 
comparison of the IL-8 response between CF and PCD subjects would be particularly interesting 
as previous studies have reported a higher level of IL-8 in sputum from subjects with PCD, 
compared to subjects with CF [327].  
 
Theses results support the previous studies that demonstrated no systematic differences in 
inflammatory cytokine production between CF and non-CF cells both at baseline or following pro-
inflammatory stimulation (refs). The inclusion of subjects with PCD, who were shown to mount 
comparable levels of IL-6 and TNF- α to both other patient groups, suggests that defective MCC, 
common to PCD and CF, does not contribute towards a modified immune response. The level of 
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TNF- α was shown to peak earlier than IL-6, which may be as a result of the inhibitory effect of IL-6 
on TNF-α, amongst other cytokines.  
 
A large variability in the inflammatory response between individuals was observed for all patient 
groups. This is similar to other studies that have used human airway epithelial cell models, 
highlighting that genetic and environmental factors specific to the patients that provide the tissue 
samples contribute in a variable measure to the inflammatory response [317]. This wide degree of 
inter-cell variability makes it difficult to interpret subtle trends as there is a low signal-to-noise ratio. 
To mitigate against this effect, the experiment was designed to stabilise the conditions of each cell 
line, and care was taken to culture as many cell lines as possible, as discussed below.  
 
1. Recent exposure to either bacterial or viral infections, or therapies may affect the response via 
altered inflammatory gene expression. The cells used in this experiment were cultured for a 
minimum of 6 weeks to help minimise these effects. In addition, the cells were taken back to a 
basal cell phenotype, re-differentiated and passaged twice so very few cells originally from the 
patient remained. However, larger numbers of subjects in each group would help to establish 
true trends, and determine if a difference in response, or variability exists between patient 
groups.  
 
2. Despite a large number of subjects being recruited into the study (51), only 13 (25.5%) of the 
cilia brushing samples taken were successfully cultured to produce 4 wells of ciliated primary 
epithelial cell cultures. This percentage success rate was less than that for cells that are 
cultivated for clinical and research purposes by the PCD diagnostic service department, RBH; 
which was 32% when audited in 2013 and 52% in 2014. Prior studies have demonstrated lower 
rates of culture success in CF epithelial cells compared to non CF cells; thought to be as a 
results of the presence of opportunistic pathogens, CFTR mutation phenotype, and elevated 
airway IL-8 [329]. In addition, the audit included samples that were obtained when the patient 
was under anaesthetic for a bronchoscopy, which yield a better cell count.  
 
 
These results showed that whilst suspended nasal epithelial cells from patients with PCD have an 
attenuated inflammatory response, this is not intrinsic to the PCD cellular phenotype, as 
demonstrated by a rise in cytokines following bacterial stimulation when cultured at ALI. The pilot 
study may however accurately reflect the in vivo behaviour, with the blunted response 
demonstrated in PCD cells a result of the effects of chronic nasal infection (references) producing 
altered inflammatory gene expression and also, as hypothesized in this thesis, secondary CFTR 
dysfunction. Chronic upper airway infection is more common in PCD than CF and controls, 
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accounting for the difference in response between the patient groups. This study highlights that in 
vitro model systems for studying airway epithelial cell behaviour may not replicate the complexity of 
the airway. In particular, interpretation of the ALI results comes with the caveat that it illustrates 
only the response of nasal epithelial cells cultured in a controlled environment, and may not exactly 
replicate bronchial epithelial cell reactions in vivo. 
 
This model does not support the hypothesis that cells with reduced CFTR function (CF), at an ALI, 
give rise to excessive inflammatory cytokines, it does not explore the effect of dysfunctional CFTR 
in many other elements of the immune system, as discussed Chapter 1, namely, myeloid-derived 
cells, neutrophils, macrophages [96, 330-333]. It is possible that a combination of many of these 
pathways affect the immune response in patients with CF and contribute, at different stages, to the 
chronic inflammatory picture characteristic of the disease. A better understanding of the exact 
mechanisms may provide future potential approaches for dampening inflammation by targeting 
specific cells or interactions.   
 
 
Study limitations and future work 
 
This study has several limitations. Crucially, the group numbers were very small meaning that the 
study was underpowered. Ideally this experiment would be continued to increase patient numbers 
to account for the large variability in data. A further potential weakness of this study is that different 
multiplex ELISA platforms were used in the cell suspension protocol and pilot studies; the Life 
Technologies Human ELISA compared to the MSD plate used to analyse the cell culture 
supernatant in the main study. IL-8 levels in cell suspension samples measured with both platforms 
revealed results of a similar magnitude suggesting that the 2 sets of data could be interpreted 
along side each other, however experimental conditions need to be refined in order to compare 
cytokines like for like. It is essential for future work to determine the dose-cytokine response 
relationship for each bacterium, which lies within the dynamic range of the MSD plate, and 
compare the top dose of each in order to draw conclusions for different bacterial stimulation. 
Following this, repeat measurements on cell cultures from the same donor, and from the same 
supernatant samples are required to ensure reliability of the measurements.   
 
Furthermore, this study makes the assumption that CFTR function in the cells of patients with PCD 
is normal and any dysfunction is limited to the CF subjects. There is emerging evidence that CFTR 
function might be affected by localised inflammatory mediators, which is explored further in vivo in 
the next chapter. Culturing PCD cells ex-vivo, meant that secondary CFTR function was unlikely, 
however future experiments should quantify the CFTR function using a patch clamp.  
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Summary 
 
In summary, cells with absent CFTR function, from subjects with CF, when cultured at an ALI, 
produced a similar level of inflammatory mediators at baseline and following bacterial exposure to 
cells from patients with PCD and healthy controls. This does not support the hypothesis, that 
absent CFTR function results in hyperinflammatory epithelial response.  
 
However, these in vitro experiments may not mimic in vivo cellular and molecular interactions, so in 
the next chapter I have studied the interactions between CFTR function as demonstrated by nPD 
and airway inflammation in vivo.   
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6 The relationship between secondary CFTR dysfunction and inflammation in subjects 
with Primary Ciliary Dyskinesia  
 
6.1 Introduction 
 
Impaired CFTR function in CF is caused by a genetic defect in the CFTR gene, resulting in 
abnormal expression, or structure and function of the protein. There is increasing evidence to 
suggest that CFTR ion channel function can also be affected by external modulators, resulting in a 
secondary dysfunction. Section 1.2.4 provided a detailed overview of the studies that have been 
performed to explore the effect of inflammatory mediators and infective microbes on CFTR 
function, followed by the evidence of CFTR dysfunction in other respiratory diseases, which to date 
has focused on COPD. Together, these results indicate that external factors may cause an 
acquired dysfunction in CFTR. These findings have implications for subjects with CF, and for other 
respiratory conditions, in which the presence of abnormal ion transport may contribute to the 
burden of disease. 
 
To date, no studies have measured CFTR function in patients with PCD, which has a similar 
pathophysiology to CF, with defective MCC, resulting in a comparable inflammatory profile. This 
chapter describes a study designed to explore the relationship between localised inflammation and 
CFTR ion channel function, measured in vivo in subjects with CF, healthy controls and patients 
with PCD, to determine whether there is evidence of secondary CFTR dysfunction in PCD.  
 
This study aims to test part of my second hypothesis, namely that dysregulated chloride and 
sodium transport leads to inflammation and inflammation which in turn further impairs ion transport, 
which will be tested in another chronic suppurative lung disease, PCD. 
 
6.2 Study aim:  
 
• To define the relationship between CFTR function as demonstrated by chloride and sodium 
transport, and inflammation by measuring NPD in patients with PCD, and relating it to the 
severity of nasal inflammation 
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Objectives; 
 
• To perform NPD measurements and compare the indices; basal values, amiloride response 
and chloride secretion, in patients with CF with reduced/absent CFTR function (positive 
controls), patients with PCD and healthy (negative) controls 
• To measure the levels of inflammatory cytokines in nasal secretions by nasosorption (upper 
airway), and to correlate these markers of inflammation with levels of CFTR function  
 
 
The protocol was written by Dr Suzanne Crowley and Professor Jane Davies. All subject 
recruitment, data collection and analysis and statistics were performed by myself.   
 
 
6.2.1 Recruitment and consent 
 
Recruitment and study visits took place between 1 April 2013 and 30 September 2014. The 
diagnosis of PCD, CF and healthy controls were confirmed as described in Section 2.1. Patients 
with PCD were recruited from outpatient clinics at the RBH. Patients were identified as eligible by 
advance screening of electronic clinic lists, followed by a discussion with their lead clinician to 
ensure suitability. Patients were asked to attend for a study visit at a time of clinical stability. 
Patients with CF were recruited from in-patients in the ward. Eligibility was confirmed by reviewing 
electronic notes followed by a discussion with the clinical team. Patients were approached whilst 
on the ward and the trial visit was performed at the end of their stay, when their lead clinician 
deemed them to be clinically stable. Healthy controls were recruited as described in Section 2.1.   
 
Subjects were given the PIS 1 week before the study visit, and given the opportunity to ask 
questions and discuss to study, prior to obtaining consent. 
 
6.2.1.1 Inclusion and exclusion criteria 
 
Inclusion criteria 
Males and females aged 16 years or above 
A stable baseline state of health and free of viral infection in the preceding 4 weeks. 
Non-smokers, based on patient history 
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Exclusion criteria 
Infection with Burkholderia cepacia complex or MRSA (for infection control reasons) 
Significant nasal pathology including polyps, clinically-significant acute rhinosinusitis, or recurrent 
severe epistaxis  
Acute upper respiratory tract infection within the last 4 weeks  
 
 
6.2.2 Ethics 
 
Prior approval was given by the NRES Committee London-Brent (REC: 13/LO/0391) 
 
 
6.2.3 Study design 
 
All measurements were performed on a single day at the Clinical Research Facility, RBH, London. 
Subjects consented to have the following investigations performed:  
 
6.2.3.1 Investigations 
 
The following investigations were performed on all subjects: 
 
• Baseline height and weight measurements 
• CFTR mutation analysis (unless result already available) 
• Complete a short medical questionnaire  
• Spirometry 
• Sweat test (unless result already available) 
• Nasal potential difference (NPD) 
• Nasosorption 
 
 
CFTR mutation analysis was performed on all subjects if the results were not already available. 
This was used to ensure that no patient in either the PCD or control group carried a single CFTR 
mutation, which may affect the results. Spirometry was performed as a generalised marker of 
airway disease and measurements of localised inflammation were obtained by performing 
nasosorption. NPD measurements were used as surrogate markers of CFTR function in the nasal 
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epithelium. Sweat chloride measurements were performed to assist in the interpretation of results 
and determine whether any potential secondary CFTR dysfunction is localised or systemic.  
 
Nasosorption, using synthetic absorptive matrices (SAM) was chosen to sample nasal mucosal 
lining fluid (MLF). This method has the advantage that it is non-invasive, and it is possible to 
sample neat MLF, allowing detection of higher levels of chemokines and cytokines than after nasal 
lavage. It has recently been employed in children with rhinitis and in relation to nasal allergen 
challenge [334, 335]. The samples were analysed on a multiplex immunoasssay designed to 
simultaneously quantitate the presence of multiple cytokines including IL-1β, IL-6, IL-8, IL-10, IFN-
γ and TNF-α. This plate was chosen as these cytokines have all been previously measured in 
nasal mucosal lining fluid from nasosorption samples, and demonstrated a dose dependent 
response to a lipopolysaccharide challenge which is a stimulus to the innate immune system [239]. 
 
 
6.2.3.2 Sample size 
 
Previous studies have derived the sample sizes needed to detect a within group differences in total 
chloride response using NPD measurements, demonstrating that a patient group between 30 and 
40 provides a 90% power to demonstrate a difference in chloride response of -5mV [296]. 
 
 
6.3 Method 
 
25 subjects consented to participate: PCD n=8, CF n= 9, and healthy control n=9. 3 subjects were 
subsequently excluded as it was revealed that 1 subject (PCD) had received laser surgery on his 
nostril, 1 subject was unable to tolerate NPD measurements (CF) and 1 subject was not well on the 
day of the appointment and was unable to re-attend (control). This is less than the intended 
number of subjects due to both recruitment difficulties and time limitations; hence the study is 
underpowered, however it provides useful pilot data to take forward to a larger study.  
 
All measurements were performed on the same day.  The methods used to measure height and 
weight, to perform spirometry and for CFTR mutation detection are described in Sections 2.2.1, 
2.2.2, and 2.2.7. 
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Care was taken to insure that nasosorption was performed prior to the NPD measurements, as it 
was considered that the perfusion of solutions on the nasal mucosa might affect the nasosorption 
results.  Other interventions were performed in any order depending on the machine and 
equipment availability. 
 
 
6.3.1 Medical questionnaire 
 
All subjects were asked to fill in a short medical questionnaire to obtain information about their 
previous medical issues and current status (Table 6.3-1) 
 
Chest problems  Yes No Comments 
Neonatal chest problems        
Current chest problems        
Age of onset and details:       
Persistent cough        
Purulent sputum        
Family history        
     
Nose and ear problems  Yes No Comments 
Neonatal nose problems        
Current nose problems        
Age of onset and details:       
Pooled pus in nose        
Purulent sputum        
Sinus involvement        
Any sinus surgery        
 
Table 6.3-1: Symptom questionnaire of past and current chest an ENT symptoms 
 
6.3.2 Sweat test 
 
Sweat test was performed as described in Section 2.2.6. It was not repeated if it had previously 
been performed for clinical reasons and the information was available. The value taken forward for 
the analysis was the mean of the chloride concentration (mmol/L) for both arms. 
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6.3.3 Nasal Potential Difference (NPD) 
 
NPD measurements were performed and the individual indices calculated as described in Section 
2.2.8.1.  
 
 
Analysis of the NPD traces 
 
2 methods of scoring NPD measurements, devised by Wilschanski and by Sermet, have been 
developed to attempt to quantify CFTR function in nasal epithelium. These analyses take into 
account measurements of both the CFTR-dependent sodium and chloride ion transport, and 
provide a globalised measure of ion transport across the entire NPD trace [336] [337]. 
 
Wilschanski index: values are calculated using the equation e Δ chloride/ Δ amiloride. A cut off value of 
>0.70 has been shown to predict a diagnosis of CF, with values greater than 0.7 consistent with 
CF. 
Sermet: values are calculated using the equation -0.11 Δ low Cl-/Iso – 0.05 Δ amiloride. A 
diagnostic cut off of <0.27 was shown to discriminate patients with CF (values <0.27) from healthy 
controls.  
 
The Wilschanski index was shown to better differentiate between atypical CF and non-CF patients 
than analysis of either sodium or chloride components alone. The method devised by Sermet was 
shown to be useful diagnostic tool for young children with inconclusive investigations at newborn 
screening, and further validated in an adult population of patients with CF and controls.  
 
For all traces performed in this study, both the Wilchanski index and the Sermet score were 
calculated to see if the these methods demonstrated a difference in CFTR function between 
patients with PCD and healthy controls, and how this compared to patients with CF. 
 
6.3.4 Nasosorption 
 
Nasosorption was performed using SAM strips, which are comprised of synthetic fibrous 
hydroxylated polyester medium (Accuwick Ultra, Pall) cut into two strips, designed to absorb nasal 
secretions for analysis of the levels of cytokines and chemokines.  
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6.3.4.1 Collection: 
 
With the patient sitting comfortable upright and head extended backwards, a SAM strip was placed 
under direct vision, on the lateral wall of the nasal cavity, using blunt ended forceps if required. 
Light pressure with the patient’s finger was used to ensure that the SAM remained in place for 1 
minute. The process was repeated, with fresh strip, on the other nostril. Strips were immediately 
placed in a Corning Costar Spin-X centrifuge tube filter, with 500 µl of chilled 0.9% saline and 
centrifuged at 16,000g for 10 minutes, cooled to 4oC. The filter cup with the dry SAM was removed 
and discarded, and fluid retained in the tube was stored in Eppendorfs at -80oC. 
 
6.3.4.2 Sample analysis:  
 
The samples were thawed and the cytokine profile measured using the MSD platform for the 
presence of 9 proinflammatory cytokines: GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, 
and TNF-α as described in Section 2.2.5.2.  
 
To assess the repeatability of the nasosorption values, 2 aliquots were taken from the same 
Eppendorf tube from samples from 6 of the patients with PCD, and analysed on the same MSD 
plate. No further samples were analysed in duplicate due to space limitation on the MSD plate.  
 
6.3.5 Statistics 
 
Data were analysed using Prism 6 statistical software (GraphPad Software Inc, CA, USA). Data 
are presented as median and interquartile range (IQR). Non-parametric paired comparison of pre 
treatment and post treatment values were analysed using the Wilcoxon matched-pairs Signed 
Rank Test. Correlation between two outcome measures were assessed with Spearman’s rank 
correlation coefficient and p values < 0.05 were considered significant. 
 
6.4 Results  
 
The demographic data are summarised in Table 6.4-1. Subjects were comparable for age and 
gender.  
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 Control CF PCD 
Total no: 8 8 7 
Gender: female (%) 63 50 57 
Age: median (IQR) 31.1 (25.0-34.9) 27.4 (24.9-28.93) 35.6 (28.3-43.4) 
CFTR Genotype None detected All F508del/F508del None detected 
PCD Defect N/A N/A 
4 ODA  
1 IDA+ODA 
1 Transposition 
1 Normal (HYDIN gene) 
 
Table 6.4-1: Baseline characteristics of the subjects. The total numbers of patients recruited into each group 
are listed along with the age (years) median (IQR), gender, CF genotype or PCD defect/ gene. Outer dynein 
arm defect = ODA, inner dynein arm defect=IDA. 
 
6.4.1 Questionnaire 
 
The results of the questionnaire are summarised in  
Table 6.4-2. All of the subjects with CF reported chest symptoms as many of them were at the end of an 
admission for a pulmonary exacerbation. More subjects in the PCD group reported ongoing nasal symptoms 
than the CF group and controls, in keeping with the known distribution of the disease. 
 
Group Time Nasal symptoms 
Sinus 
involvement 
Chest 
symptoms 
  Control (n=8)   Current 0 0 0 
  Past 0 0 0 
  CF (n=8)   Current 0 0 0 
  Past 1 2 8 
  PCD (n=7) 
  Current 0 0 1 
  Past 4 3 5 
 
Table 6.4-2: Results from the symptom questionnaire. The number of subjects from each subject group who 
reported symptoms as either ‘current’ or ‘past’ is documented. 
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6.4.2 Spirometry 
 
Acceptable measurements were achieved in all 23 subjects. The FEV1 (% predicted) was 
significantly lower in the CF group, with a median (IQR) of 50.1 (38.1-58.6) compared to the 
healthy controls, median (IQR) 88.7 (82.4-101.1) % predicted (p<0.001). The values for subjects 
with PCD lay between these 2 groups with a median (IQR) of 69.8 (64.4-85.3) % predicted (not 
significantly different to either group). Similar results were seen when comparing values for FVC (% 
predicted).  
 
6.4.3 Sweat Chloride 
 
Results for sweat chloride concentration were obtained in only 22/23 subjects as 1 sample was an 
insufficient quantity for analysis (healthy control). The results were as expected for the patient 
groups; with CF subjects demonstrating a significantly higher concentration of chloride in the sweat 
sample with a median (IQR) mmol/L of 99.5 (98.3-106.3) (p<0.05) than patients with PCD (18.5 
(14.0-29.5) mmol/L) and healthy controls; 19.5 (12.5-37.5) mmol/L). 
 
 
6.4.4 Nasal PD 
 
The traces for all patients (23) were reviewed and considered to be of acceptable quality. For 1 
subject with CF, the trace was of poor quality after the perfusion of ZCl solution and for this trace 
only the basal values and amiloride phase are used in the analysis. The basal values are 
presented in Figure 6.4-1, illustrating that patients with CF show a significantly more negative 
reading median (IQR) mV: -52 (-51 - -60) compared to PCD, -17 (-16 - -24) mV, and control, -24 (-
19 - -28) mV. 
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Figure 6.4-1:  Comparison of baseline voltage (mV) between study groups demonstrating that subjects with 
CF have a significantly more negative basal PD than both control and PCD subjectsc. Each patient is 
represented by a single data point with the median (mV) and IQR indicated.   
 
 
The changes in voltage following perfusion of amiloride solution are displayed on Figure 6.4-2 
illustrating the absolute change, and change expressed as a percentage of the baseline 
respectively. The greatest change was seen in the CF patients, with a median (IQR) change of 
+34.3 mV (25.4 – 38.2), reflecting the over-activity of ENaC, which relates to absence of CFTR 
function. Controls showed a moderate change; median (IQR) +16.61 mV (8.8 -19.7), consistent 
with previous data whilst the patients with PCD showed only a very minimal change with a median 
(IQR) of +3.6 mV (0.0-10.2) [338]. There was a statistical difference between the amiloride 
response between the PCD subjects and the CF group, though not between the PCD and the 
control group. Furthermore there was a statistical difference between the percentage of amiloride 
response compared to the baseline between PCD and CF (with PCD showing a reduced 
response), though not between PCD and control. These results suggest no disinhibition of ENaC 
activity in the PCD group, and contrary to expected either normal or reduced ENaC function.  
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Figure 6.4-2 a) Absolute change in voltage (mV) following perfusion of Ringers/Amiloride and b) amiloride 
response expressed as a percentage (%) of the baseline demonstrating a difference between CF and PCD, 
however not between either of these groups and controls. Each patient is represented by a single data point 
with the median (mV) and IQR indicated. 
 
 
Figure 6.4-3 shows the total change in voltage following the perfusion of both the ZCl and ZCl/Iso 
solutions (reflecting the total chloride secretion). The control group showed a significantly larger 
change in voltage with median (IQR) -35 mV (-24 - -54), compared to the CF group -0.97mV (+3.4 
- -3.7). The PCD group showed significantly reduced chloride secretion compared to controls, with 
a median of -7 mV (-3.6 - -17), which was comparable to that seen with subjects with CF 
(p<0.001). 
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Figure 6.4-3: Comparison of total chloride secretion (mV) between study groups showing a significant 
difference between the control group and both the CF and PCD group. Each patient is represented by a 
single data point with the median (mV) and IQR indicated. 
 
 
The Wilchanski index and Sermet score were calculated for the individual traces to take account of 
both the sodium and chloride transport elements of the NPD, illustrated in Figure 6.4-4. It was not 
possible to calculate the Wilchanski index for one of the subjects with PCD, as the amiloride phase 
had resulted in a small negative deflection. The Sermet score was calculated for all traces.  
 
The Wilchanski index indicated a difference between PCD and controls in 4 of the 6 traces 
analysed and the Sermet score in 2 of the 7.  
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Figure 6.4-4: Evaluation of CFTR function using global scoring systems a) Wilchanski index where the dotted 
line represents the cut off above which indicates abnormal CFTR function and b) Sermet score where the 
dotted line represents the cut off below which indicates abnormal CFTR function. For each patient the score 
was calculated and represented as a single data point with the median an IQR range indicated.  
 
Of the 6 PCD traces in which both scoring systems could be performed; 2 were categorized as 
normal CFTR function with both indices, 2 had abnormal CFTR function compared to healthy 
controls using the Wilchanski index alone nil with Sermet score alone, and 2 by both illustrated in 
Figure 6.4-5) 
 
 
 
Figure 6.4-5: Venn diagram demonstrating how the NPD traces from subjects with PCD were categorised 
according to Wilchanski index and Sermet score. The traces in which the CFTR function was categorised as 
abnormal are documented. 
 
 196 
6.4.5 Nasosorption 
 
Nasosorption samples were collected on 22/23 subjects. Results are unavailable on 1 control 
subject due to equipment failure, and only a single nostril was sampled on 1 patient with CF as the 
subject found the procedure uncomfortable. In total 41 samples were analysed: control 14 (2x7), 
CF 13 (2x6 +1) and PCD 14 (2x7). 2 aliquots from the same samples were analysed on the MSD 
plate for 6 of the patients with PCD from both the right and left nostril samples (12 samples in total 
analysed in duplicate). This was only performed in the PCD group due to space limitation on the 
MSD plate.  
 
6.4.5.1 Comparison of patient groups: 
 
The results for the nasosorption samples for each cytokine are displayed below in Figure 6.4-6.The 
graphs illustrate a trend towards increased levels of all cytokines in nasal secretions in subjects 
with PCD compared to the CF and healthy control groups, which reached statistical significance for 
PCD vs CF for: IL- 1β, IL-2, IL-6, IL-10, TNF-α, IFN-γ, and PCD vs healthy control: IL-10. In 
particular, it was 3 of the subjects in the PCD group that showed consistently high levels across the 
range of cytokines 
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Figure 6.4-6: Cytokine measurements for each subject group. a) IL-2 b) IL-6 c) IL-8 d) IL-10 e) IL-12p70 f) 
IFN-γ g) GMCSF h) TNF-α i) IL- 1β. Results in which there was a statistical difference between PCD and the 
other groups are indicated. Each patient is represented by a single data point with the median (pg/ml) and 
IQR indicated. 
 
6.4.5.2 Spread of the cytokine levels 
 
Table 6.4-3 lists the upper and lower limits of detection for each cytokine assay, along with the 
number of measurements for each group which were outside this range. Most values were near the 
lower limit, with more below the level of detection in controls and CF than PCD, and none above 
the level of detection. 
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Cytokine Dynamic range 
Control CF PCD 
Below Above Below Above Below Above 
GM-CSF 0.29-10000 pg/mL 1 0 1 0 0 0 
IFN-γ 6.17-10000 pg/mL 3 0 5 0 1 0 
IL-1β 0.42-10000 pg/mL 1 0 4 0 0 0 
IL-2 0.32-10000 pg/mL 0 0 3 0 0 0 
IL-6 0.40-10000 pg/mL 1 0 2 0 0 0 
IL-8 0.17-10000 pg/mL 0 0 1 0 0 0 
IL-10 0.22-10000 pg/mL 1 0 2 0 0 0 
IL-12p70 0.32-10000 pg/mL 0 0 1 0 0 0 
TNF-α 0.90-10000 pg/mL 0 0 1 0 0 0 
 
Table 6.4-3: Display of how many measurements fell outside the limits of detection of the MSD plate for each 
group   
6.4.5.3 Variability of sample results: 
 
To calculate the coefficient of variation (CV%), values that lay outside the limit of detection were 
excluded.  
 
Intra-patient (between nostril) variability 
 
The CV% for the 2 values obtained for each cytokine from each nostril was calculated for all of the 
subjects. These are illustrated in Table 6.4-4 as the median CV% (IQR) for each group for each 
cytokine. These demonstrate a large variation between samples obtained from different nostrils in 
all groups with no statistical difference between control, CF and PCD.  
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Cytokine 
Co-efficient of variation (CV)% 
Control  CF  PCD 
GM-CSF 50.3 51.2 37.3 
IFN-γ 95.5 58.1 34.2 
IL-1β  79.9 35.3 71.5 
IL-2 43.5 25.7 13.3 
IL-6 69.2 53.6 40.6 
IL-8 62 38.4 65.9 
IL-10 71.8 35.3 67.4 
IL-12p70 74.5 33.9 50.1 
TNF-α 50.3 51.2 65.5 
 
Table 6.4-4: Coefficient of variation (%) of the cytokine measurements in the nasosorption samples between 
each nostril for control subjects, CF and PCD. For each cytokine the CV (%) for the measurements of the 3 
groups are illustrated. Data are presented as median.  
 
Intra-sample variability 
 
Following this, for the 6 patients in the PCD group, the CV% was calculated for the 12 samples (6 right 
nostril, 6 left nostril), which had been analysed in duplicate. These are illustrated in  
Table 6.4-5. The results demonstrate extremely large variation in the results obtained from the 
same sample across all 9 cytokines.  
 
Cytokine CV (%) 
GM-CSF 66.15 
IFN-γ 59.81 
IL-1β  36.72 
IL-2 23.2 
IL-6 48.03 
IL-8 57.51 
IL-10 49.78 
IL-12p70 45.63 
TNF-α 54.56 
 
Table 6.4-5: Coefficient of variation (%) of nasosorption samples taken from the same sample from the same 
nostril in patients with PCD. Data are presented as median and IQR.  
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As the CV (%) was comparable between samples taken from the same aliquot and analysed in 
duplicate and the samples taken from different nostrils, the mean of cytokine concentration 
between both nostrils for each subject was taken forward for further analysis.  
  
 
6.4.6 Relationship between the level of inflammatory cytokines and CFTR function in 
subjects with PCD  
 
The levels of CFTR function in patients with PCD, as shown by sodium transport (basal PD and amiloride 
response) and chloride transport (total chloride response) were compared to the levels of inflammatory 
cytokines; IL-2, IL-6, IL-10, TNF α and IL-1β as these were the only ones significantly elevated. The results 
are tabulated in  
Table 6.4-6, revealing no correlation between these parameters and levels of inflammation.   
 
 IL-2 IL-6 IL-10 IL-1β TNF-α 
 r p r p r p r p r p 
Basal (mV) 0.00 >0.99 -0.14 0.78 0.32 0.50 0.36 0.44 -0.21 0.66 
Amiloride response 0.21 0.66 0.25 0.59 0.61 0.17 0.50 0.27 0.46 0.30 
Chloride secretion -0.29 0.56 -0.11 0.84 -0.36 0.44 -0.46 0.30 0.11 0.84 
 
Table 6.4-6 Relationship between selected cytokines and parameters derived from NPD measuring CFTR 
ion channel transport function, revealing no correlation. r and p values are tabulated, calculated using 
spearman's rank coefficient 
 
The inflammatory cytokines were elevated consistently in 3 of the PCD subjects. All of these 3 
patients had reported past nasal or sinus symptoms in the questionnaire, in contrast to only 1 of 
the other 4 PCD patients.  
 
6.5 Discussion 
This is the first study to assess CFTR function in vivo in subjects with PCD. The aim was to define 
the relationship between the function of the CFTR protein as shown by chloride and sodium 
transport and the severity of local inflammation in this condition. CFTR function was evaluated 
using NPD and the relatively novel technique of nasosorption was used to assess inflammation in 
the nasal secretions. The NPD traces of patients with PCD suggested normal basal values, normal 
or reduced amiloride responses, and evidence of reduced chloride secretion. Patients with PCD 
 202 
also had higher levels of inflammatory cytokines in nasal MLF than either the controls of subjects 
with CF, particularly in 3 of the subjects.  Levels of inflammatory cytokine did not correlate with 
either CFTR function measured by sodium or chloride transport. These results are discussed below 
in turn.   
 
The groups were comparable for age and gender, and as expected, the subjects with CF had 
significantly worse lung function than the controls, with values for the patients with PCD lying 
between these two groups. All the sweat chloride values were in keeping with those from previous 
studies for each group. 
 
6.5.1 Nasal potential difference 
 
The NPD measurements are interesting and can be interpreted in different ways. The NPD traces 
in subjects with CF with impaired CFTR ion transport function are characterised by a high (more 
negative) basal value, a large amiloride response and no change in voltage upon perfusion of 
chloride free solution, with the first two values reflecting sodium hyperabsorption (lack of inhibition 
of ENaC) and the final measurement demonstrating reduced chloride secretion. In this study, the 
patients with PCD showed reduced chloride secretion, comparable to that seen in the subjects with 
CF, however this was not accompanied by a correspondingly high basal value, and the amiloride 
response was surprisingly shown to be less than normal. Secondary analysis of the traces using 
the Wilchanski index and Sermet analysis; which combine the contribution of the sodium and 
chloride ion transport to evaluate evidence of CFTR function, categorised 2 of the PCD traces as 
abnormal. 
 
It is plausible that these results demonstrate a secondary dysfunction of the chloride channel 
function of CFTR, with either no effect/ or increased inhibition of ENaC. Inflammatory mediators 
may differentially affect these ion functions causing an uncoupling. This hypothesis is supported by 
in-vitro cell culture studies which showed using immunodetection experiments that IFN-γ lowers 
CFTR expression and down regulates ENaC, again a disconnect between these two functions 
[161]. 
  
The results are also similar to the studies exploring CFTR dysfunction secondary to cigarette 
smoke in subjects with COPD, which reported reduced chloride secretion in the nasal and lower 
airways as evidence of CFTR dysfunction [170, 171]. In both cases, the reduced chloride secretion 
compared to controls was was not accompanied by hyperpolarized basal measurements. The NPD 
results were accompanied by a specific reduction in CFTR mRNA expression in nasal curettage 
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samples obtained from individuals with COPD, and the lower airway traces with suppressed CFTR 
protein expression in endobronchial biopsy specimens. The authors postulated that cigarette 
smoke causes a systemic abnormality, producing a widespread pro-inflammatory environment. Of 
note, in our study, sweat chloride measurements provided a multi-system marker of CFTR activity 
in the skin. No difference was detected between the sweat chloride concentration of subjects with 
PCD and controls. This suggests that if there is secondary CFTR dysfunction, it is not systemic, or 
at least, if systemic effects were present, they were not detectable by this sweat chloride assay.  
 
 
Alternatively, the reduced chloride response detected in subjects with PCD, coupled with a low 
baseline and minimal amiloride phase, may reflect a ‘blunted’ response caused by injury to the 
epithelial integrity which is a recognised limitation to NPD measurements (cross reference). 
Patients with PCD are known to manifest more disease in the upper airway than subjects with CF, 
including chronic rhino-sinusitis and chronic secretory otitis media (ref). Supporting this 
interpretation are the results from the nasosorption measurements, which are discussed below, 
and the results from the medical questionnaire. Despite all patients in this study being clinically 
stable at the visit, the questionnaires revealed that the PCD group suffer from more upper airway 
symptoms than either CF or controls and are therefore more likely to have chronically damaged 
epithelium.  
 
In order to determine which of these hypotheses is correct, it would be useful to extend the study to 
include molecular measurements of the presence of CFTR. This could be achieved by obtaining 
nasal brushing samples in the same group of subjects and measuring the quantity of CFTR protein 
using western blotting, and of CFTR mRNA using Taqman assays, although such markers are 
often insensitive. As inflammatory mediators are thought to modulate the gene expression of 
CFTR, the expectation would be that CFTR protein levels and CFTR mRNA would be high in 
controls, reduced in PCD and absent in CF [339]. In addition, it would be helpful to add an extra 
step when recording the NPD measurements and perfuse ATP onto the epithelium. ATP activates 
chloride secretion through alternative (non-CFTR) calcium channels and serves as a marker of 
epithelium integrity [340]. 
 
6.5.2 Nasosorption  
 
The results from the nasosorption samples suggest that higher concentrations of inflammatory 
cytokines are found in the nasal secretions from subjects with PCD than CF and controls. This was 
mainly as a result of samples from 3 patients, which showed high concentrations across the full 
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range of cytokines. The results for the other subjects in the PCD groups were comparable to those 
seen in both CF and control. As nasosorption is a relatively novel technique, there are no studies to 
date demonstrating that subjects who suffer from chronic rhinosinusitis, bacterial infections or 
ongoing clinical symptoms have raised inflammatory cytokines in the nasal epithelial lining. 
However, there is ongoing research in this field (NCT02284074) at Imperial College, London and 
the results will be informative for this study.  
 
Nasosorption measurements are very variable (CV 27-95%) and therefore difficult to interpret. It is 
possible that the large variation in the concentration of cytokines detected when comparing 
samples from different nostrils from the same subject is a true reflection of in-vivo conditions 
caused by localised collections of mucous and secretions. The large variability in the samples 
taken from the same Eppendorf however questions the validity of these results. The most likely 
explanation is that, as demonstrated, the concentration of cytokines detected in this study lie at the 
extreme low end of the optimal dynamic range of the MSD assay. This decreases the sensitivity of 
the assay and the very small values accentuate the CV% of the measurements. Alternatively, the 
secretions may not be homogeneously distributed in the saline, due to collections of airway debris 
and mucous. The methodology for this technique needs to be optimised in order to gain meaningful 
results. Other studies have used a nose clip during the collection of the nasal secretions to ensure 
optimal contact between the filter paper and the mucosal surface, which could be included in the 
methodology. Furthermore, studies have shown that addition of buffer (BSA 1% or Tripton X 1%) 
prior to elution of the fluid increases the mean recovery of cytokine (10.1136/thx.2010.151043.29-
google), and smaller volumes (<500mcl) would reduce the dilution effect of this stage. Following 
the addition of this step, the repeatability and validity of the samples needs to be confirmed prior to 
evaluating the difference between both nostrils and comparison of the patient groups.  
 
6.5.3 Relationship between levels of inflammatory mediators and NPD traces 
 
No correlation was revealed between the levels of CFTR function in patients with PCD, as shown 
by sodium transport (basal PD and amiloride response) and chloride transport (total chloride 
response) and levels of inflammation.  Given the limitations of both measurements as described 
above, and the small patient size, these results were expected. It would be interesting to re-
examine these relationships when the methodology has been optimised.  
 
6.5.4 Limitations 
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The main limitations of this study are the small number of patients. In addition, NPD measurements 
were only performed on 1 occasion, and a minimum of 2 sets of values would help determine if the 
flat traces in the PCD group were seen consistently, reflecting CFTR dysfunction, or were 
specifically related to a recent, not clinically detectable infection. As mentioned, this study did not 
include assays for the quantity of CFTR protein and mRNA-CFTR, or microbial culture of the nasal 
secretions, which would have been useful in the interpretation of both the NPD results and the 
nasosorption data. Instead symptom questionnaires were used, of which the main disadvantages 
as outcome measures is that they do not take into account recall bias of patients. This is 
particularly relevant to patients with chronic conditions such as CF and PCD, as often symptoms 
have been life long and there is a tendency to under report.  
 
Whilst we measured an array of cytokines, we did not measure other markers of inflammation, in 
particular NE, which has been shown in-vivo and in murine models to degrade CFTR. Finally, 
refining the methodology of the nasosorption collection and analysis is required, to better 
understand and interpret these results. This would include the measures described above, use of a 
nose clip during collection of the secretions, the addition of a buffer prior to the elution of the fluid 
and adjustment of the volume of the diluent to achieve values for cytokines better in the optimal 
range of the MSD assay. Repeat measurements on the same subjects would have helped to 
determine the repeatability of the data. 
6.6 Summary and future work 
The overarching aim of this study was to establish whether there is acquired impairment of CFTR 
function manifest by dysregulated chloride and sodium transport in subjects with PCD, and whether 
this correlates with markers of inflammation. Whilst it is not possible from this data set to determine 
whether the reduced chloride response demonstrated in the NPD measurements from subjects 
with PCD; comparable to that seen in CF, is as a result of an acquired local CFTR dysfunction 
secondary to interaction with inflammatory mediators, or a generalised response to epithelial 
damage, the work provides a basis from which to further explore CFTR dysfunction in CSLDs other 
than CF. From the data reported here, it is not possible confidently to confirm or refute my 
hypothesis that there are acquired deficits in CFTR modulated chloride and sodium transport 
secondary to local inflammation. 
 
Future work in this field would include better characterising NPD traces in subjects with PCD, by 
both performing repeat measurements in the same patients, and in a larger patient group, perhaps 
after treating upper airway infection. The inclusion of molecular measurements of CFTR would help 
with the interpretation of these results and help in the understanding of the mechanism of 
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interaction between infective agents and CFTR. Further work is required to optimise the 
methodology in the collection and analysis of nasosorption, as described above, before it can be 
utilised as a useful tool to assess upper airway inflammation. It would be useful to process the 
samples that are stored and measure and compare the levels of NE between each group. 
Following this, the effect of localised, acute and chronic infection on levels of inflammatory 
mediators can be established using microbial culture or 16sRNA analysis of nasal secretions.  
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7    Summary and general discussion 
 
This thesis aimed to explore the relationship between lack of CFTR protein function and markers of 
disease severity in chronic suppurative lung disease in order to better understand how close the 
relationship is between the loss of CFTR function and disease pathogenesis. In particular, this 
work set out to test the hypotheses: 
 
• There is a direct relationship between CFTR function and airway health 
• There is a bidirectional relationship between CFTR function and airway inflammation: 
o CFTR deficiency leads to inflammation 
o Inflammation impairs CFTR function 
 
Chapters 4-6 in this thesis have each described a study, which has aimed to further our 
understanding of the relationship between CFTR function and airway health. This chapter brings 
together the results from the individual studies and reviews how these have contributed to 
addressing the hypotheses and to our understanding of the overarching theme. 
 
7.1 Direct relationship between CFTR function and airway health 
 
A better understanding of how measures of CFTR function correlate with airway disease will guide 
the development of novel therapies which aim to restore CFTR function; to help determine how 
much correction is necessary to produce a clinical benefit, to measure efficacy of the therapy, and 
to help establish dosing regimes.  
 
The first part of this thesis set out to show that a direct relationship exists between CFTR function 
and airway health. The initiation of the gene therapy Multidose Trial which took place when I 
commenced this MD(Res) in 2012, provided a platform from which to base this section of work. 
This thesis focused on the group of patients, who in addition to the main trial, also participated in 
the bronchsocopy subgroup. These patients had LAPD measurements and bronchial biopsies 
performed to provide functional and molecular evidence of successful gene transfer, and to assess 
airway inflammation. It was hypothesised that the PD measurements of CFTR ion channel function 
in the lower airway, where CF disease predominates, would correlate with functional and structural 
markers of airway health and markers of inflammation in the serum and sputum.  
Chapter 3 described the Multidose Trial. It was a phase IIb double blind RCT designed to see 
whether repeat doses of lipid-mediated gene therapy, delivered to patients with CF results in a 
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clinical improvement. The primary outcome was relative change in FEV1; other outcomes were 
assessed including, radiographic measures of disease status, and measurements of inflammation. 
This trial reported a significant treatment effect, demonstrating a modest difference between both 
groups (3.7%) in FEV1 and a trend towards improvement in secondary outcome measures. These 
results are encouraging for gene therapy, although the treatment effect was predominantly as a 
result of deterioration in the placebo group versus stabilization on active treatment, which is 
discussed in the chapter. Further work in this field now focuses on developing a novel viral vector 
for the CFTR gene, F/HN-SIV, which has been shown in preliminary in vitro and animal studies, 
that it can be delivered repeatedly without loss of gene expression, which can last for the life-span 
of a mouse (approximately 2 years) following a single dose [287]. This vector requires extensive 
safety testing prior to progressing to clinical trials. 
 
Chapter 3 provided the context for LAPD-focused study described in Chapter 4. 22 patients in the 
bronchoscopy subgroup had pre-dosing LAPD measurements for analysis. These results revealed 
a correlation between the most negative distal basal measurements and FEV1, but no correlation 
between basal measurements at the carina or the distal chloride response and other outcome 
measures. Paired LAPD pre and post treatment traces (n=17) showed a modest, but statistically 
significant, difference in chloride secretion in the lower airway in the active group compared to 
placebo (mean difference of 4.4mV). There were no changes in other LAPD parameters, and levels 
of vector-specific mRNA were below the limits of detection. The change in chloride secretion did 
not correlate with any of the changes in physiological (including LCI) or inflammatory markers of 
disease. 
 
These results suggest that there may be a relationship between sodium hyperabsorption (reflecting 
lack of inhibition of ENaC by defective CFTR) and FEV1, supporting published literature in which 
studies have shown a correlation between NPD basal measurements/amiloride response and 
disease severity. There are several reasons why no direct correlation was revealed between the 
CFTR-chloride ion transport at baseline and following interventions, and physiological outcome 
measures of disease status and inflammation. These have been discussed in detail in the relevant 
chapters, and are outlined below, noting that they are not mutually exclusive. 
 
Limitations on outcome measures 
 
Measures of CFTR function 
LAPD measurements had a high variability, both within-measurements and between 
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measurements in the placebo group (Section 4.6.6); higher than that seen for NPD measurements 
[190-191], likely reflecting the increased complexity of the procedure in addition to inherent 
fluctuations in airway physiology. I have shown that the measurements are not sensitive enough to 
detect small treatment effects unless large numbers of patients are studied, and the number of 
patients in the bronchoscopy subgroup was too small to reveal subtle correlations. Furthermore 
LAPD has limitations as an outcome measure for detecting efficacy of topically delivered gene 
therapy. CF airways have large quantities of mucus and airway secretions; therefore it is likely that 
gene therapy is unevenly distributed. As LAPD measurements are only performed on a small area 
of the overall epithelial surface, they might not capture areas that have received the product. 
 
Measures of disease severity 
 
FEV1 is recognised to be an insensitive disease outcome measure, particularly in subjects with mild 
lung disease, and the rate of annual decline has decreased [124]. FEV1 is also thought mainly to 
reflect disease in the proximal airways, thus may not detect changes in the distal airway. LCI is 
more sensitive to detect airway damage, and thought to reflect distal airway disease however there 
are still inherent limitations to the technique. Interventions that cause movement of mucus or 
airway secretions may result in recruitment of additional lung units not previously contributing to the 
MBW, or blockage of other lung units, leading to variable changes in the LCI (Section 2.2.3). The 
bronchoscopy subgroup was small; therefore individual abnormal results could bias the data. 
 
In the main trial, when the patients were stratified into more severe disease (FEV1=50-69%) and 
more mild disease (69-89%), the severe group showed a greater treatment effect in FEV1, whilst 
the mild group revealed a trend towards improvement in LCI. This may reflect more deposition of 
gene therapy in the proximal airways of severe patients and more distal in the mild subjects [280]. 
This highlights that CF is a heterogeneous disease, and particular outcome markers may be more 
applicable to certain patients. 
 
I described a lack of correlation between CFTR ion channel function and levels of inflammatory 
mediators in the serum, sputum and endobronchial biopsies; however, these biomarkers also have 
limitations. Serum inflammatory markers assess systemic inflammation, and whilst often elevated 
during pulmonary exacerbation, they are usually normal in CF patients during periods of clinical 
stability; limiting their use as outcome measures for therapeutic studies [215]. Sputum biomarkers 
of inflammation are increasingly being used to monitor disease activity, however studies examining 
the relationship between changes in airway inflammation have varied results. Sputum IL-8 and NE 
in particular have been shown to correlate with FEV1 in a large cross-sectional analysis [236, 341] 
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and to be elevated during pulmonary exacerbations [342], whilst other studies have reported only 
changes in sputum DNA concentrations [343]. Currently it is not known which sputum biomarkers 
are the most informative, and more research is required on short-term and long-term variability of 
measurements in CF subjects, and their responses to treatment. Endobronchial biopsies are a 
relatively novel outcome measure for measurement of airway inflammation. Studies have only 
been cross sectional and longitudinal studies are required to see how changes progress over time 
to evaluate its use as an outcome measure. Analysis of biopsies also only measures changes in 
the proximal airway (accessible by bronchoscope), and not in the peripheral small airways where 
CF disease is thought to originate. 
 
 
The effect of gene therapy on the airway 
 
It is possible that the improvement in FEV1 demonstrated with gene therapy was not due to CFTR 
restoration itself, but a non-specific reaction to the plasmid complex. Although unlikely, in view of 
only modest changes in LAPD electrophysiological outcome measures and absence of detection of 
vector-specific mRNA, this cannot be ruled out. In which case, a correlation between LAPD 
measures and physiological outcome measures would not be expected. 
 
 
Underlying physiology 
 
Although CFTR is thought to function predominantly as a chloride ion channel, it is plausible that 
there is not a direct correlation between chloride function and disease. 
 
• CFTR has more roles than solely controlling chloride secretion. There has been increasing 
research into the role that the inhibition of control of ENaC, and subsequent sodium 
hyperabsorption plays in disease pathogenesis [294,294]. Whilst our results from the basal 
LAPD measurements support this theory, it requires exploration in larger patient groups. As 
discussed (Section 3.1.1.1), to date no gene therapy trials have reported a change in 
sodium absorption, as it is though to require almost 100% CFTR correction. Initial studies 
exploring NPD traces following ivacaftor treatment did not report a change in the 
parameters reflecting sodium absorption and only chloride transport has been reported. 
More sensitive measures of sodium transport may be needed to explore this correlation 
further. 
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• CFTR is also thought to be expressed on immune cells, which may be integral to their rolein 
host defence (Section 1.2.3.3). Studies have shown that treatment with ivacaftor in vivo and 
ex vivo results in alteration of airway surface markers of inflammation suggesting that their 
activity is affected by CFTR restoration. This may affect the correlation between airway 
CFTR ion channel function and disease and inflammation. 
 
•  Other factors may also impact on the progression of disease including; infectious status, 
airway irritants, pancreatic function and modifier genes, including, polymorphism in genes 
close to CFTR and environmental factors. In addition, lower socioeconomic status and 
reduced adherence to medications has been shown to be associated with worse pulmonary 
outcomes [344, 345]. 
 
 
The most notable limitation to this work is the small patient group. Whilst this is inherent studying 
rare diseases, it meant that the study was underpowered to produce significant results. The large 
variability in the LAPD values means that this measure is too insensitive to draw firm conclusions 
from, and questions its use as a feasible outcome measure in future trials. 
 
This study did not support the hypothesis that there is a direct relationship between CFTR function 
and airway health. It is possible that there is a correlation between distal basal LAPD values and 
FEV1, indicating the role of ENaC in disease pathogenesis, however this requires further 
exploration in larger studies. The relationship between CFTR chloride ion transport and disease 
pathogenesis appears to be complex. Future work in this field requires developing assays for 
CFTR, which are sensitive and reproducible. In addition, there is ongoing need for more sensitive 
measures of airway disease, which can be used to monitor patients with CF longitudinally, and 
response to therapies. 
 
Since this study failed to confirm a direct effect of dysregulated chloride and sodium transport on 
CF airway disease, in the next chapter I explored the hypothesized bidirectional relationship 
between CFTR and inflammation. If shown to exist, this may explain the indirect relationship 
between the two that had been observed. 
 
 
7.2 There is a bidirectional relationship between CFTR function and airway inflammation 
 
Recent evidence suggests that the relationship between the CFTR protein and inflammation is 
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complex and bi-directional with suggestions that impaired CFTR function results in a 
hyperinflammatory response, and that inflammatory mediators may cause secondary CFTR 
dysfunction. A better understanding of the inflammatory profile in subjects with CF may reveal new 
therapeutic targets and for both patients with CF and other CSLDs, an acquired defect in CFTR 
protein function may contribute to disease pathogenesis. 
 
This thesis describes two studies designed to assess these hypotheses in turn. In both studies 
patients with CF were compared to controls and subjects with PCD. PCD shares similar 
characteristics, with defective MCC and a similar inflammatory profile to CF, but with presumed 
normal CFTR function. 
 
 
7.2.1   Impaired CFTR function leads to a hyper-stimulated inflammatory profile 
 
Chapter 5 describes a study designed to explore whether CF epithelial cells contribute to the high 
levels of inflammation characteristic of the airway disease, with defective CFTR causing a 
hyperinflammatory response, at baseline and/or in response to bacterial stimulation. Cells from 
controls, patients with CF and PCD were cultured at an ALI. 9 pro-inflammatory cytokines in the 
cell culture supernatant were measured at baseline and after stimulation with respiratory 
pathogens; PA, SA and HI at regular time-points. The hypothesis was that CF cells would elicit 
higher levels of inflammatory mediators at baseline and following bacterial stimulation than non-CF 
cells. In total only 13 ALIs were cultured (control=5, CF=4, PCD=4), underscoring the complexity of 
the technique. A comparable inflammatory response was elicited in select cytokines (IL-6, IFN-γ, 
TNF- α) in all 3 groups, whilst other cytokines, including IL-8, failed to demonstrate a measurable 
response, not supporting the theory that CFTR dysfunction results in a hyper inflammatory 
response. This is either due to limitations in the study design, or because impaired CFTR function 
in epithelial cells does not make them innately hyperinflammatory; outlined below. 
 
Study design 
 
We only achieved 25% success rate in obtaining ciliated ALI samples therefore this study was 
ultimately underpowered. The levels of the cytokine responses were shown to be very variable in 
all the groups, and could have been skewed by individual results. 
Despite managing to elicit an IL-8 response to bacterial stimulation in the pilot studies, this was not 
achieved in the main study. The measurements were performed on different ELISA platforms, 
however they had a comparable optimal dynamic range therefore this result is unexplained. The 
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methodology needs to be refined in order to address this, as IL-8 is a major pro-inflammatory 
cytokine present in CF inflammatory airway disease [236].  
 
It would also be useful to measure the levels of NE in the supernatant, as this has both been 
shown to be elevated in CF airway and to correlate with disease severity [236]. NE has also been 
implicated in promoting inflammation in the CF airway due to its interaction with epithelial surface 
molecules involved in the inflammatory pathways (Section 1.2.3.4). 
 
 
Cell culture 
 
The limitations of cell culture models have been discussed in Chapter 5. They are a useful model 
to explore cell behaviour in-vitro however they do not replicate the complexity of the airway 
environment or bronchial epithelial cell reactions in-vivo. Cell culture removes epithelial cells from 
the effect of other parts of the immune system such as circulating cells in the blood, which may 
alter their inflammatory response. Culturing and passaging cells can alter the expression of cell-
specific characteristics, such as cell polarity, tight junction formation, mucus secretion and cilia 
formation. Our results, showing extremely variable inflammatory responses are similar to the 
published literature [317]. Genetic and environmental factors also likely have an effect on the tissue 
cultures and influence the inflammatory response. Of note, we used cells cultured from nasal 
epithelium as a surrogate for the lower airway, for ease of accessibility. These may not accurately 
reflect the cell behaviour of the lower airway, where different levels of CFTR are expressed [346]. 
CFTR but not epithelial cells 
 
It is plausible that the CF airway is hyperinflammatory, but that this is not directly as a result of 
CFTR dysfunction in the epithelial cells. Dysfunctional CFTR may effect other elements of the 
immune system, including myeloid-derived cells, neutrophils and macrophages [330-333] all of 
which were not assessed in this study. It is possible that combinations of many of these pathways 
affect the immune response in patients with CF and contribute, at different stages, to the chronic 
inflammatory picture characteristic of the disease. 
 
In summary, cells with absent CFTR function, from subjects with CF, when cultured at an ALI, 
produced a similar level of inflammatory mediators at baseline and following bacterial exposure to 
cells from patients with PCD and healthy controls. This does not support the hypothesis, that 
absent CFTR function results in hyperinflammatory response. Future work in this field would 
initially involve: increasing the number of cell cultures studied, the inclusion of NE in the assays, 
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and optimising the study design to elicit an IL-8 response. Simultaneous measurements of the 
inflammatory profile of bronchial and nasal epithelium in the same subjects would evaluate whether 
nasal cells can be used as a surrogate for the bronchial epithelium. In addition, the measurement 
of CFTR function in the cell culture specimens using a cell clamp, prior to bacterial stimulation, 
would allow for comparison of the levels of CFTR ion channel function with the subsequent 
inflammatory response. 
 
As in vitro experiments may not mimic in vivo conditions, including cellular and molecular 
interactions, I went on to study the interactions between CFTR function as demonstrated by nPD 
and airway inflammation in vivo. 
 
 
7.2.2 Inflammation impairs CFTR function 
 
To date, studies exploring secondary CFTR function have been limited to subjects with COPD. 
However, it is difficult to disentangle the role of inflammatory mediators and tobacco on the airway 
epithelium. Chapter 6 describes a study of NPD in subjects with PCD, CF and controls designed to 
compare CFTR function in-vivo with localised inflammatory mediators. The expectation was that 
the NPD traces in subjects with PCD would show evidence of CFTR dysfunction, which would 
correlate with increased levels of localised inflammation. Nasal MLF was collected using 
nasosorption, and the samples were analysed for a range of inflammatory cytokines. 
 
The NPD traces in patients with PCD demonstrated decreased total chloride secretion, comparable 
to that seen in subjects with CF, however this was not accompanied by a hyper-polarised baseline      
and exaggerated amiloride response that would be expected with CFTR dysfunction and      
associated disinhibition of the ENaC channel; in fact, several of the traces demonstrated ‘blunted’ 
responses suggestive of secondary inflammatory damage. Nasosorption samples revealed      
elevated levels of inflammation in patients with PCD compared to the other groups (consistent with 
previous in vivo work), however levels of inflammation did not correlate with altered sodium or 
chloride ion transport. Notably, there was a large variability in the levels of all cytokines measured 
by nasosorption. These results suggest either an isolated effect of inflammatory mediators on  
CFTR, uncoupled from ENaC, or may represent damage to the epithelial integrity, a known 
limitation of NPD measurement. These are discussed. 
 
 
Isolated effect on CFTR 
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Previous studies exploring a secondary CFTR defect support that the NPD traces may reflect an 
isolated CFTR defect. In-vitro studies using immunodetection methods have demonstrated that 
IFN-γ lowers CFTR expression and down regulates ENaC, thus affecting both channels differently, 
and studies exploring CFTR dysfunction in the lower airways of patients with COPD also revealed 
reduced chloride secretion but without a hyperpolarised baseline. 
 
 
Effect of epithelial cell integrity 
 
It is well established that PD measurements are affected by non-specific tissue damage such as 
exposure to inflammation, which disrupt the epithelial integrity and produce a ‘blunted’ trace with a 
lower (less negative) basal value and reduced amiloride and chloride response. These traces are 
indistinguishable from the traces obtained in the subjects with PCD in whom no deflection was 
seen on the perfusion of different solutions.  
 
The nasosorption samples revealed higher levels of inflammatory cytokines in MLF obtained from 
PCD subjects compared to CF and healthy controls, which are consistent with in-vivo studies 
[48,49]. Unfortunately the results were too variable to draw firm conclusions from, although higher 
levels of inflammatory markers did not correlate with altered levels of sodium or chloride transport. 
Further work is required to establish whether nasosorption will be a useful tool to explore airway 
inflammation. 
 
Other tools may be required to assess the link between inflammatory mediators and acquired 
CFTR dysfunction in CSLD. Previous studies have used techniques to quantify the CFTR protein 
using immunodetection, and CFTR mRNA with real-time polymerase chain reaction (RT-PCR) 
TaqMan assays. The main limitation in this study was the small numbers of patients in each group, 
meaning that it was underpowered. In addition, the techniques utilised to collect the nasosorption 
samples and analysis need to be optimised in order to determine whether these accurately reflect 
the in-vivo inflammatory profile. 
 
We revealed that subjects with PCD have reduced chloride secretion detected by NPD 
measurements, however we were not able to conclude that this was due to the effect of 
inflammatory mediators on CFTR function. Further studies will involve additional assays to detect 
and quantify the CFTR protein to help determine the cause of the abnormal NPD traces. 
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Combined, these studies do not provide evidence that there is a bidirectional relationship between 
CFTR and inflammation, but provide a basis upon which to base future studies to try and better 
understand how CFTR interacts with its environment. This will be beneficial to both patients with 
CF and CSLDs, and may reveal potential therapeutic targets. The development of animal models 
of CF, and advances in cell-modeling tools such as organoids may facilitate this research. 
 
 
7.3 Overall conclusion 
 
When it was first discovered in 1989 that patients with CF had a defect in the gene encoding for 
the CFTR protein, and the subsequent elucidation of this protein predominantly as a chloride 
channel, it was thought that a treatment for CF would rapidly follow. This did not prove to be case, 
as it was increasingly understood that the pathogenesis of CF airway disease is complex. Despite 
this, in the last decade there have been phenomenal advances in CF care and resultant survival in 
patients with CF. This thesis described a trial of gene therapy in patients with CF, demonstrating 
promising results, in addition to the advancing field of CFTR modulators, such as ivacaftor, which 
are beginning to change the clinical course of patients with CF, albeit currently only with select 
mutations. 
 
This thesis has set out to explore the relationship between CFTR function and airway disease in 
both CF and other CSLDs. The findings support the theory that it is not the chloride function of 
CFTR in the airway epithelium that is solely responsible for disease progression and that other 
consequences of CFTR dysfunction play a role. This thesis provides the basis for more studies to 
explore these complex interactions, with the hope that this will help guide the development of future 
therapies for CF.	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9 Appendices 
Appendix A: Formulation of nasal and lower airway potential difference perfusate solutions 
 
Solution 1: Ringer’s (Basal) Solution 
 
Compound Concentration 
mM/L g/L 
Sodium Chloride   NaCl 135 7.83 
Calcium Chloride Dihydrate   
CaCl2-
2H2O 2.25 0.33 
Magnesium Chloride Hexahydrate   
MgCl2-
6H2O 1.2 0.24 
Monobasic Potassium Phosphate   K2HPO4 2.4 0.42 
Dibasic Potassium Anhydrous   KH2PO4 0.4 0.05 
 
 
Solution 2: Zero Chloride Solution 
 
Compound Concentration 
mM/L g/L 
Sodium Gluconate   C6H11NaO7 135 29.43 
Calcium Gluconate Anhydrous   C12H22CaO14 2.22 0.95 
Monobasic Potassium Phosphate   K2HPO4USP 2.4 0.42 
Dibasic Potassium Phosphate Anyhydrous   KH2PO4 0.4 0.24 
Magnesium Sulphate 7H2O   MgSO4-7H2O 1.2 0.3 
 
 
 
Ringer’s + Amiloride (0.1 mM) Solution (RA) 
 
Amiloride 0.03 mg/ml (0.1 mM) is added to Ringer’s Solution (Solution 1) 
 
 
Zero Chloride + Amiloride (0.1 mM) Solution (ZCl/A) 
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Amiloride 0.03 mg/ml (0.1 mM) is dissolved in a ZCl Solution (Solution 2) 
 
This solution is used for the measurement of nasal PD 
 
 
Isoprenaline (0.01 mM) containing Solutions 
 
To all solutions containing isoprenaline (listed below), isoprenaline hydrochloride (1mg/5ml) 0.625 
ml (=0.125 mg) is added to 50 ml of ‘base’ solution and agitated 
 
Isoprenaline must be added just prior to use, owing to expiry time of 2 hours from the time 
dissolved 
 
 
 
Zero Chloride + Amiloride (0.1 mM) + Isoprenaline (0.01 mM) Solution (ZCl/A/Iso) 
 
Isoprenaline dissolved in ZCl/A solution.  
 
This solution is used for measurements of nasal PD 
 
 
Zero Chloride + Isoprenaline (0.01 mM) Solution (ZCl/A/Iso)  
 
Isoprenaline dissolved in ZCl solution.  
 
This solution is used for measurements of lower airway PD. It does not contain amiloride.  
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Appendix B: Patient assessment for fitness to dose 
 
A clinical assessment was made by either of the trial Doctors (myself or Dr Michael Waller) on the 
fitness of the patient to dose, ensuring the patient had not deviated outside pre-defined criteria and 
assessing for relative clinical stability 
 
• Percentage predicted FEV1 >40% 
• Fall in FEV1 <20% from the last visit (Pre-dosing) 
• Patients’ body temperature <37.7oC 
• Patients’ oxygen saturation >94% 
• No new abnormality identified at clinical examination 
• Not commenced iv antibiotics within the last 7 days 
• Not taken nebulised rhDNase (pulmozyme) within the past 24 hours 
 
If patients had fallen outside these dosing criteria the dose could be deferred to a new date within 
the patient’s dosing window (28 + 5 days) to prevent missed doses, otherwise the dose was 
forfeited (a maximum of 3 missed dose being allowed during the study) 
 
 
 
 
 
 
 
 
 
